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Abstract
Cost-Effectiveness Analyses of Typhoid Interventions in Epidemic and Endemic Settings
Maile Thayer Phillips
2021
Background: Typhoid fever is a major source of morbidity and mortality in developing
countries, accounting for approximately 12-21 million infections, 119,000-269,000 deaths, and
2-23 million disability-adjusted life years (DALYs) annually. Typhoid fever is caused by
infection with the bacteria Salmonella enterica serovar Typhi, which is mainly transmitted
through fecal contamination of food or water. Due to these modes of transmission, most cases
occur in low- and middle-income countries (LMICs) where sanitary conditions are poor and
access to clean water and sanitation is not common. However, the scale of disease incidence is
uncertain. Studies suggest that facility-based laboratory-confirmed estimates, the numbers used
for reporting and decision-making, are considerably lower than the actual numbers. As a result,
typhoid likely has an even higher global burden than is reported.
While typhoid remains a major cause of morbidity and mortality, it is preventable.
Interventions against typhoid exist, with varying degrees of efficacy and costs. Investments in
water and sewer systems in the early 20th century are thought to have been responsible for the
decline of typhoid in many developed countries; however, no economic evaluations have
quantified the costs and impact of improvements in sanitation. Additionally, a typhoid conjugate
vaccine (TCV) has been approved, but research regarding its long-term efficacy and use in
outbreak settings is limited. Cost-effectiveness evaluations of TCVs recommend their use in
endemic settings, but modelling suggests that vaccination alone will not eliminate disease.

Methods & Results: Before we can evaluate the impact of interventions, we need accurate
estimates of baseline disease incidence. Therefore, in Chapter 1, we developed a Bayesian
framework to combine multiple data sources to estimate the population-based typhoid incidence
based on passive surveillance data from Blantyre, Malawi; Kathmandu, Nepal; and Dhaka,
Bangladesh. The ratio of observed to adjusted incidence rates was 7.7 (95% credible interval
(CrI): 6.0-12.4) in Malawi, 14.4 (95% CrI: 9.3-24.9) in Nepal, and 7.0 (95% CrI: 5.6-9.2) in
Bangladesh. Adjusted incidence rates were within or below the seroincidence rate limits of
typhoid infection. Estimates of blood-culture-confirmed typhoid fever without these adjustments
results in considerable underestimation of the true incidence of typhoid fever.
In Chapter 2, we evaluated the cost-effectiveness of typhoid conjugate vaccine use in
response to outbreaks of typhoid fever. We fit a modified version of an existing dynamic
compartmental model of typhoid fever to Malawi outbreak data and evaluated preventive and
reactive vaccination strategies. We then conducted a cost-effectiveness analysis using the netbenefits framework to compare no vaccination to routine vaccination at 9 months of age with and
without a catch-up campaign up to 15 years old. We examined variations in outbreak definitions,
delays in implementation of reactive vaccination, and the timing of preventive vaccination
relative to the outbreak. We estimated that vaccination would prevent 15-60% of disabilityadjusted life-years (DALYs) in the outbreak scenarios. Some form of routine vaccination with a
catch-up campaign was preferred over no vaccination for willingness-to-pay (WTP) values of at
least $110 per DALY averted. Countries where outbreaks of typhoid fever due to introduction of
antimicrobial resistant strains are likely to occur should consider TCV introduction. Reactive
vaccination can be a cost-effective strategy, but only if delays in vaccine deployment are

minimal; otherwise, introduction of preventive routine immunization with a catch-up campaign
should be considered.
Lastly, in Chapter 3, we quantified the relationship between investments in water and
sanitation infrastructure and long-term typhoid transmission rates using historical data from 16
U.S. cities. We fit two models for each city: (1) we modified a Time-series SusceptibleInfectious-Recovered (TSIR) model and extracted long-term transmission rates, and (2) we
measured the association between the transmission rates and financial variables using
hierarchical regression models. Overall historical $1 per capita ($16.13 in 2017) investments in
the water supply were associated with approximately 5% (95% confidence interval: 3-6%)
decreases in typhoid transmission, while $1 increases in the overall sewer system investments
were associated with estimated 6% (95% confidence interval: 4-9%) decreases.

Conclusions: A combination of statistical and mathematical modeling permits us to evaluate the
cost-effectiveness of typhoid interventions across settings. We are able to estimate the true
population-based incidence of typhoid fever in Africa and Asia, weigh the costs and effects of
vaccination strategies in an outbreak setting, and estimate the impact of water and sanitation
investments in an endemic setting. These findings can help to inform decision-making regarding
typhoid control and prevention. The results can play an essential role in making the case for
improvements in water and sanitation and/or vaccination to reduce the global burden of typhoid
fever.
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Introduction
The importance of accurate estimates of population-level typhoid fever incidence
Typhoid fever is a major source of morbidity and mortality in developing countries.
Approximately 12-21 million infections and 119,000-269,000 deaths are attributed to typhoid
each year [1, 2], accounting for 2-23 million disability-adjusted life years (DALYs) [3]. Most
cases occur in Asia and Africa, predominantly among children [4].
Humans are the only hosts for the bacteria Salmonella enterica serovar Typhi [5], which
causes typhoid fever. Once ingested through feces-contaminated food or water, S. Typhi has an
incubation period of 7-14 days. Bacteria enter the gut mucosa, replicate, and travel to the liver,
spleen, and gallbladder before entering the bloodstream, marking the onset of clinical symptoms
[5]. Symptomatic cases generally present with fever, abdominal pain, malaise, and headache [6].
Symptoms can last 4-6 weeks if untreated. Following recovery from symptomatic illness, an
estimated 1-5% of hosts become long-term carriers [5].
Decisions for typhoid control are often based on crude estimates of incidence. These
estimates depend on facility-based laboratory-confirmed cases, which are likely substantial
underestimates of the actual incidence. Limits of using facility-based estimates alone—lack of
specific clinical diagnostic criteria, poorly sensitive diagnostic tests, and scarcity of data—
contribute to difficulties in calculating population-level incidence of typhoid.
Studies estimate that 60-90% of individuals with typhoid do not receive medical
attention, likely because they either do not seek treatment, or they seek help through less
traditional avenues[4, 7]. Even if a person seeks care, typhoid fever is often confused with other
febrile illnesses [8]. Symptoms of typhoid, particularly fever onset, are also the main symptoms
of other common diseases [8]. Furthermore, not all patients have a blood culture test performed,
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usually because parents sometimes do not want their sick child to have blood drawn, or people
are turned away due to lack of supplies or healthcare personnel [9]. Suboptimal diagnostic tests
further contribute to underestimation of disease incidence. Blood culture is the mainstay of
typhoid diagnosis and is highly specific, but its sensitivity ranges from 0.51-0.65 [10].
Modeling is needed to estimate the true incidence of typhoid fever in order to establish
the baseline disease burden against which to evaluate the need for potential interventions.
Models must take into account the cases lost at each step of the reporting process to be accurate.

Complications with treatment and antimicrobial resistance
Typhoid can be effectively treated with antibiotics, given correct diagnosis and strain
susceptibility [6]. However, due to the widespread availability of antimicrobials without a
prescription in many parts of the world, antimicrobial resistance has been increasing in recent
years [11-14]. The first reports of emerged before 1970, leading to outbreaks and resulting in the
need for alternative treatments [15-17]. Resistance to ampicillin and trimethoprimsulfamethoxazole soon followed, such that multi-drug-resistant (MDR) strains (defined as
resistance to all three antimicrobials) now pose a threat to typhoid control [18-20]. More
recently, extensively drug-resistant (XDR) S. Typhi, which also exhibits non-susceptibility to
fluoroquinolones and resistance to third-generation cephalosporins, were reported in 2017 in a
large typhoid outbreak Pakistan [21-23]. Increasing rates of MDR and XDR have led to clinical
treatment failures, the need for more expensive treatments, and a rise in complications and
hospital admissions [11]. Alternative interventions are needed to reduce antibiotic use and limit
the threat of MDR and XDR S. Typhi [11, 24, 25].
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The existence of effective typhoid fever control interventions
In many developed countries, typhoid incidence declined drastically in the early 20th
century such that occurrences of the disease are now rare. This decline has been attributed to
investments in water and sanitation, though the relationship has not been fully characterized.
Prior studies estimate that investments in clean water technologies reduced typhoid mortality by
25% and overall mortality by half in the early 20th century [26, 27]; however, these estimates do
not take into account the disease transmission process.
In 2018, the World Health Organization (WHO) recommended programmatic use of
typhoid conjugate vaccines (TCV) in addition to other interventions in settings with high rates of
typhoid [6]. In endemic settings, studies suggest that the most cost-effective strategy is either no
vaccination or routine vaccination plus catchup campaigns, depending on the typhoid incidence
rate [28, 29].
The WHO also recommends the use of TCV in outbreak settings [6]. However, current
data are limited on how and when it might be introduced, and vaccine stockpiles do not yet exist
[11, 30]. While reactive vaccination can be effective, if implemented late or focused
inappropriately, the number of cases averted will be small [31-33]. To ensure that the appropriate
vaccine stockpiles, accurate estimates of disease incidence and knowledge of vaccine coverage
requirements are also necessary.
Research comparing typhoid interventions in endemic and epidemic settings is limited.
With recent WHO recommendations for TCV use and pilot studies assessing efficacy and impact
underway [6, 34], governments are looking to prioritize the allocation of resources to prevent
typhoid. With recent typhoid epidemics across Africa [35-39] and high burdens in endemic
countries, studies are needed to compare prevention strategies across different settings, including
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the use of TCV in response to outbreaks and in comparison to water and sanitation investments.
Typhoid control can be expensive; cost-effectiveness analyses are needed to inform decisions for
the optimal allocation of funding.
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Abstract
Decisions about typhoid fever prevention and control are based on estimates of typhoid
incidence and their uncertainty. Lack of specific clinical diagnostic criteria, poorly sensitive
diagnostic tests, and scarcity of accurate and complete datasets contribute to difficulties in
calculating age-specific population-level typhoid incidence. Using data from the Strategic
Alliance across Africa & Asia (STRATAA) programme, we integrated demographic censuses,
healthcare utilization surveys, facility-based surveillance, and serological surveillance from
Malawi, Nepal, and Bangladesh to account for under-detection of cases. We developed a
Bayesian approach that adjusts the count of reported blood-culture-positive cases for blood
culture detection, blood culture collection, and healthcare seeking—and how these factors vary
by age—while combining information from prior published studies. We validated the model
using simulated data. The ratio of observed to adjusted incidence rates was 7.7 (95% credible
interval (CrI): 6.0-12.4) in Malawi, 14.4 (95% CrI: 9.3-24.9) in Nepal, and 7.0 (95% CrI: 5.69.2) in Bangladesh. The probability of blood culture collection led to the largest adjustment in
Malawi, while the probability of seeking healthcare contributed the most in Nepal and
Bangladesh; adjustment factors varied by age. Adjusted incidence rates were within the
seroincidence rate limits of typhoid infection. Estimates of blood-culture-confirmed typhoid
fever without these adjustments results in considerable underestimation of the true incidence of
typhoid fever. Our approach allows each phase of the reporting process to be synthesized to
estimate the adjusted incidence of typhoid fever while correctly characterizing uncertainty,
which can inform decision-making for typhoid prevention and control.
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Background
Current estimates of typhoid fever incidence serve as a basis for decision-making around
typhoid control. However, facility-based cases of blood-culture-confirmed typhoid fever are
considerably lower than the true number of those with the disease [1] because the reported
numbers do not account for individuals with typhoid fever who do not seek healthcare, fail to
receive a diagnostic test, or falsely test negative for typhoid (Fig 1). Annually, typhoid fever is
estimated to cause 11-18 million infections and 100,000-200,000 deaths [2, 3], but there is
considerable uncertainty in these estimates.
Studies suggest that somewhere between 60-90% individuals with typhoid fever do not
receive adequate medical attention, in part because they do not to seek formal treatment [4, 5].
Previous studies have found that healthcare utilization is correlated with the number of
household members, distance to the healthcare facility, financial affordability, and trust in formal
healthcare [6, 7]. Furthermore, typhoid fever is often misdiagnosed based on physical
examinations alone [1]. Inconsistent clinical diagnoses arise because symptoms of typhoid,
particularly prolonged fever, are also the main characteristics of other common infectious
diseases in typhoid endemic settings [1, 8]. Even if a blood culture test is recommended and
laboratory facilities are available, not all patients will consent. Diagnostic tests can be invasive,
and parents or guardians of young children sometimes do not want their children to have large
amounts of blood drawn when they are already ill. In resource-poor countries in particular, lack
of supplies and personnel lead to long wait times for receiving healthcare, further adding to
lower rates of confirmatory testing. Clinical opinion on the cause of fever can also affect the
likelihood of blood being drawn for culture [9].
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Suboptimal diagnostic tests further contribute to underestimation of cases. Blood culture
collection is the mainstay diagnostic test for typhoid fever [10], but it fails to capture
approximately half of the true cases. The test sensitivity depends on the volume of blood drawn
and whether a patient has recently received antibiotics [11]. Thus, even if an individual with
typhoid receives a blood culture test, he or she may falsely test negative and not be included in
the reported number of confirmed cases.
The true incidence of typhoid fever cannot be directly assessed but can be estimated by
accounting for steps in the reporting process. Methods to combine data from several sources to
adjust for underestimation while accurately quantifying the uncertainty have been previously
applied to estimate the incidence of HIV and influenza [12-16]. Bayesian methods are conducive
to integrating multiple data sources in this way. In this work, we developed a Bayesian multiplier
framework to estimate population-based incidence of typhoid fever based on data collected from
study sites in Africa and Asia.

Methods
Study design & data.
We developed a framework within the Bayesian setting to integrate data from multiple
sources to estimate the population-based incidence of typhoid fever based on passive
surveillance in Malawi, Nepal, and Bangladesh, three typhoid-endemic countries with different
demographics, healthcare systems, and access to diagnostics [17]. Using this model, we sought
to estimate the adjustment factors needed to calculate the “true” incidence of typhoid fever
occurring in the population under surveillance, and to examine how these values varied by age
across the three study sites, by combining information collected from the study population with
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estimates from prior published studies. We also compared our final estimates to serosurveillance
data collected from the same population catchment areas.
Data came from the Strategic Typhoid Alliance across Africa & Asia (STRATAA)
Programme, a prospective observational, population-based epidemiological study of typhoid
incidence, transmission, and antibiotic resistance. From 2016-2018, the STRATAA investigators
conducted demographic censuses, healthcare utilization surveys (HUS), passive surveillance, and
serosurveys at each of three sites (Blantyre, Malawi; Kathmandu, Nepal; and Dhaka,
Bangladesh). STRATAA’s study design and methods have been detailed elsewhere [17], and are
briefly described below.
Demographic census data.
The demographic census was used to estimate the overall person-time contribution for
incidence rate calculations. The survey documented household locations and individual
characteristics for each geographically demarcated study area. The census provided information
on each individual’s birthdate, sex, position in the household, marital status (if applicable),
education level, and employment status (if applicable). Participants were surveyed and consented
as households. Approximately 100,000 individuals were enrolled at each site, and census updates
were carried out one to three times depending on the site. Over the two-year study period, this
population amounted to 200,018 person-years of observation (pyo) in Malawi, 203,444 in Nepal,
and 222,636 in Bangladesh.
Passive surveillance.
Clinical cases of culture-confirmed typhoid fever were identified through passive
surveillance. Individuals living in the study areas who presented at partner facilities with a
documented temperature of > 38.0°C or a history of fever lasting at least two days upon
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presentation were eligible for enrollment. Healthcare workers collected clinical and demographic
information from enrolled febrile individuals, as well as microbiological samples (urine, feces,
and blood).
Healthcare utilization survey.
To estimate the proportion of cases captured by study facilities, we collected data from
the head of household regarding actual and hypothetical usage of healthcare facilities for febrile
episodes among household members from each of three age groups (<5 years, 5-14 years, >14
years), if available. Approximately 735 households were randomly chosen at each site, with the
requirement that all households have at least one child (14 years or younger). The HUS
contained questions regarding household and individual health behavior; house and household
characteristics; water, sanitation and hygiene practices; and healthcare utilization (actual and
hypothetical).
Serosurveillance.
Serosurveys were conducted in the census population to assess the underlying rate of
seroconversion to typhoid, and to identify potential chronic carriers, initially based on anti-Vi
immunoglobulin G (IgG). Approximately 8,500 participants from each site were randomly
selected in an age-stratified manner. Healthcare workers collected serum samples from each
individual upon enrollment and again three months later. Seroconversion was defined as a > 2fold rise in anti-Vi IgG titre between the first and second sample drawn and an absolute titre >50
EU/ml at the second time point to account for small variations above the lower limit of detection
for the assay. We estimated the seroincidence by dividing the number of seroconversions by the
person-time contribution between serum samples in each age group; 95% binomial confidence
intervals (CI) were estimated.
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Approach and data analysis.
We adjusted the reported number of blood-culture-positive cases of typhoid fever for
each of the three phases of the reporting process: blood culture detection, blood culture
collection, and healthcare seeking. We used information on healthcare seeking for fever and the
proportion of fever cases who were enrolled and had blood taken for culture and combined this
information with published data on risk factors for typhoid fever to reach our final adjusted
numbers. We then examined whether our adjusted estimates were within the maximum range
expected based on seroincidence estimates, which capture all clinical and sub-clinical cases.
The estimation of typhoid fever incidence is complicated by the relationship between
fever and typhoid fever. In each phase of the reporting process, we can observe whether a person
has a fever, but not necessarily whether he/she has typhoid fever. Thus, the symptomatic typhoid
fever pyramid is nested within a larger fever pyramid (Fig S1).
We assumed that the observed number of blood-culture-positive individuals ("observed,$,% )
follows a Poisson distribution given as
.

/0123425,6,7
"observed,$,% ~Poisson -89:;<=_?@A9
B
6,7

(1)

where C<D;9:E9F,$,% is the observed incidence rate of typhoid fever, adjusted for pyo from the
demographic census (person_time$,% ) (Fig 1, Table 1). Subscript a represents age category, where
1 for children < 5 years old
⎧2 for children 5 − 9 years old
⎪
L = 3 for children 10 − 14 years old ,
⎨4 for individuals 15 − 29 years old
⎪
⎩5 for individuals ≥ 30 years old
and subscript c represents the site, where
1 for Malawi
e = f2 for Nepal
.
3 for Bangladesh
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The incidence rate of reported cases can be rewritten as the product of the healthcare-seeking
typhoid incidence rate and the probability of a case being captured at each of the three steps of
the reporting process,
t
u
v
C<D;9:E9F,$,% = C$lmnopql,$,% ∗ s$,%
∗ s$,%
∗ s$,%
,

(2)

t
where C$lmnopql,$,% is the final adjusted incidence of typhoid fever incidence, s$,%
is blood culture
u
v
sensitivity, s$,%
is the probability of receiving a blood culture test, and s$,%
is the probability of

seeking healthcare for typhoid fever. Superscript S denotes that the parameter refers to the blood
culture detection (i.e. sensitivity) phase of reporting, superscript B denotes that the parameter is
referring to the blood culture collection (i.e. testing) phase of reporting, and superscript H
denotes that the parameter is referring to the healthcare-seeking phase of reporting.
All model input parameters, with their prior distributions and corresponding data sources,
are listed in Table 1. The three steps in the adjustment process (blood culture detection, blood
culture collection, and healthcare seeking), are detailed below.
t
Adjustment for blood culture sensitivity (s$,%
)

For each individual who received a blood culture test, we inferred whether or not they
were a “true” typhoid fever case by adjusting for the specificity and sensitivity of blood culture
for typhoid diagnosis (Table S1). First, we assumed that the specificity of blood culture is 100%;
thus, all individuals who tested positive for typhoid were assumed to be true cases of the disease.
Second, we assumed that among those who tested negative, the probability of being an actual
typhoid fever case depended on the volume of blood drawn and prior antimicrobial use, both of
which were recorded in the passive surveillance data. Previous studies have shown that the
sensitivity of blood culture for typhoid diagnosis is on average 59% (95% CI: 54-64%) but
increases by 3% for each additional mL of blood drawn, and decreases by 34% with antibiotic
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use in the past two weeks [11]. Thus, each individual who tested negative for typhoid had a
probability 1-wi,v(i),u(i) of being a false negative and thus a true case of typhoid fever, where
wi,v(i),u(i) is the blood culture sensitivity for individual i, v(i) is the volume of blood collected from
individual i, and u(i)=1 if individual i reported prior antibiotic use in the previous two weeks and
u(i)=0 otherwise. Blood culture sensitivity is defined as
wx,y(x),n(x) = (| }~.ÄÅÇ~.~Åy(É) ) ∗ (1 − 0.34Ñ(x) ).

(3)

The use or non-use of antibiotics created a bimodal distribution for the sensitivity based
on the observed individual-level data calculated using Equation 3 (Fig S2). Thus, we chose to
model the distribution of sensitivity among the full population using a normal mixture model
with a separate mean and standard deviation for the distribution of blood culture sensitivity with
and without the use of antibiotics, varied over blood culture volume. This mixture model is
denoted
t
s$,%
|Ü$,% ~N(án,$,% , àn,$,% )
Ü$,% ~Bernoulliâä$,% ã

(4)

t
where s$,%
is the blood culture sensitivity adjustment from Equation 2, ä$,% is the proportion of

individuals who took antibiotics in the past two weeks, and án,$,% and àn,$,% represent the mean
and standard deviation of the distribution of blood culture sensitivity after adjusting for blood
culture volume among those who did (U=1) and did not (U=0) take antibiotics (from the
distribution created using Equation 3), again estimated separately for each age category and site.
u
Adjustment for the probability of receiving a blood culture test (s$,%
)

The probability of receiving a blood culture test was estimated differently for Malawi
versus Nepal and Bangladesh due to data availability and differences in the primary reasons why
individuals were not tested. In Malawi, the main reason why individuals meeting the fever
criteria for enrollment did not receive a blood culture test was due to limited capacity and long
15

waiting times at the primary health facility. Individuals often arrived at the clinic early in the
morning for clinical review. Once they had seen the government clinician, they were referred for
study enrollment and blood-culture collection. If there was a delay in enrollment activities,
individuals often left prior to blood cultures being collected. Thus, we assumed that data for
those who did not receive a blood culture test were missing completely at random. We used the
passive surveillance screening data to estimate the probability of receiving a blood culture test in
Malawi, and assumed that the probability followed a beta distribution,
u
u
u
s$,å
~ Beta(ç$,åx
, é$,å
),

(5a)

u
u
where ç$,å
was the number of eligible patients enrolled and é$,å
was the number of eligible

patients who were not enrolled.
In Nepal and Bangladesh, the primary reason febrile individuals did not receive a blood
culture test likely depended on factors associated with their probability of testing positive (e.g.,
age, number of days of fever, and clinical suspicion of the disease); furthermore, screening data
for the passive surveillance were not available. Instead, we relied on published estimates of the
relative risk of typhoid fever among those who did not have blood taken for culture and
screening data from the Typhoid Vaccine Acceleration Consortium (TyVAC) [18]. As part of
TyVAC, typhoid conjugate vaccine trials are being conducted in the same populations as
STRATAA utilizing the same passive surveillance facilities. Baseline information on eligible
patients presenting to fever surveillance facilities was recorded both for those who did and did
not have blood drawn for culture. Based on the analysis of these data in the TyVAC population
in Nepal, the relative risk of blood culture positivity (RS) was 1.87 times higher (95% CI: 0.93.9) among those who received a blood culture test compared to those who did not [9]. Thus, the
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overall probability of receiving a blood culture test, after taking into account variations in the
risk of typhoid fever among those who are and are not tested, is
u
s$,%
= 1−

â1−è6,7 ã

êë

for e = 2 íä 3,

(5b)

where ì$,% is the probability of receiving a blood culture test prior to adjusting for the relative risk of
blood culture positivity. Prior to adjusting for the relative risk, the probability of receiving a blood
u
u
u
culture test was assumed to follow a beta distribution, ì$,% ~ Beta(ç$,%
, é$,%
), where ç$,%
was the
u
number of eligible patients in age category a in country c who were enrolled and é$,%
was the

number of eligible patients who were not enrolled during TyVAC (for e = 2 or 3). While the
previous analysis focused only on Nepal, we used the same adjustment for the relative risk of
blood culture positivity in Bangladesh, since the reasons for having or not having blood drawn
were similar.
v
Adjustment for healthcare-seeking behavior (s$,%
)

Previous multiplier methods assume that reported healthcare-seeking for a fever is the
same as that for typhoid fever; however, this is not necessarily the case. Individuals with typhoid
fever may be more or less likely to seek healthcare. In preliminary analyses, we found no
difference in reported healthcare seeking by severity of a person’s reported fever, but other
factors may explain differential healthcare seeking among those with typhoid fever versus fever
due to other causes. To correct for this difference, we measured the probability of seeking care
for a fever adjusted for a specified typhoid risk factor to estimate the probability of seeking care
for typhoid fever (Fig S1), as described below.
For this phase of reporting, we assumed that everyone in the population either had or did
not have a typhoid risk factor, identified from the literature. For each site, we used a different
risk factor, based on studies carried out in that specific site and variables for which data was
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collected as part of STRATAA. The risk factor identified in Malawi was soap available after
defecation [19]; in Nepal, it was unshared toilets [20], and in Bangladesh it was boiled drinking
water [21].
In Malawi, the odds ratio for having typhoid fever was 2.0 (95% CI: 1.3-2.5) comparing
those who did not use soap after defecation to those who did [19]. In Nepal, the odds ratio for
having typhoid fever was 5.7 (2.3-14.4) comparing those who used a household latrine to those
who shared a community latrine [20]. In Bangladesh, the odds ratio for having typhoid was 7.6
(2.2-26.5) comparing those who did not boil drinking water to those who did [21]. Since the
overall prevalence of typhoid in the population is low, we used these odds ratio estimates from
the literature to approximate relative risks for typhoid. We used the same relative risk estimates
for all age groups. All other values for the healthcare-seeking adjustment were estimated
separately by age and site, as noted below.
We can calculate the marginal probability of seeking care for a fever among those with
typhoid fever (alternatively, the incidence of typhoid after adjusting for blood culture sensitivity
and the probability of receiving a blood culture test) as:
Ct,u
$,% = C~,$,% âℎå,$,% ê ïñ,% ó$,% + ℎ~,$,% (1 − ó$,% )ã

(6)

where pa,c is the probability of having the risk factor for typhoid fever among individuals in age
group a in site c, C~,$,% is the incidence of typhoid fever among those without the risk factor,
êïñ,% is the relative risk for typhoid among those with the risk factor (and hence êïñ,% C~,$,% is the
incidence among those with the risk factor), and h1,a,c and h0,a,c are the probability of selfreported healthcare seeking for a fever among those with and without the risk factor,
respectively.
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We can also estimate the overall adjusted incidence of typhoid as the weighted average of
the population-based typhoid fever incidence (after adjusting for blood culture sensitivity, the
probability of receiving a blood culture test, and healthcare-seeking) among those with or
without the typhoid fever risk factor:
Cadjusted,$,% = êïñ,% C~,$,% ó$,% + C~,$,%, â1 − ó$,% ã.

(7)

Combining Equations 6 and 7, we can estimate the standardized risk of seeking healthcare for
v
typhoid fever (s$,%
) as:
v
s$,%
=.

.ô,ö
6,7

adjusted,6,7

=

õú,6,7 ùûü,7 †6,7 Çõ°,6,7 âå}†6,7 ã
ùûü,7 †6,7 Çâå}†6,7 ã

.

(8)

The numbers of individuals with the risk factor and who sought healthcare for a fever were
observed directly in a sample of the population in the HUS. We assumed that the probabilities
for the occurrence of these numbers (p, h0, h1) followed an underlying beta distribution based on
the observed values (Table 1).

Model validation and sensitivity analyses
The final adjusted incidence of symptomatic typhoid fever should be less than or equal to
the seroincidence of typhoid infections captured in the serosurveillance data. In this study,
seroconversion to typhoid was defined as a > 2-fold rise in anti-Vi IgG titre between the first and
second sample drawn and an absolute titre >50 EU/ml at the second time point. The
seroincidence was estimated as the quotient of the number of people who seroconverted between
the first and second blood sample and person-time in years (the number of people sampled
multiplied by the mean time between serological samples in age group a in country c). The final
adjusted incidence should fall below the estimated seroincidence rates.
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To ensure the model was correctly formulated, we simulated data with known
probabilities and incidence rates and compared model estimates to the true values used to
generate the data. We simulated high and low values for all of the parameters estimated in the
model, starting with a “true” typhoid fever incidence of 1,000 infections per 100,000 pyo. We
began by assuming there were 1,250 cases of typhoid fever among 25,000 individuals with a
typhoid fever risk factor (Xi=1) and 750 cases among 75,000 individuals without the risk factor
(Xi=0) over two years of surveillance, such that RTF=5. We then sampled from independent
Bernoulli random variables, ¢x ~Bernoulliâℎ£É ã, §x ~Bernoulliâ• ïñÉ ã, and Üx ~Bernoulli(Ñ),
for the probability of seeking healthcare (H), the probability of having blood drawn for culturing
(B), and the probability of antibiotic usage (U). We considered high and low values for each
probability, which also varied depending on the risk-factor and typhoid fever status of individual
i for h and b, respectively:
ℎ£É ¶å = ß
•ïñÉ¶å = ß

0.1 for low scenario
0.2 for low scenario
, ℎ£É¶~ = ß
0.5 for high scenario
0.7 for high scenario

0.68 for low scenario
0.4 for low scenario
, •ïñÉ¶~ = ß
0.95 for high scenario
0.9 for high scenario
Ñ=ß

0.2 for low scenario
.
0.8 for high scenario

Among individuals with TFi=1 and antibiotic usage Ui, the probability of testing positive for
typhoid fever (i.e., test sensitivity) was ëx ~Bernoulli(´¨É ), where
´¨É ¶å = ß

0.4 for low scenario
0.6 for low scenario
, ´
=ß
.
0.5 for high scenario ¨É ¶~
0.75 for high scenario

Under both scenarios, the mean test sensitivity was ~55%. We assumed perfect test specificity,
such that si=0 if TFi=0. The incidence of fever due to other causes was assumed to be 5% per
year; we did not allow for multiple episodes of fever over the two-year period, such that
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≠other,x ~Bernoulli(0.10)
Moreover, we assumed that the incidence of fever due to any cause was
≠x = max (Ø≠x , ≠other,x ),
i.e. all individuals could have at most one episode of fever, either due to typhoid fever or another
cause. We then generated vectors for whether or not individuals who sought healthcare (HC),
had blood drawn for culturing (BC), and tested positive for typhoid fever (Y) as:
¢∞x = ≠x ∗ ¢x ,
¢∞ ∗ §x if ¢∞x = 1
§∞x = ± x
,
≤≥ otherwise
§∞ ∗ µx if §∞x = 1
¥x = ± x
.
≤≥ otherwise
We simulated four scenarios using these probabilities: 1) low probability of seeking care,
high probability of being tested, and low prior antibiotic usage; 2) low probability of seeking
care, high probability of being tested, and high antibiotic usage; 3) high probability of seeking
care, low probability of being tested, and low prior antibiotic usage; and 4) high probability of
seeking care, low probability of being tested, and high prior antibiotic usage.
To evaluate whether the final estimates were sensitive to the number of individuals
sampled in the HUS, we compared estimates for models that sampled approximately the same
number of individuals in each age category as the HUS (735) to models that sampled more
individuals (1,000 and 2,000 individuals).
We additionally compared the adjusted incidence estimates from our model to those from
a simpler approach that assumed there was no variation in blood culture sensitivity due to prior
t
antibiotic use (i.e., we used a normal distribution for s$,%
instead of a normal mixture model) and

no variation in typhoid incidence among those who were or were not tested (i.e. using the
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u
simpler approach to estimate s$,%
given in Equation 5a) and those who did or did not seek care
v
(i.e. assuming s$,%
is equal to the probability of seeking care for fever). This simpler approach is

more commonly used in multiplier methods for adjustments; however, this approach often faces
criticism since it inherently assumes that data are missing completely at random and that reported
healthcare-seeking behavior for a fever is the same as that for typhoid fever.
Model fitting
To estimate the posterior distributions of the adjusted incidence rates, we collected
100,000 posterior samples from the adjustment factors described above following a burn-in
period of 10,000 iterations prior to convergence. Convergence was assessed using the GelmanRubin diagnostic [22] for individual parameters. To ensure the model validation was done
without knowledge of the true values, one person simulated the data and another person fit the
model to the simulated data. Code for generating simulated data was written in MATLAB
version 9.3.0 [23]. All other analyses were performed using JAGS version 4.3.0 [24] in R version
3.4.0 [25]. Model code, including code for generating the simulated data, is provided at
https://github.com/mailephillips/adjusted-typhoid-incidence [26].

Results
The magnitude of the adjustment factors used to estimate the incidence of typhoid fever
varied among the three sites (Table 2). In Nepal and Bangladesh, the probability of seeking
v
v
healthcare was low (s%¶∂
=0.15, 95% credible interval (CrI): 0.09-0.22; and s%¶Å
=0.27, 95%

CrI: 0.22-0.33, for all ages) and thus contributed the most to the adjustments, while the
u
probability of receiving a blood culture test when eligible was high (s%¶∂
=0.84, 95% CrI: 0.67u
0.92; and s%¶Å
=0.96, 95% CrI: 0.92-0.98) and contributed the least to adjustments. However, in
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v
Malawi, the probability of seeking healthcare was relatively high (s%¶å
=0.71, 95% CrI: 0.64u
0.77), while the probability of receiving a blood culture test was low (s%¶å
=0.35, 95% CrI: 0.34-

0.36). Blood culture sensitivity was fairly consistent across sites, with median estimates of
s%t =0.54-0.55.
The different adjustment factors also varied by age. Blood culture sensitivity was slightly
higher in older age groups compared to younger age groups (median estimates of individuals >14
t
t
years, s$∈(∏,π)
=0.56-0.58; compared to children ≤14 years, s$∈(å,∂,Å)
=0.53-0.54). While there

was no consistent pattern in prior antibiotic use by age, the amount of blood drawn for a blood
culture test generally increased with age. As a result, blood culture sensitivity slightly increased
with age. Had we not adjusted for blood culture volume or prior antibiotic use, the estimate for
blood culture sensitivity would have been higher for all ages and countries (Fig S5, in blue).
The probability of receiving a blood culture test had different patterns across age groups
depending on the country. In Malawi, the probability of receiving a blood culture test decreased
u
u
with age (så,å
=0.40, 95% CrI: 0.38-0.41 for children <5 years versus sπ,å
=0.20, 95% CrI: 0.17u
0.23 for adults 30+ years), while in Nepal and Bangladesh, the probability increased (så,∂
=0.81,
u
u
95% CrI: 0.61-0.91 and så,Å
=0.94, 95% CrI: 0.87-0.97 for children <5 years versus sπ,∂
=0.91,
u
95% CrI: 0.71-0.98 and sπ,Å
=0.98, 95% CrI: 0.96-0.99 for adults 30+ years). If we had used a

simpler approach (not adjusting for the variation in the risk of typhoid fever among those who
were and were not tested) to adjust for the probability of receiving a blood culture test in Nepal
and Bangladesh, we would have underestimated the probabilities and thus overestimated the
contribution of this adjustment (Fig S5). In Nepal in particular, the simpler approach would have
substantially underestimated the probability of receiving a blood culture test among younger age
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groups. In Bangladesh, the unadjusted proportion of individuals receiving a blood culture test
was already close to one, so the adjusted value did not increase the estimate considerably.
The probability of seeking healthcare did not have a consistent pattern across age groups,
likely due to the different components contributing to the final estimate. Malawi overall had the
highest rates of healthcare seeking, with the lowest rates among children under 5 and the highest
rates among children 5-14 (Table 2). Nepal had the lowest rates of healthcare seeking overall,
with slightly higher rates among children under 5. Bangladesh also had low healthcare seeking
rates, with the lowest rates among adults 15+ years of age (Table 2). In Malawi and Bangladesh,
the proportion of those with the relevant typhoid risk factor did not differ by age group (Table
S2). Healthcare seeking for a fever was higher among those with the typhoid risk factor in
Malawi, but lower among those with the risk factor in Bangladesh and Nepal. When compared to
the simpler approach to estimate the probability of healthcare seeking (using the unadjusted
proportion of those who sought care for fever), the estimates were similar but slightly higher in
most age groups in Malawi but slightly lower in Nepal and Bangladesh (Fig S5).
The magnitude of the overall adjustment to estimate typhoid fever incidence
}å

t
u
v ã
ªCadjusted,$,% /Cobserved,$,% = âs$,%
s$,%
s$,%
º varied between countries and age groups. Nepal had

the highest adjustment factors in every age group, with an overall adjustment factor of 14.4 (95%
CrI: 9.3-24.9). Malawi and Bangladesh were similar, with adjustment factors of 7.7 (95% CrI:
6.0-12.4) and 7.0 (95% CrI: 5.6-9.2), respectively (Table 3). The highest adjustment factor was
for the 5-9-year age group in Nepal (19.7, 95% CrI: 9.0-54.9), while the lowest was for the 5-9and 10-14-year age groups in Bangladesh (5.8, 95% CrI: 4.1-8.6; and 5.8, 95% CrI: 3.9-8.9,
respectively).
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Most of the final adjusted incidence estimates fell within or below the range of the
estimated seroincidence of typhoid infection (Table 4). In Malawi, all of the upper bounds of the
estimates were well below the seroincidence values. However, in Nepal and Bangladesh, the
bounds of the adjusted incidence rates overlapped with the estimated seroincidence. In Nepal, the
adjusted incidence among children 5-9 years of age was higher than the seroincidence; however,
the confidence/credible intervals overlapped. Similarly, children 10-14 years of age in
Bangladesh had higher adjusted incidence rates than seroincidence (which was the lowest across
all age groups and sites), but again the confidence/credible intervals overlapped.
When we evaluated the model against simulated data, the full model was able to reliably
estimate both the “true” incidence of typhoid fever and the probabilities used to generate the
simulated data for a range of values, while the simpler approach over- or under-estimated the
true incidence in some scenarios (Figs 2 and S3). Estimates of blood culture sensitivity were
similar to the true value, but incorporated additional uncertainty compared to the simpler
approach, consistent with the different sensitivity of blood culture in those who reported prior
antibiotic use compared to those that did not (Fig S3). The probability of receiving a blood
culture test contributed most to the difference in accuracy between the two approaches. In every
scenario, the full model reliably estimated the true value, while the simpler approach
underestimated the true value (Fig S3). The adjustment for healthcare seeking in the full model
again consistently captured the true value across levels of the probability as compared to the
simpler approach, which generally had a narrower 95% CrI that did not always contain the true
value (Fig S3). As expected, in both models, the uncertainty in the probability of seeking
healthcare decreased as the sampling fraction for the hypothetical HUS increased. As a result, the
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95% CrIs in the overall incidence estimates also narrowed as the sampling fraction increased
(Fig 2).

Discussion
In order to make informed decisions regarding typhoid control and prevention, it is
important to have accurate estimates of population-based typhoid fever incidence. Unreliable
reports, inconsistent healthcare utilization, inconsistent clinical diagnoses, suboptimal diagnostic
tests, and scarcity of accurate or full data contribute to difficulties in calculating the populationbased incidence of typhoid fever. We developed a new methodology within the Bayesian setting
to estimate population-based incidence in a context where cases often go undetected and underreported. Through this approach, we were able to calculate the adjustment factors that can be
applied to estimate the “true” incidence of typhoid fever in the STRATAA surveillance sites.
These estimates suggested that the adjusted incidence of typhoid fever in Malawi, Nepal, and
Bangladesh is 7- to 14-fold higher than the reported blood-culture-confirmed numbers.
It is commonly accepted that cases of typhoid fever go unrecognized at each phase of the
reporting process, but the degree to which each step contributes to the underestimation of and
uncertainty in the population-based incidence is often not fully quantified. Each of the three
intervening processes contributed differently to the underestimation in each country and age
group. The probability of seeking healthcare was responsible for the largest portion of
underestimation in Nepal and Bangladesh, while the probability of receiving a blood culture test
was the biggest factor in Malawi. These results reflect differences in the healthcare systems and
fever surveillance processes at the different sites. In Nepal and Bangladesh, antibiotics are
widely available and individuals tend to seek care first at a pharmacy instead of a healthcare

26

facility [27]. In Nepal, a considerable proportion of people with fever neither seek healthcare nor
visit a pharmacy possibly due to lack of funds. In Malawi, healthcare seeking is high, but the
resources at healthcare facilities are limited. As a result, many people report to healthcare
facilities with a fever, receive antibiotics, but do not remain in the facility long enough to receive
an additional blood culture test due to prolonged wait times.
Other studies use different approaches to estimate the true incidence of typhoid fever. In
many cases, studies simply double the reported cases to account for blood culture sensitivity
[28]. Numerous studies make use of a simple multiplier method [29-32], which often do not
accurately reflect the uncertainty associated with the reporting process. Previous studies have not
attempted to integrate data sources to account for potential differences between the observed
healthcare seeking and testing probabilities for fever versus the corresponding unobserved
probabilities specific to typhoid fever, which our analysis suggests can impact the final
adjustment factors. Our approach can be used to estimate typhoid fever incidence in other study
populations. Moreover, some of the issues we encountered (e.g. under-detection due to poor test
sensitivity that varies depending patient characteristics, preferential testing of individuals more
likely to have the disease of interest, and potential differences in healthcare seeking for those
who have the syndrome versus disease of interest) are common to other diseases as well.
By utilizing a Bayesian approach, we were able to measure the contribution to
underestimation at each phase of the reporting process while also properly quantifying the
uncertainty for each of our estimates. When comparing our model to simulated data, we showed
that having more data available (due to higher probabilities of seeking care and receiving a blood
culture test) reduced uncertainty in the estimates. Furthermore, we showed that if more people
had been sampled in the HUS, uncertainty would also have been reduced.
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Our analysis and approach had some limitations. We assumed that healthcare-seeking
behavior for fever in households without children is the same as households with children,
because the HUS only sampled households with children. Less than a third of households did not
have children and were not included in this survey across sites. Studies suggest that households
with children are more likely to seek healthcare [33], which means that if our estimates are
biased, the adjusted incidence estimates are likely conservative. We also were not able to
differentiate between febrile illnesses at different parts of the reporting process. We addressed
this issue by adjusting for possible differences in healthcare seeking among those with typhoid
fever compared to other febrile etiologies using weighted averages based on known risk factors
for typhoid fever, but other factors may also lead to differences in healthcare seeking for fever
versus for typhoid fever. By comparing our adjusted incidence estimates to estimates of
seroincidence, we are able to provide some assurance that the adjusted incidence is within the
range of plausible values. However, methods and immunological markers for estimating the
seroincidence of typhoid fever are not well established, and the cut-off we used (a ³2-fold and
absolute value of ³50 EU/mL in anti-Vi IgG) may not be a reliable indicator of acute typhoid
infection across all individuals and immunological backgrounds. Another limitation of the
approach is that it can very labor-intensive and time-consuming to collect the necessary data.
Calculation of incidence based on data from passive surveillance of blood-cultureconfirmed typhoid fever results in considerable underestimation of the true incidence of typhoid
fever in the population. Our model provides an approach for estimating typhoid fever incidence
while accounting for different sources of information from the reporting process. Typhoid fever
remains a major cause of morbidity and mortality in developing countries, so control and
prevention are needed. To effectively prioritize, implement and evaluate interventions, estimates
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of the number of cases should accurately reflect the uncertainty in the reporting process. This
analysis provides a platform that can be updated with new or additional data as they become
available and can be adapted to other contexts. This model framework could also be used to
adjust for underreporting in other diseases.
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Figures and tables.
Figure 1. Flowchart of typhoid disease and observation process, and adjustment method to estimate
the true number of cases. The pyramid (left) illustrates the different steps in the observation process for
reporting typhoid incidence, with details on how parameters are estimated at each step. The flowchart
(right) illustrates the corresponding Bayesian framework for each step of the observation process and
which datasets and variables are used for adjustment. Adjustments for blood culture sensitivity are shown
in purple, the probability of receiving a blood culture test is shown in red, and the probability of seeking
healthcare is shown in blue. Variable definitions: C, typhoid incidence rate; s, a probability estimated in
the model; S, sensitivity of blood culture; B, blood culture collection; H, healthcare seeking; a, age
category; c, site. Abbreviations: BC, blood culture.
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Figure 2. Estimated typhoid incidence based on simulated data: Full model vs. simplified
approach. The typhoid incidence per 100,000 person-years of observation was estimated from
simulated data based on a true incidence of 1,000 typhoid infections per 100,000 person-years
(dashed horizontal black line). Data were simulated for low and high probabilities of seeking
healthcare, receiving a blood culture diagnostic test, and antibiotic use. Scenarios were as
follows: 1) low probability of seeking care, high probability of being tested, and low prior
antibiotic usage; 2) low probability of seeking care, high probability of being tested, and high
prior antibiotic usage; 3) high probability of seeking care, high probability of being tested, and
low prior antibiotic usage; and 4) high probability of seeking care, high probability of being
tested, and high prior antibiotic usage. Each simulation was performed sampling 735; 1,000; and
2,000 individuals from the population for the hypothetical healthcare utilization survey.
Estimated “true” values are shown for models that did (red) and did not (blue) account for
variation in blood culture sensitivity and variation in typhoid incidence among those who did or
did not seek care and were or were not tested.
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Table 1. Model input parameters. Parameters used in the incidence adjustment model are
described below, with their corresponding uncertainty distributions and data sources. The
symbols appear in the table in the order that they appear in the text, organized by the steps in the
reporting process (Main model, Adjustment for blood culture sensitivity, Adjustment for the
probability of receiving a blood culture test, and Adjustment for healthcare-seeking). All
parameters are both age- and country-specific, except for p and RTF, for which only a countrylevel estimate was available. Note that some of parameters in the adjustment for the probability
of receiving a blood culture test are specific to only some countries (s u , çu , éu , ì u , and êt ).
Symbol

Description

Main model (Equations 1-2)
Observed incidence rate of typhoid
Cobserved
fever among febrile individuals who
sought care
Number of blood-culture-positive
"observed
individuals
Person-years of observation over the
person_time
two year study period

Uncertainty distribution
"Ωæoqøyql ~Poisson -

C<D;9:E9F
B
person_time

See rest of table.

Observed directly

STRATAA PS

Observed directly

STRATAA
Demographic
Census
See rest of table.

The incidence rate of typhoid fever
C<D;9:E9F = C$lmnopql ∗ s t ∗ s u ∗ s v
after adjusting for all three phases of
reporting (blood culture sensitivity,
the probability of receiving a blood
culture test, and the probability of
seeking healthcare)
Adjustment for blood culture sensitivity (Equations 3-4)
Blood culture sensitivity
st
s t |Ü~≤(án , àn )
An indicator variable for whether or
Ü
Ü ~Bernoulli(ä)
not an individual took antibiotics in
the past two weeks
The proportion of individuals who
Observed directly
ä
took antibiotics in the past two weeks
The mean blood culture sensitivity
Calculated using observed data with adjustment
án
for those who did and did not take
from Antillon et al
antibiotics the past two weeks.
àn
The standard deviation of blood
Calculated using observed data with adjustment
culture sensitivity for those who did
from Antillon et al
and did not take antibiotics the past
two weeks.
Adjustment for the probability of receiving a blood culture test (Equations 5a-b)
Malawi: Probability of receiving a
su
s u ~§|¿L(ç u , éu )
blood culture test
(1 − ì)
Nepal and Bangladesh: Probability
su = 1 +
of receiving a blood culture test after
êt
adjusting for variation in risk of
typhoid fever among those who are
and are not tested
Malawi: number of people who
Observed directly
çu
presented to a STRATAA facility
with fever, were enrolled, and
received a blood culture test
Nepal and Bangladesh: number of
Observed directly
people who presented to a TyVAC
Cadjusted

Data Source

See rest of table.
See rest of table.
STRATAA PS
STRATAA PS,
Antillon et al
[11]
STRATAA PS,
Antillon et al
[11]
See rest of table.
See rest of table.

STRATAA PS

TyVAC [18]
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facility with fever, were enrolled, and
received a blood culture test
Malawi: number of people who
Observed directly
éu
presented to a STRATAA facility
with fever but were not enrolled
Nepal and Bangladesh: number of
Observed directly
people who presented to a TyVAC
facility with fever but were not
enrolled
Nepal and Bangladesh: probability
ì
ì~§|¿L(ç u , éu )
of receiving a blood culture test prior
to adjusting for the relative risk of
blood culture positivity
Nepal and Bangladesh: Relative risk
êt
log(êt ) ~≤(¡íç(1.87),0.37)
of blood culture positivity among
those who received a blood culture
test compared to those who did not
Adjustment for the probability of healthcare seeking (Equations 6-9)
C t,u
Probability of seeking healthcare
sv
v
s =

Ct,u

C~

The incidence rate of typhoid fever
after adjusting for blood culture
sensitivity and the probability of
receiving a blood culture test
Incidence of typhoid fever among
those without the risk factor

êïñ

Relative risk for typhoid fever among
those with the risk factor compared
to those without it

ℎ~

Probability of self-reported
healthcare seeking for a fever among
those without the risk factor
Number of individuals who sought
care out of those without the risk
factor
Number of individuals who did not
seek care out of those without the
risk factor
Probability of self-reported
healthcare seeking for a fever among
those with the risk factor
Number of individuals who sought
care out of those with the risk factor
Number of individuals who did not
seek care out of those with the risk
factor
Probability of having the selfreported risk factor. In Malawi this
was soap available after defecation,
in Nepal this was unshared toilets,
and in Bangladesh this was boiled
drinking water.

¡õ°
√õ°
ℎå
¡õú
√õú
p

Ct,u =

STRATAA PS
TyVAC [18]

See rest of table.

[9]

See rest of table.

C$lmnopql

Cobserved
ë

See rest of table.

§

s ∗s

Ct,u
âℎå êïñ ó + ℎ~ (1 − ó)ã
log(êïñ ) ~≤(áïñ , àïñ )

C~ =

Malawi: mean á ïñ = log(0.5);
standard deviation àïñ = 0.34
Nepal: á ïñ = log(5.71); àïñ = 0.47
Bangladesh: á ïñ = log(7.6); àïñ = 0.64

ℎ~ ~§|¿Lâ¡õ° , √õ° ã

See rest of table.
[19-21]

See rest of table.

Observed directly

STRATAA
HUS

Observed directly

STRATAA
HUS

ëå ~§|¿L(¡ tú , √ tú )
Observed directly
Observed directly
ó~§|¿Lâ¡† , √† ã

See rest of table.
STRATAA
HUS
STRATAA
HUS
See rest of table.

33

¡†

Number of individuals with the
identified typhoid fever risk factor
Number of individuals without the
√†
identified typhoid fever risk factor
PS = Passive Surveillance
HUS = Healthcare Utilisation Survey

Observed directly

STRATAA
HUS
STRATAA
HUS

Observed directly

Table 2. Posterior probability estimates for each adjustment factor by age and site. Each
estimate (posterior mean) is shown with its 95% credible interval for the sensitivity of the blood
t
culture (BC) given that healthcare (HC) was sought and a blood culture was taken (s$,%
), the
u
probability of receiving a blood culture test given that healthcare was sought (s$,%
), and the
v
probability of seeking healthcare (s$,%
). Estimated adjustment factors are shown by age category
(a) and country (c).
Probability

Sensitivity of
BC, given HC
sought, BC
t
taken (s$,%
)
Probability BC
was drawn,
given HC
u
sought (s$,%
)
Probability of
seeking HC
v
(s$,%
)

Country
(c)

Age category (a), in years
<5

5-9

10-14

15-29

30+

all

Malawi

0.53 (0.48-0.57)

0.53 (0.51-0.55)

0.53 (0.50-0.56)

0.58 (0.55-0.62)

0.58 (0.54-0.62)

0.54 (0.35-0.60)

Nepal

0.54 (0.51-0.57)

0.54 (0.51-0.57)

0.54 (0.51-0.58)

0.56 (0.54-0.58)

0.56 (0.55-0.57)

0.55 (0.51-0.58)

Bangladesh

0.53 (0.52-0.53)

0.53 (0.53-0.53)

0.53 (0.53-0.53)

0.56 (0.54-0.58)

0.56 (0.56-0.56)

0.54 (0.51-0.57)

Malawi

0.40 (0.38-0.41)

0.38 (0.36-0.41)

0.33 (0.29-0.36)

0.21 (0.19-0.24)

0.20 (0.17-0.23)

0.35 (0.34-0.36)

Nepal

0.81 (0.61-0.91)

0.87 (0.72-0.94)

0.87 (0.73-0.94)

0.91 (0.71-0.98)

0.91 (0.71-0.98)

0.84 (0.67-0.92)

Bangladesh

0.94 (0.87-0.97)

0.97 (0.94-0.99)

0.97 (0.94-0.99)

0.98 (0.96-0.99)

0.98 (0.96-0.99)

0.96 (0.92-0.98)

Malawi

0.62 (0.52-0.72)

0.83 (0.74-0.90)

0.83 (0.74-0.90)

0.71 (0.60-0.81)

0.71 (0.60-0.81)

0.71 (0.64-0.77)

Nepal

0.21 (0.11-0.34)

0.11 (0.04-0.22)

0.11 (0.04-0.22)

0.13 (0.05-0.25)

0.13 (0.05-0.25)

0.15 (0.09-0.22)

Bangladesh

0.32 (0.21-0.45)

0.34 (0.24-0.45)

0.33 (0.24-0.45)

0.19 (0.11-0.27)

0.19 (0.11-0.27)

0.27 (0.22-0.33)

Table 3. Estimated adjustment factors from final models. The ratio of the median estimate
(95% credible interval) of adjusted-to-observed incidence rates is shown for each country and
age category.
Age (years)

Malawi

Nepal

Bangladesh

0-4

7.6 (4.8-11.6)

10.7 (4.3-26.8)

6.3 (4.2-10.2)

5-9

5.9 (4.1-8.3)

19.7 (9.0-54.9)

5.8 (4.1-8.6)

10-14

6.9 (4.3-10.4)

19.6 (8.6-55.2)

5.8 (3.9-8.9)

15-29

11.4 (6.9-18.0)

15.8 (7.4-42.4)

9.8 (6.2-16.7)

30+

12.0 (6.0-21.7)

15.0 (4.6-48.8)

9.7 (5.5-17.9)

All ages

7.7 (6.0-12.4)

14.4 (9.3-24.9)

7.0 (5.6-9.2)
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Table 4. Adjusted typhoid incidence estimates compared to seroincidence. The final adjusted
typhoid incidence estimates from the models are shown with 95% credible intervals, as well as
the seroincidence estimates with their 95% confidence intervals, by age and site.
Age

Malawi
Crude
rates

Adjusted
rates

0-4
years

83
(53-124)

5-9
years

146
(103-201)

10-14
years

88
(56-132)

15-29
years

32
(20-48)

30+
years

21
(10-37)

All
ages

58
(48-70)

Nepal
Seroincidence

Crude
rates

Adjusted rates

632
(398-965)

2,868
(1,153-5,911)

72
(33-136)

861
(599-1,203)

1,205
(146-4,352)

341
(250-455)

3,061
(631-8,946)

191
(128-275)

3,774
(1,384-8,213)

92
(71-119)

2,076
(762-4,518)

6
(2-13)

2,505
(1,605-3,728)

74
(62-87)

602
(377-915)
361
(219-567)
248
(124-447)
444
(347-717)

Bangladesh
Seroincidence

Crude
rates

Adjusted
rates

Seroincidence

764
(307-1,921)

7,813
(2,537-18,232)

417
(337-511)

2,625
(1,764-4,244)

3,401
(1,904-5,610)

6,713
(3,085-18,730)

5,217
(1,915-11,356)

554
(456-666)

3,228
(2,276-4,757)

3,435
(1,571-6,521)

8,910
(4,075-16,916)

268
(203-348)

10,169
(5,255-17,764)

98
(76-124)

7,322
(5,100-10,183)

29 (19-42)

7,631
(5,914-9,691)

161
(145-179)

3,750
(1,653-10,559)
1,457
(684-3,918)
92
(29,301)
1,062
(683-1,839)

599
(15-3,336)

1,564
(1,050-2,384)
956
(603-1,635)
279
(157-514)
1,135
(898-1,480)

5,310
(2,744-9,275)
2,988
(1,672-4,928)
3,256
(2,432-4,270)
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Supplementary figures and tables.
Fig S1. Typhoid fever pyramid and febrile pyramid. The typhoid pyramid (green) is nested within the
fever pyramid (grey). Some fraction of symptomatic typhoid fever cases and febrile cases seek care
(shaded regions, TF and F, respectively). The average probability of seeking care for fever is measured
(h; dashed purple line), but this may vary for individuals with typhoid fever versus fever due to other
causes. Within the typhoid fever and fever pyramids, individuals may (X=1) or may not (X=0) have a risk
factor for typhoid fever; the probability of seeking healthcare varies for those with or without the risk
factor, and the risk factor is more prevalent among those with typhoid fever. One can observe whether a
person has a fever, but not whether they have typhoid fever.
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Fig S2. Plots of prior antibiotic use, blood culture volume, and blood culture sensitivity. The average
proportion of those with antibiotic use in the past two weeks (A) and the average blood culture volume
(B) by country and age group is shown in plots A and B, respectively. In plot C, the distribution of overall
(across all age groups) blood culture sensitivity after adjusting for prior antibiotic use and blood culture
volume drawn is shown.
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Fig S3. Estimated probabilities from simulated data. Data for the estimated typhoid incidence were
simulated for low, medium and high probabilities of seeking healthcare (s v ), receiving a blood culture
diagnostic test (s u ), and blood culture sensitivity (s t ) (row panels); and each simulation was performed
sampling 735; 1,000; and 2,000 individuals (column panels) from the population to be “observed” from
the healthcare utilization portion. The true values used for simulation are shown in dashed horizontal
black lines. The value for blood culture sensitivity without adjusting for prior antibiotic use is shown in
dotted gray lines. Estimated values are shown for models that did (red) and did not (blue) account for
variation in blood culture sensitivity and variation in typhoid incidence among those who did or did not
seek care and were or were not tested.
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Fig S4. Estimated STRATAA typhoid incidence with full model versus a simplified approach. The
estimated typhoid incidence per 100,000 person-years of observation is shown for models that did (red)
and did not (blue) take into account variation in blood culture sensitivity and variation in typhoid
incidence among those who did or did not seek care and were or were not tested for each age group and
country. Note that the upper bounds on children 5-9 and 10-14 in Nepal are not shown.
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Fig S5. Estimated STRATAA probabilities from full model versus a simplified approach. The
estimated probabilities of seeking healthcare (s v receiving a blood culture diagnostic test (s u ), and
blood culture sensitivity (s t ) are shown for models that did (red) and did not (blue) take into account
variation in blood culture sensitivity and variation in typhoid incidence among those who did or did not
seek care and were or were not tested for each age group and country.
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Table S1. Contingency table of an individual’s sensitivity and specificity for blood culture
diagnostic test. In this study, we assumed that all individuals who tested positive for typhoid fever were
true cases of typhoid. Among those who tested negative, an individual i’s probability of being a true case
of typhoid (wi,v(i),u(i)) depended on the volume of blood drawn v and his or her reported prior antibiotic use
u.

Typhoid

No typhoid

BC+

wi,v(i),u(i)

0

BC-

1 - wi,v(i),u(i)

1

Table S2. Prevalence of typhoid fever risk factor, rates of reported febrile illness, and probability of
healthcare seeking from the Healthcare Utilization Surveys. The prevalence (prev.) and numerator
used to calculate the prevalence (N) of each factor used to estimate the probability of healthcare seeking
by age and country are show in the table below. Values are shown for the probability of having the risk
factor for typhoid fever (p), and the proportion of those who sought care at a STRATAA partner health
facility among those with (h1) and without (h0) the risk factor are shown.
p

Nepal

Bangladesh

Malawi
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h0

RTF

Age

prev.

N

prev.

N

prev.
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5
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0.10

3
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5

15+
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3

0.20

7
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0.29
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0.29
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Mean (95% CI)
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Abstract
Background. Several prolonged typhoid fever epidemics have been reported since 2010
throughout eastern and southern Africa, thought to be caused by the spread of multidrug resistant
Salmonella Typhi. The World Health Organization recommends the use of typhoid conjugate
vaccines (TCVs) in outbreak settings; however, current data are limited on how and when TCVs
might be introduced in an outbreak setting. While vaccination can be an effective public health
intervention, if resources are implemented late or focused inappropriately, fewer infections will
be averted.
Methodology. We modified a dynamic transmission model of a typhoid fever outbreak in Malawi
to evaluate preventative and reactive vaccination strategies. We then conducted a costeffectiveness analysis using the net-benefits framework to compare no vaccination to routine
vaccination at 9 months of age with and without a catch-up campaign up to 15 years old. We
considered a 10-year time horizon and compared reactive vaccination strategies to preventative
strategies with randomized outbreak timing over the 10-year period. We also compared this
analysis to the cost-effectiveness of TCV introduction given the pre-outbreak typhoid incidence
(with no outbreak on the horizon) and one with post-outbreak incidence (10 years after the
outbreak). We examined variations in outbreak definitions, delays in implementation of reactive
vaccination, and the timing of preventive vaccination relative to the outbreak.
Results. We estimated that vaccination would prevent 15-60% of disability-adjusted life-years
(DALYs) in the outbreak scenarios. In the cost-effectiveness analyses, some form of routine
vaccination with a catch-up campaign was preferred over no vaccination for WTP values of at
least $110 per DALY averted. Reactive vaccination was the preferred strategy for WTP values of
$110-430 per DALY averted, but became less optimal as delays in TCV deployment increased.
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For WTP values >$430, introduction of preventative routine TCV immunization with a catch-up
campaign was the preferred strategy assuming the outbreak occurred within 10 years. However,
when no outbreak occurred and assuming the pre-outbreak incidence, no vaccination was the
optimal strategy for WTP values <$980. For the current post-outbreak incidence, routine
vaccination with a catch-up campaign is preferred for WTP values of $280 and above, consistent
with previous analyses for Malawi.
Conclusions. Countries where outbreaks of typhoid fever due to introduction of antimicrobial
resistant strains are likely to occur should consider TCV introduction. Reactive vaccination can
be a cost-effective strategy, but only if delays in vaccine deployment are minimal; otherwise,
introduction of preventive routine immunization with a catch-up campaign should be considered.
Keywords: typhoid fever; reactive vaccination; preventive vaccination; typhoid conjugate
vaccines; economic evaluation
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Introduction
Typhoid fever is a major source of morbidity and mortality in developing countries.
Approximately 12-21 million infections and 119,000-269,000 deaths are attributed to typhoid
fever each year [1-3], accounting for 2-23 million disability-adjusted life years (DALYs) [4].
Since 2010, there have been several prolonged typhoid outbreaks in eastern and southern Africa,
which have imposed considerable costs to the populations impacted [5-8]. These outbreaks are
thought to be caused by antimicrobial-resistant (AMR) strains and, as a result, more outbreaks
are likely [5, 8, 9].
Typhoid conjugate vaccines (TCVs) are an effective means of typhoid prevention and
control. They have been approved and recommended by the World Health Organization (WHO)
and Gavi, the Vaccine Alliance, has pledged support for introduction of TCVs in typhoidendemic countries. However, research regarding the vaccines’ long-term efficacy and use in
outbreak settings is lacking. Current data is limited on how and when TCVs should be
introduced, and vaccine stockpiles do not yet exist [10, 11].
Reactive vaccination has become an important prevention measure for outbreaks of
diseases such as cholera, influenza, and Ebola [12-19]. While reactive vaccination can be
effective, if implemented late or focused inappropriately, the number of cases averted will be
small [12, 16, 17]. While TCVs are recommended by the WHO for use in outbreak settings, there
is no clear way of defining an outbreak of typhoid fever. Furthermore, policy makers are faced
with inevitable delays in securing TCVs for outbreak response and applying for Gavi support to
implement vaccination. Early introduction of TCVs may provide an effective means of
preventing prolonged outbreaks of typhoid fever associated with introduction of AMR strains,
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but the cost-effectiveness of preventative versus reactive vaccination strategies over different
time horizons needs to be evaluated.
Here, we use a dynamic transmission model fitted to data from a typhoid fever outbreak
in Blantyre, Malawi to investigate the health impact and costs associated with alternative vaccine
delivery strategies to inform the use of TCVs in an outbreak setting. We explored a range of
preventative and reactive vaccination scenarios to allow for uncertainty in outbreak timing,
outbreak identification, and delays in vaccine introduction.

Methods
Transmission model and outbreak threshold
We developed an age-specific stochastic model to simulate typhoid fever transmission
dynamics in Blantyre, Malawi from January 1995 to December 2031. Details of the model are
provided in the Appendix. The model was parameterized based on the equivalent deterministic
model fitted to routine blood-culture surveillance data from Queen Elizabeth Central Hospital
(QECH) in Blantyre from January 1996 to February 2015 [9], which captures the multi-year
outbreak of typhoid fever that occurred in Blantyre between 2011-2015. We assumed the
outbreak was caused by an increase in the duration of infectiousness of Salmonella Typhi
associated with the emergence of the multidrug-resistant H58 haplotype [9, 20]. We validated the
model by comparing to blood-culture surveillance data from QECH for March 2015-December
2016. To scale the number of blood-culture-confirmed cases at QECH to the population-based
incidence of typhoid fever in Blantyre, we used data from the recently completed Strategic
Typhoid Alliance across Africa and Asia (STRATAA) cohort study (S1.1.4 Text) [21].
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The stochastic model incorporated uncertainty in the transmission dynamics using a
Poisson process for each transition between states and a binomial observation process for the
(under)reporting of cases over the duration of an individual’s infection. To simulate the impact
of vaccination, we incorporated further uncertainty in vaccine efficacy at time 0, the waning of
vaccine-induced immunity, and vaccine coverage during the catch-up campaign by sampling
from the associated uncertainty distribution for each stochastic iteration (S1 Text). The dynamic
model parameters, their estimates and uncertainty distributions, and sources are listed in Table 1.
For each intervention strategy, we simulated the outbreak 1,000 times.
Table 1. Dynamic model input parameters
Characteristic
Demographic parameters
Birth rate (B)
Mortality rate (includes
migration) (ƒ)
Disease parameters
Duration of
infectiousness (1⁄≈ )
Seasonal offset parameter
(timing of seasonal peak)
(s)
Fraction infected who
become chronic carriers
(«)
Disease-induced
mortality (»)
Duration of temporary
full immunity to infection
(1⁄…)
Basic reproductive
number (R0)
Amplitude of seasonal
forcing (q)
Relative infectiousness of
chronic carriers (r)
Outbreak parameters
Beginning week of
increase in duration of
infectiousness (t1)
End week of increase in
duration of infectiousness
(t2)

Value

Source

31.3-55.0 live births per 1,000 per
year
7.7-27.8 deaths per 1,000 per year

[9]

4 weeks

[9, 22]

4.9 weeks

[9]

0.003-0.101 depending on age

[23]

0.001

[9, 24]

104 weeks

[9, 22]

3.29

Refit parameters from modified
Pitzer et al model [9]
Refit parameters from modified
Pitzer et al model [9]
Refit parameters from modified
Pitzer et al model [9]

0.35
0.09

[9]

April 10, 2011

Refit parameters from modified
Pitzer et al model [9]

November 23, 2014

Refit parameters from modified
Pitzer et al model [9]
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Magnitude of increase in
duration of infetiousness
(m)
Reporting process
Underreporting
adjustment factor (a)
Vaccine-related parameters
Age groups vaccinated
Routine
Catch-up
campaign
Initial efficacy of TCV
( ~)
Waning of vaccineinduced immunity
(1/…y ) (years)
Vaccine coverage
Routine (Ãù )
Catch-up
campaign (ÃÕ )

3.1954

Refit parameters from modified
Pitzer et al model [9]

7.7 (95% CrI: 6.0-12.4)

[21]
Based on WHO recommendation

9 months
9 months to <15 years
0.89 (95% CrI: 0.78-0.98)
18.9 (95% CrI: 8.4-83.3)

Increases from 0.85 to 0.95 over
ten years
Uniform(0.6,0.9)

Re-analysis based on Malawi
TCV efficacy trial data from [25]
and a previous estimate from [26]
Re-analysis based on Malawi
TCV efficacy trial data from [25]
and a previous estimate from [26]
Gavi demand forecasts under
assumption of unconstrained
supply, and commonly assumed
coverage during a catch-up
campaign during an outbreak

Since there is no globally-defined threshold for a typhoid fever outbreak, we explored
different definitions of the epidemic threshold. For the purposes of our analysis and to facilitate
outbreak identification from passive hospital-based surveillance data across different populations
and contexts, we specified the epidemic threshold in terms of the number of standard deviations
(SD) above the mean monthly reported typhoid fever cases for the baseline period of 2000-2010.
We examined thresholds ranging from 6-16 SD above the mean, and defined the “true” start of
the outbreak as April 10, 2011, identified previously during model-fitting. Setting a threshold too
low would trigger too many false positive identifications of the outbreak, while setting the
threshold too high could fail to identify a true outbreak in a timely manner. To address this issue,
we compared the sensitivity and specificity of each definition of outbreak definition. We defined
the sensitivity of each threshold as the percentage of simulations in which the outbreak was
identified within 18 months of April 2011, while the specificity was defined as the percentage of
simulations in which the outbreak threshold was not exceeded prior to April 2011. Once the
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outbreak threshold was crossed, all subsequent months were considered to be part of the
outbreak. For our primary analysis, we used the outbreak identification threshold that yielded the
highest sum of sensitivity and specificity.
Vaccination scenarios
We compared scenarios in which TCV introduction occurs before the outbreak
(preventive, assuming an outbreak is likely) versus after the outbreak starts (reactive). We
modeled the impact of routine vaccination with TCV at 9 months old with or without a catch-up
campaign up to 15 years of age. We assumed an initial vaccine efficacy of approximately 89%
(95% credible interval (CrI): 78-98%) and an average duration of protection of 18.9 years (95%
CrI: 8.40-83.3 years); we updated prior distributions for these parameters by fitting to data from
a phase 3, double-blind, randomized active-controlled clinical trial of single-dose Typbar TCV in
Blantyre, Malawi [25, 26] (S1.1.2.2 Text). Routine vaccination coverage was assumed to
increase from 85% to 95% over the first ten years of vaccination and then remain at 95% [26].
For catch-up campaign coverage, we assumed that the proportion vaccinated varied uniformly
from 0.6-0.9.
Since it is typically not known when an outbreak will occur, we randomized the timing of
the start of the outbreak over a 10-year time horizon. The randomized timing followed a discrete
uniform distribution over Years 0-10. We assumed only a single outbreak occurs. We simulated
four alternative vaccination strategies: no vaccination, preventive routine TCV introduction at 9
months of age (in Year 0), preventive routine vaccination plus a one-time catch-up to age 15, and
reactive routine vaccination plus a catch-up campaign once the outbreak was identified (Table
2[26]).
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Table 2. Strategy comparisons for deploying typhoid conjugate vaccines to prevent or
respond to an outbreak. Each of the scenarios examined compares four strategies: a base case
(no vaccination), a preventive strategy with routine vaccination at 9 months of age (“routine”), a
preventive strategy with routine vaccination and a catch-up campaign up to 15 years of age
(“routine + catch-up”), and a reactive vaccination strategy with routine vaccination and a catchup campaign.
Strategy type
Vaccination strategies
Base
no vaccination
Preventive
routine at 9 months
Preventive
routine + catch-up to age 15
Reactive
routine + catch-up to age 15
We compared our results to two scenarios in which an outbreak does not occur over the
10-year time horizon. These analyses are more comparable to previous cost-effectiveness
analyses, and allow us to examine whether it would be beneficial to introduce TCV in an
endemic setting when typhoid fever incidence is lower (pre-outbreak incidence) or higher (postoutbreak incidence). For the pre-outbreak scenario, we assume typhoid fever incidence is
comparable to that estimated for Blantyre for 1995-2005, whereas for the post-outbreak scenario,
we assume it is comparable to that estimated for Blantyre for 2021-2031.
Economic evaluation
We used the stochastic transmission model to simulate the number of typhoid fever cases
and vaccine doses administered under each strategy, then used the model output to calculate the
disability-adjusted life-years (DALYs) due to typhoid, costs of treatment, and costs of vaccine
delivery. Costs of vaccination programs are generally incurred by the government and donors in
Malawi; hence, we considered the healthcare-payer perspective and only accounted for direct
treatment and vaccination costs accrued by the healthcare system. Costs were converted to 2020
USD, to convert to the most recent full year. We conducted the analysis in accordance with
WHO guidelines and recommendations of the Bill and Melinda Gates Foundation’s reference
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case [27-30]. All costs and effects were discounted at a rate of 3% per year. We followed the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) [27] (S2.2.3).
Consistent with WHO guidelines and recommendations of the Bill and Melinda Gates
Foundation’s reference case [27-30], we evaluated the effectiveness of each strategy in terms of
DALYs. DALYs represent the total years of life lost due to death (YLL) and lived with disability
(YLD) due to the disease: Œ≥œ¥ = ¥œœ + ¥œŒ [31]. To estimate the YLLs due to typhoid fever,
we multiplied the number of cases of typhoid fever by the probability of hospitalization and the
probability of death for inpatients (S1.2.4 Text) [32, 33]. We then divided by the proportion of
deaths occurring in hospital, which we assumed was uniformly distributed between 0.25-1 [26],
to obtain an estimate of the total number of deaths, and subtracted the average age of death from
typhoid fever from Malawi’s life expectancy [34]. The YLDs were calculated based on the
number of cases, duration of illness, and disability weights (S1.2.2 Text).
To estimate the treatment costs for typhoid fever, we assumed 71% (95% CrI: 64-77%)
of typhoid fever cases would seek medical care and 4% (95% CrI: 1-11%) would be
hospitalized; we updated prior distributions for these parameters based on data from the
STRATAA cohort study [21] (Table 3; S1.2.3-1.2.4 Texts). The number of outpatient cases was
calculated by subtracting the number of hospitalized cases from the number of individuals
seeking care. We assumed cases not seeking medical care would not incur treatment costs. As
this cost-effectiveness analysis was carried out from the healthcare provider perspective, we
included only direct medical costs. We estimated treatment costs for each individual with
typhoid fever using WHO-CHOICE data [35].
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Table 3. Input parameters for cost-effectiveness analysis.
Characteristic
Median value (95% CrI)
Typhoid incidence and age distribution
Annual number of
26.1 (14.0-45.7) before outbreak;
symptomatic typhoid
Up to 916 (823-1,543) during
fever cases per 100,000
outbreak;
people (without
224 (169-368) after outbreak
vaccination)
Average age of patients
15.9 (13.8-19.3)
with typhoid infection
(without vaccination)
(years)
Typhoid mortality
Probability of death if
0.09 (0.02-0.28)
patients are admitted to
hospital for typhoid
infection
Proportion of deaths from 0.38 (0.02-0.73)
typhoid infection
occurring in patients not
hospitalized
Average age at death
15.9 (13.8-19.3)
from typhoid infection
Antimicrobial resistance
Proportion of patients
with typhoid infection
with an AMR strain
Burden of AMR cases
relative to antimicrobialsensitive cases
Healthcare use
Probability of infected
patients seeking
healthcare
Probability that infected
patients are admitted to
hospital
Length of stay in hospital
(days)
Number of visits to
medical doctors by
inpatients and outpatients
Treatment costs
Cost of inpatient
treatment
Cost out outpatient
treatment

Source
Based on output from
transmission dynamic model fit to
incidence of typhoid
Based on output from
transmission dynamic model fit to
incidence of typhoid

[33, 36] [37]

Assuming that on average about
one of three deaths occur outside
the hospital setting from [26]
Assuming age distribution of
deaths is the same as the age
distribution of patients with
typhoid

0.001 (0.00-0.63) before
outbreak;
Up to 0.96 (0.86-1.00) during
outbreak;
0.65 (0.31-0.98) after outbreak
2 (1-3)

[20, 37]

0.71 (0.64-0.77)

[21]

0.04 (0.01-0.11)

[38] [37]

6 (3-9)

[26]

1

[26]

$34.00 ($9.00-107.00)

[26]

$1.30 ($0.30-3.20)

[26]

[26]
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Cost of treatment for a
patient not seeking
professional medical care
Unit cost per bed-day for
inpatients and unit cost
per outpatient visit
Relative adjustment
factor for overestimation
of unit cost per outpatient
visit
Cost of drugs per
inpatient
Costs of laboratory tests
per inpatient
Cost of drugs per
outpatient
Costs of laboratory tests
per outpatient
Vaccine-related costs
Vaccine procurement
Injection and safety
equipment
Routine vaccine delivery
cost per dose
Number of years during
which start-up costs of
vaccine delivery program
are incurred
Routine vaccine delivery
costs (%)
Campaign vaccine
delivery cost per dose
Disability-adjusted life-years
Disability-weights from 0
(perfect health) to 1
(death)
Relationship between
disability weights for
mild, moderate, and
severe illness and
outcomes on healthcare
use
Duration of illness in
inpatients and outpatients
(days)
Relative duration of
illness for patients not
seeking medical care (vs
inpatients and
outpatients)
Life expectancy

$0.81 (0.039-2.28)

[26]

$3.36 (0.81-9.02)
$0.85 (0.14-2.66)

[26]

0.63 (0.25-1.00)

[26]

$8.30 (0.30-50.8)

[26]

$0.20 (0.00-60.00)

[26]

$0.81 (0.039-2.28)

[26]

$0

[26]

See Bilcke et al for details
$0.23 (0.21-0.24)

[26]
[26]

$1.61 (0.36-4.23)

[26]

2 (1-3)

[26]

64% (48-78)

[26]

$0.040 (0.23-0.62)

[26]

Severe illness, 0.21 (-.14-0.29);
moderate illness, 0.052 (0.0310.079); mild illness, 0.005 (0.0020.011)
See description in supplement

[39]

16 (12-20)

[26]

0.5 (0.02-0.98)

[26]

62.7

[34]

[39]
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Antimicrobial resistance is likely to affect the burden and costs associated with typhoid
fever. In the absence of sufficient data to parameterize the relative burden and costs of AMR
typhoid fever, we assumed the case fatality risk, years of life lived with disability, and treatment
costs were twice as high on average (uniformly 1-3 times higher) for AMR cases. Since recent
outbreaks are thought to be caused by new AMR strains of typhoid, we allowed the proportion of
AMR typhoid cases to vary with time based on data from a longitudinal study in Blantyre (S1.2.5
Text) [20].
For routine and campaign doses, we assumed a vaccine procurement cost of US$1.50 per
dose and US$0.23 (95% confidence interval (CI): $0.21-0.24) per dose for injection and safety
equipment, as in a previous study [26]. For routine doses, the delivery cost was assumed to be
$1.76 (95% CI: 0.36-4.23) per dose based on the price of adding a new vaccine to routine
vaccination across Gavi-eligible countries [26]; for campaign doses, we assumed the cost was
$0.41 (95% CI: 0.23-0.62) based on a literature review that explored operational costs per
vaccine doses for Supplementary Immunization Activities from 1992-2012 [40].
Sensitivity analyses
To assess the robustness of our economic evaluation to the underlying parameter
uncertainty, we conducted two types of sensitivity analyses: 1) probabilistic sensitivity analyses,
in which we examined cost-effectiveness acceptability frontiers to assess how parameter
uncertainty contributes to uncertainty in the optimal strategy; 2) value of information analysis to
identify the most influential parameters, by estimating the expected value of partially perfect
information (EVPPI) for each parameter. We randomly drew 5,000 independent samples from
the uncertainty distributions of each input parameter in the economic evaluation (Table S2). Each
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sample was combined with one of the samples from the stochastic transmission model (1,000
simulations repeated five times to achieve a manageable computational burden) to estimate 5,000
net monetary benefit (NMB) values for each strategy and for a range of willingness-to-pay
(WTP) values from $0-$1,000 in increments of $10. The NMB framework is represented as
≤–§ = ∆“ ∗ ”Øµ − ∆∞, where ∆“ is the averted DALYs through a strategy compared to the
base case of no vaccination, ∆∞ is the incremental cost of the strategy compared to the base case,
and WTP is the willingness-to-pay threshold. By calculating the proportion of samples for which
a strategy yielded the highest NMB for each WTP, we quantified the uncertainty surrounding the
optimal strategy. We also measured the contribution of parameter uncertainty to identifying the
optimal vaccination strategy by calculating the EVPPI.
Scenario analyses
While countries have the option of introducing TCVs into the routine immunization
program, to date no vaccine stockpile exists for TCV introduction in the event of an outbreak.
To address this uncertainty, we account for varying delays in reactive vaccine deployment. For
our primary analysis, we assumed an “idealized” scenario in which vaccination is introduced
within 1 month of identifying the outbreak. In scenario analyses, we explored deployment delays
of 6, 12, and 24 months after the epidemic threshold was exceeded.
Similarly, while decision-makers typically do not know when an outbreak may occur, the
optimal strategy may depend on how far away the outbreak will start. We simulated TCV
introduction occurring exactly 10 years to 1 year before the epidemic threshold was crossed. For
these comparisons, we assessed the burden of typhoid fever and costs of treatment and
vaccination for the preventative and reactive vaccination scenarios over a 20-year time horizon
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spanning from 2000 to 2020. For all other analyses, we used the same 10-year time horizon to
match previous cost-effective analyses.
The stochastic transmission model and economic model were implemented in R version
3.4.0 [41]. The transmission model code is available on GitHub at
https://github.com/mailephillips/typhoid-outbreak.

Results
The model accurately reproduced the number and age distribution of observed bloodculture confirmed typhoid fever cases at QECH during both the fitting period (January 1996February 2015) and the validation period (March 2015-December 2016) (Fig S5-S6). Over the
10-year simulation period with randomized outbreak timing in Blantyre, Malawi, we estimated a
median of 7,019 (95% CrI: 742-12,380) cases and 63 (95% CrI: 3-517) deaths for a total of 1,389
(95% CrI: 76-11,394) DALYs and $32,672 (95% CrI: 2,099-133,417) in treatment costs for
typhoid fever under the strategy of no vaccination (Table S3).
All vaccination strategies substantially reduced the expected number of typhoid fever
cases, but did not completely prevent the outbreak from occurring. Preventive routine
vaccination with a catch-up campaign delayed the start of the outbreak and reduced typhoid fever
incidence substantially more than routine vaccination alone. When reactive vaccination was
deployed within 1 to 6 months of the outbreak threshold being crossed, the epidemic was
substantially smaller and delayed by 1-2 years (Fig S8). However, when reactive vaccination
occurred 12 to 24 months after the outbreak was identified, it failed to prevent the peak in
typhoid fever cases, although incidence was substantially reduced after vaccine deployment. The
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number of typhoid fever cases, deaths, and DALYs averted by each vaccination strategy
compared to no vaccination, as well as the associated costs, are detailed in Table S4.
When we consider the cost-effectiveness of each strategy, our findings suggest that TCV
introduction was optimal compared to no vaccination for WTP values greater than $100 (Table 4
and Fig 1B). Reactive vaccination (with a 1-month delay in implementation) was preferred for a
WTP range of $110-$430, whereas preventive routine vaccination with a catchup campaign was
optimal for WTP values above $430. Routine vaccination including a catch-up campaign to 15
years of age was always preferred over routine vaccination alone.
Table 4. Expected cost-effectiveness of vaccination strategies. Expected total costs, total
disability-adjusted life-years (DALYs), incremental costs, DALYs averted, and incremental costeffectiveness ratios (ICERs) are shown for each strategy in the scenarios in which (1) an
outbreak is likely, (2) an outbreak is unlikely and the typhoid incidence is low (pre-oubreak
incidence), and (3) an outbreak is unlikely and the typhoid incidence is high (post-outbreak
incidence). Strategies are sorted from lowest to highest expected total costs.
Strategy

Expected
Total
Costs

base case
reactRC
prevR
prevRC

40,840
153,858
251,851
262,712

base case
prevR
prevRC

1,330
105,110
112,190

base case
prevR

308,822
3,382,410

prevRC

3,654,473

Expected
Total
DALYs

Expected
Incremental Costs

Expected
DALYs Averted

When an outbreak is likely
2,533
--1,421
113,018
1,112
1,738
--1,172
108,854
249
When an outbreak is unlikely (low incidence)
154
--82
--40
110,860
114
When an outbreak is unlikely (high incidence)
22,039
--12,649
--10,102

3,345,651

11,937

ICER

16
102
Dominated
437
9
Dominated
972
14
Dominated
280
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Fig 1. Cost-effectiveness planes and acceptability frontiers. The cost-effectiveness planes
(left) and cost-effectiveness acceptability frontiers (CEAFs; right) are plotted for randomized
outbreak timing (A-B), no outbreak assuming the pre-outbreak incidence (C-D), and no outbreak
assuming the post-outbreak incidence (E-F). In the cost-effectiveness planes, each dot represents
the additional cost (in 2020 USD) and DALYs averted for one simulation when compared with
the strategy of no vaccination. The bold Xs denote the expected additional cost and DALYs
averted for one strategy with respect to the strategy of no vaccination. Strategies are indicated by
the color of the dot or X (purple: preventive routine vaccination; green: preventive routine
vaccination plus a catchup campaign up to 15 years; or orange: reactive routine vaccination plus
a catchup campaign). In the CEAFs, the preferred strategy (i.e. the strategy that yielded the
highest average net benefit) for each willingness-to-pay threshold ($0-1,000; x-axis, 2020 USD)
is again indicated by the color of the line (black: no vaccination; and same strategy colors as
other panels), while the proportion of samples in which that strategy yielded the highest net
benefit is indicated by the value on the y-axis (which can be interpreted as our certainty in the
optimal strategy).
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In the absence of an outbreak, and assuming the lower pre-outbreak incidence from 19952005, no vaccination is the preferred strategy for all WTP thresholds <$980 (Fig 1D). With the
higher post-outbreak incidence, routine vaccination with a catch-up campaign is preferred for
WTP values of $280 or higher (Fig. 1F). Again, routine vaccination alone is never the preferred
strategy. The number of typhoid fever cases, deaths, and DALYs averted, as well as the costs for
each scenario, are presented in Table S4.
The range of WTP values for which reactive vaccination strategy was the optimal
strategy decreased as the delay in TCV deployment increased. For a 6-month delay, reactive
vaccination was the preferred strategy for WTP threshold between $110-330, while for a 12month delay, reactive vaccination was preferred at $130-200 (Fig 2). If the delay extended up to
24 months, reactive vaccination was never preferred; preventative vaccination with a catch-up
campaign was the optimal strategy when the WTP threshold was at least $180.
The optimal vaccination strategy did not vary substantially depending on how
long before the outbreak preventive vaccination was implemented. Whether the outbreak
occurred within 10 years or 1 year of vaccine introduction for the preventive strategies, the
preferred strategy remained essentially the same for the different WTP values. When the delay in
reactive vaccination was 12 months or less, no vaccination was preferred for WTP thresholds up
to $100. Reactive vaccination was the optimal strategy for WTP values of approximately $200500 when the delay in reactive vaccination was 1 month, for WTP thresholds of approximately
$200-400 for a 6-month delay, and for WTP thresholds of around $200-300 (10 years before) or
$200 (1 year before) for a 12-month delay. Preventive routine vaccination with a catchup
campaign was the preferred strategy for higher WTP thresholds, and for WTP thresholds >$200
when there was 24-month delay in reactive vaccination (Fig 3).
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Fig 2. Cost-effectiveness acceptability frontiers for randomized outbreak timing with
varying delays in reactive vaccination. The cost-effectiveness acceptability frontiers for
randomized outbreak timing are shown for a range of willingness-to-pay thresholds ($0-1,000; xaxis, 2020 USD). The preferred strategy (i.e. the strategy that yielded the highest average net
benefit) is indicated by the color of the line (black: no vaccination; purple: preventive routine
vaccination; green: preventive routine vaccination plus a catchup campaign up to 15 years; or
orange: reactive routine vaccination plus a catchup campaign), while the proportion of samples
in which that strategy yielded the highest net benefit is indicated by the value on the y-axis
(which can be interpreted as our certainty in the optimal strategy). Results are plotted for (A) a 6month delay in reactive vaccination after the outbreak threshold is exceeded, B) a 12-month
delay in reactive vaccination after the outbreak threshold is exceeded, and C) a 24-month delay
in reactive vaccination after the outbreak threshold is exceeded.
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Fig 3. Heatmap of optimal intervention strategy and its estimated uncertainty across a
range of willingness to pay values for each strategy comparison and a range of deployment
delays, and years before the outbreak. Each column in a single panel shows the preferred
strategy (i.e. the strategy that yields the highest average net benefit) for one cost-effectiveness
analysis comparing no vaccination (grey), preventive routine vaccination (purple), preventive
routine vaccination with a catch-up campaign (green), and reactive vaccination with a catch-up
campaign (orange) for delays of 1, 6, 12, or 24 months after the outbreak has been identified (xaxis). The y-axis represents willingness-to-pay (WTP) values ranging from $0-$1000 (USD
2020). The shading represents the probability that the preferred strategy yields the highest net
benefit (lighter: lower probability; darker: higher probability). Results are plotted for whether
preventive vaccination is introduced 10 years (top panel) or 1 year (bottom panel) before the
outbreak. Note that preventive routine vaccination without a catchup campaign is never a
preferred strategy, and as a result does not appear in the plots.

The degree of uncertainty in the preferred strategy varied depending on the WTP
threshold, the length of delay in the deployment of reactive vaccination, and (to a lesser extent)
how many years before the outbreak preventive vaccination was introduced. The greatest
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uncertainty in the preferred strategy occurred for WTP values of $100-$200. For WTP values of
$0-$100, the probability that no vaccination would yield the highest net benefit was high
(median probabilities of 0.60-0.95). The probability that reactive vaccination would yield the
highest net benefit was generally lower, but was higher for shorter delays in deployment (median
probabilities of 0.28-0.40 for a 1-month delay compared to 0.23-0.25 for a 12-month delay at
WTP values between $100-500). The probability that preventive routine vaccination with a
catch-up campaign would yield the highest net benefit increased as the delay in reactive
vaccination deployment and WTP threshold increased (median probabilities of 0.27-0.64 for
WTP values between $200-1,000).
For all of the economic evaluations, uncertainty around the probability of death among
inpatients was estimated to contribute most to uncertainty in the preferred strategy, followed by
the probability of hospitalization, percentage of deaths occurring among hospitalized patients,
and routine vaccine delivery costs (Figs S9-S11).
Discussion
The analyses in this study depend on the information available to decision-makers at the
time of decision-making. In a country where prevalence of AMR is low and a prolonged
outbreak of typhoid fever has not yet occurred, but where surrounding regions are experiencing
outbreaks of drug-resistant typhoid fever, it is likely that AMR will spread, triggering an
outbreak in that country as well. Our findings indicate that if an outbreak of typhoid fever is
likely, TCV routine vaccination with a catch-up campaign is preferred over no vaccination above
a WTP threshold of $100. At WTP thresholds of $110 to $430, it is generally more cost-effective
to wait to vaccinate until the outbreak has started, as long as the delay in deployment is short. As
the WTP threshold increases, it is generally better (in terms of cost-effectiveness) to preventively
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introduce routine vaccination with a catch-up campaign. These findings hold true regardless of
when the outbreak occurs, provided it occurs within 10 years. However, if no outbreak occurs
and incidence is low, TCV introduction is unlikely to be cost-effective for WTP thresholds
<$980. At the higher post-vaccination incidence currently estimated for Blantyre, routine
vaccination with a catch-up campaign is the preferred strategy for WTP thresholds of $280 and
above. Routine vaccination alone is never a preferred strategy.
As TCV stockpiles do not yet exist, there is uncertainty in how long it will take to
mobilize vaccine introduction once an outbreak is identified. The cost-effectiveness of reactive
vaccination largely depends on the length of delay in vaccine deployment. We found that the
range of WTP thresholds for which reactive vaccination is optimal decreases as the length of
time for vaccine deployment increases. Decision-makers should try to determine how quickly
they would be able to mobilize resources when considering reactive vaccination strategies and
seek to minimize delays in vaccine deployment.
There is currently no threshold for defining and identifying outbreaks of typhoid fever
across different settings. In our analysis, we found that an increase in the monthly number of
blood-culture-confirmed typhoid fever cases of more than 15 standard deviations above the mean
accurately identified the start of the outbreak in Blantyre, Malawi. It is not yet clear whether this
threshold may be applicable to other settings. However, the results of our analysis are unlikely to
depend on the outbreak identification threshold used. While lower thresholds may falsely
identify an outbreak before it occurs, a false positive in this case may not be as problematic as it
can be with other diseases. If the outbreak is falsely identified too early, “reactively” vaccinating
in response to the false outbreak is comparable to a preventative vaccination strategy, which in
our analysis was still cost-effective for WTP thresholds above $100 provided an outbreak is
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likely to occur within the next 10 years. These findings are encouraging as typhoid resources and
surveillances systems are not always optimal in areas where typhoid is endemic.
For scenarios in which an outbreak does not occur, our results are consistent with
previous cost-effectiveness analyses. Before the outbreak in Blantyre, we estimate that typhoid
fever incidence was approximately 26.1 cases (95% CrI: 14.0-45.7 cases) per 100,000 personyears; we found that no vaccination is the preferred strategy for WTP thresholds up to $970. In
general, previous analyses have found that TCV introduction is unlikely to be cost-effective
when incidence is less than 30-50 cases per 100,000 person-years [26, 42, 43]. Similarly, we
estimate that the post-outbreak incidence in Blantyre was approximately 224 typhoid fever cases
(95% CrI: 169-368 cases) per 100,000 person-years, and routine vaccination with a catch-up
campaign was preferred at WTP thresholds of $300 and above, similar to results of a previous
economic analysis for Malawi [26].
There is considerable uncertainty surrounding the incidence and burden of typhoid fever,
which leads to uncertainty in the preferred vaccination strategy. Nevertheless, some of the
uncertainty has been reduced in our analysis compared to previous cost-effectiveness analyses
for Malawi. In Bilcke et al [26], lack of data surrounding the probability of hospitalization, the
case fatality rate among inpatients, vaccine delivery costs, and typhoid incidence contributed
substantially to uncertainty in the results. Since then, additional data have been collected in
Malawi. While the parameters contributing most to uncertainty in our analysis included
parameters that were and were not updated with new data, the overall expected value of
information for the parameters contributing the most to uncertainty was substantially lower
compared to the previous cost-effectiveness analyses.

67

There are several important limitations to our analysis. We assume TCV reduces the
burden of typhoid fever by reducing the number of infections and lowering transmission.
However, we lack direct data on vaccination impact in this population. We used results from the
recent TyVAC trial in Malawi to update our estimates of vaccine efficacy and duration of
protection, but observations of vaccine impact following widespread implementation are not yet
available. This analysis also uses parameters and data based on an outbreak in one location.
Since the timing of a typhoid fever outbreak is unknown, it is difficult to plan for control. The
peak and length of outbreaks, as well as treatment costs and severity of disease, may differ in
other contexts. It can also be difficult to collect site-specific data, as typhoid fever surveillance is
limited in many countries. We made every effort to incorporate additional uncertainty in the
model parameters (which were not only Malawi-specific) and the outbreak itself (using a
stochastic model that varied the peak and length of the outbreak). The framework we present
may be generalizable to other settings where the introduction of drug-resistant strains may lead
to prolonged outbreaks of typhoid fever.
Research comparing typhoid vaccination strategies in epidemic settings is limited. With
recent WHO recommendations for TCV use and pilot studies assessing efficacy and impact
underway, governments are looking to prioritize the allocation of resources to prevent typhoid
fever. With recent typhoid epidemics across Africa and high burdens in endemic countries,
studies are needed to compare prevention strategies across different settings, including the use of
TCV in response to outbreaks. Typhoid control can be expensive; cost-effectiveness analyses are
needed to inform decisions for the optimal allocation of funding. Results from this research can
inform policy- and decision-making regarding typhoid prevention and control strategies.
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outbreak timing (A-B), no outbreak assuming the pre-outbreak incidence (C-D), and no outbreak
assuming the post-outbreak incidence (E-F). In the cost-effectiveness planes, each dot represents
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the strategy of no vaccination. The bold Xs denote the expected additional cost and DALYs
averted for one strategy with respect to the strategy of no vaccination. Strategies are indicated by
the color of the dot or X (purple: preventive routine vaccination; green: preventive routine
vaccination plus a catchup campaign up to 15 years; or orange: reactive routine vaccination plus
a catchup campaign). In the CEAFs, the preferred strategy (i.e. the strategy that yielded the
highest average net benefit) for each willingness-to-pay threshold ($0-1,000; x-axis, 2020 USD)
is again indicated by the color of the line (black: no vaccination; and same strategy colors as
other panels), while the proportion of samples in which that strategy yielded the highest net
benefit is indicated by the value on the y-axis (which can be interpreted as our certainty in the
optimal strategy).
Fig 2. Cost-effectiveness acceptability frontiers for randomized outbreak timing with
varying delays in reactive vaccination. The cost-effectiveness acceptability frontiers for
randomized outbreak timing are shown for a range of willingness-to-pay thresholds ($0-1,000; xaxis, 2020 USD). The preferred strategy (i.e. the strategy that yielded the highest average net
benefit) is indicated by the color of the line (black: no vaccination; purple: preventive routine
vaccination; green: preventive routine vaccination plus a catchup campaign up to 15 years; or
orange: reactive routine vaccination plus a catchup campaign), while the proportion of samples
in which that strategy yielded the highest net benefit is indicated by the value on the y-axis
(which can be interpreted as our certainty in the optimal strategy). Results are plotted for (A) a 6-
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month delay in reactive vaccination after the outbreak threshold is exceeded, B) a 12-month
delay in reactive vaccination after the outbreak threshold is exceeded, and C) a 24-month delay
in reactive vaccination after the outbreak threshold is exceeded.
Fig 3. Heatmap of optimal intervention strategy and its estimated uncertainty across a
range of willingness to pay values for each strategy comparison and a range of deployment
delays, and years before the outbreak. Each column in a single panel shows the preferred
strategy (i.e. the strategy that yields the highest average net benefit) for one cost-effectiveness
analysis comparing no vaccination (grey), preventive routine vaccination (purple), preventive
routine vaccination with a catch-up campaign (green), and reactive vaccination with a catch-up
campaign (orange) for delays of 1, 6, 12, or 24 months after the outbreak has been identified (xaxis). The y-axis represents willingness-to-pay (WTP) values ranging from $0-$1000 (USD
2020). The shading represents the probability that the preferred strategy yields the highest net
benefit (lighter: lower probability; darker: higher probability). Results are plotted for whether
preventive vaccination is introduced 10 years (top panel) or 1 year (bottom panel) before the
outbreak. Note that preventive routine vaccination without a catchup campaign is never a
preferred strategy, and as a result does not appear in the plots.
Table S1. Options for disability weights assigned to different healthcare use groups.
Disability weights presented for the two options are for infectious disease, acute, and for the
specified level of typhoid episode (mild, moderate, or severe).
Table S2. Input parameters for transmission model and cost-effectiveness analysis, with
distributions.
Table S3. Predicted disease and economic burden in the absence of vaccination. The median
(95% credible interval) estimates for predicted cases, deaths, DALYs, and treatment costs are
shown for each non-vaccination strategy.
Table S4. Predicted vaccine impact with randomized outbreak timing, fixed outbreak
timing, pre-outbreak incidence and post-outbreak incidence. The median (95% credible
interval) estimates for averted cases, deaths, DALYs, treatment costs, costs of vaccinations and
net costs are shown for each vaccination strategy compared to no vaccination for randomized
outbreak timing (“randomized”), fixed outbreak timing (“fixed”), pre-outbreak incidence (“pre”),
and post-outbreak incidence (“post”). Preventive routine vaccination strategies include routine
vaccination at nine months of age in year 0 with or without a catchup campaign up to 15 years of
age. Reactive routine vaccination strategies (with a catchup campaign) include delays of 1, 6, 12,
and 24 months to deployment (“1m”, “6m”, “12m”, “24m”, respectively). In the fixed outbreak
timing scenario, preventive strategy results are shown for 10, 5, 2, and 1 year(s) (“10y”, “5y”,
“2y”, “1y”) before the outbreak starts. Results for the randomized and fixed outbreak timing
strategies are shown using an outbreak identification definition of 15 standard deviations above
the monthly mean number of typhoid cases. R=routine vaccination; RC=routine vaccination plus
a catchup campaign.
Fig S1. Ordinary differential equations and corresponding dynamic compartmental model
for typhoid disease dynamics. Black compartments and text indicate the scenario in which there
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is no vaccination, and blue compartments and text indicate the added scenario in which there is
vaccination. Note that this model is also age-structured, though not shown.
Fig S2. Sensitivity and specificity of outbreak identification threshold definitions. The
sensitivity (purple) and specificity (green) are shown for each outbreak identification definition
(x-axis; ranging from 6-16 standard deviations above the mean monthly reported typhoid fever
cases).
Fig S3. Estimated specificity of outbreak identification thresholds 6 to 16 standard
deviations above the monthly mean reported typhoid fever cases. The median outbreak
identification date (dot) and 95% credible interval (line) is shown for outbreak identification
thresholds of 6-16 standard deviations above the monthly mean number of typhoid cases for
1,000 simulations of the dynamic model. The black dashed line represents the “true” start date of
the outbreak, and the shaded grey area represents 0-18 months after the outbreak started
(sensitivity window).
Fig S4. Observed and fitted proportion of typhoid infections that are resistant to
antimicrobial treatment in Blantyre, Malawi from 1995-2025. Observed data points of the
yearly proportion of antimicrobial resistant typhoid fever infections over time are shown in black
dots, while the fitted estimates from the beta regression model are shown in the dashed blue line
and the prediction intervals are shown in the turquoise dotted lines.
Fig S5. Predicted and observed typhoid fever infections in the absence of vaccination. The
1,000 stochastic realizations of weekly typhoid infections individuals in the absence of
vaccination from the dynamic transmission model are show in purple. The observed (reported)
typhoid incidence used to fit the dynamic model is represented by the bold black line, while the
observed incidence collected after model fitting is represented by the dashed red line.
Fig S6. Observed versus fitted age distribution of reported typhoid cases. The proportion of
observed cases in each age group are denoted by light blue bars, while the fitted age distribution
is shown in darker blue.
Fig S7. Predicted typhoid fever cases per 100,000 individuals in preventive vaccination
scenarios. The 1,000 stochastic realizations of weekly typhoid cases per 100,000 people are
shown in purple, with the median of all simulations shown in orange for each preventive
vaccination strategy. Eight situations are shown, representing each preventive routine
vaccination timing strategy (10, 5, 2, and 1 year(s) before; routine vaccination at 9 months of
age) with and without a catchup campaign up to 15 years of age. The median number of typhoid
infections per 100,000 individuals in the absence of vaccination from 1,000 realizations is shown
in black, and the date of vaccination deployment for each situation is denoted by the vertical
dashed green line.
Fig S8. Predicted typhoid infections per 100,000 individuals in reactive vaccination
scenarios. The 1,000 simulated predictions for weekly typhoid infections per 100,000 people are
shown in purple, with the median of all stochastic realizations shown in orange for each reactive
vaccination strategy. Eight situations are shown, representing each of the outbreak identification
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thresholds of 12 and15 standard deviations above the monthly mean (SD12 and SD15; columns)
and the four different delays in timing to implement vaccination once the outbreak is identified
(1, 6, 12, and 24 months; rows). The median typhoid infections per 100,000 individuals in the
absence of vaccination from 1,000 realizations is shown in black, and the median date of
vaccination deployment for each situation is denoted by the vertical dashed green line.
Fig S9. Expected value of partially perfect information for differing delays in vaccination
deployment for reactive strategies with randomized outbreak timing. The expected value of
partial perfect information (EVPPI) for each parameter is shown for a range of willingness-topay values. Results are shown for 5,000 parameter samples and 2020 $USD. Each panel shown
represents the EVPPI for one cost-effectiveness analysis comparing 4 strategies: no vaccination
(base case), preventive routine vaccination at 9 months, preventive routine vaccination with a
catchup campaign up to 15 years, and reactive routine vaccination with a catchup campaign.
Each panel shows the results for a cost-effectiveness analyses with the specified delay in months
for the reactive strategy (1-, 6-, 12-, or 24-month delays).
Fig S10. Expected value of partially perfect information for pre-outbreak (non-outbreak)
incidence. The expected value of partial perfect information (EVPPI) for each parameter is
shown for a range of willingness-to-pay values. Results are shown for 5,000 parameter samples
and 2020 $USD.
Fig S11. Expected value of partially perfect information for post-outbreak (non-outbreak)
incidence. The expected value of partial perfect information (EVPPI) for each parameter is
shown for a range of willingness-to-pay values. Results are shown for 5,000 parameter samples
and 2020 $USD.
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Transmission-dynamic model
S1.1.1. Description of the dynamic model. We simulated the conditions under which an outbreak
may occur using an existing dynamic transmission model. Briefly, in this model, individuals are
born completely susceptible to typhoid, and they move through susceptible, infectious, chronic
carrier, and immune compartments as specified through a system of differential equations (Fig
S1). Individuals in the susceptible population (S1) become infected at rate C. Primary infections
å

(Is) may be symptomatic and remain infectious for length of time ‘ , after which they experience
one of three options: a proportion die from typhoid (»), a fraction «$ become chronic carriers
(∞), and the remaining 1 − «$ − » recover and are temporarily immune (ê). Since age (a) is a
factor in the development of the chronic carrier state[1], «$ is age-dependent. Immune
individuals lose immunity and become susceptible to reinfection (ë∂ ) at rate …. If an individual
becomes re-infected, we assume the infection is subclinical (’÷ ). Subclinically infected people
can become chronic carriers (at rate ≈«$ ) or recover (at rate ≈(1 − «$ )). The same process of
reinfection can occur. In all compartments, individuals die from non-typhoid causes at rate ƒ$ .
Symptomatic and subclinically infected individuals and chronic carriers all contribute to
the force of infection, although chronic carriers contribute at a reduced rate (ä). The force of
infection C$ is age-dependent (where a = 0 to <9 months; 9 months to <5 years; five-yearinterval age groups from 5 to <80 years; and 80 years and older) and is the product of the agedependent transmission rate (◊$ ) and the sum of all infectious states, divided by the total
population N: C$ =

ÿ6
Ÿ6

∑All ages(’t,$ + ’÷,$ + ä∞$ ).
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With and without vaccination
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Fig S1. Ordinary differential equations and corresponding dynamic compartmental model
for typhoid disease dynamics. Black compartments and text indicate the scenario in which there
is no vaccination, and the blue compartments and text indicate the added scenarios in which
vaccination is introduced. Note that this model is also age-structured, though not shown.
Observed symptomatic cases are a fraction s t s u s v of the true number of cases (S1.1.4
Text) [2]. The culture-confirmed cases are adjusted to account for the sensitivity of the blood
culture test (s t ), the probability of receiving a blood culture test (s u ), and the probability of
å

healthcare seeking (s v ), which occurs sometime during the period ‘ of infection.
To adjust for the outbreak and vaccination scenarios, we simulated the weekly number of
symptomatic cases for the 18 age groups. We modelled the outbreak by allowing for an increase
in multidrug-resistant typhoid by increasing the duration of infectiousness. We estimated the date
it increased (April 10, 2011) and the date it ended (November 23, 2014). The magnitude of the
increase m was estimated to be 3.1954.
To stay consistent with recent estimates of the contribution of chronic carriers to
transmission, we applied a prior distribution of •|¿L(6.34,19.4) on the range of values for r in
the model-fitting process [3]. With these changes, we re-fit the dynamic model using the same
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process to the same Malawi outbreak data to update the remaining parameters. This dynamic
model and its model-fitting process are described in more detail elsewhere [4].

S1.1.2. Modeling vaccination.
S1.1.2.1. Vaccination compartments. To simulate vaccination and measure the overall impact of
each strategy (with vaccine coverage k), we added two vaccination compartments to the dynamic
model (Fig S1, in blue). One compartment (V1) represents individuals who have never been
infected and hence may be protected from symptomatic disease if they successfully mount a
protective immunological response to the vaccine. The second compartment (V2) represents those
who were previously infected and would only be protected against reinfection (and hence
transmission), since they already have immunity to clinical disease. In both cases, vaccineinduced immunity eventually wanes at rate …› (S1.1.2.2).
S1.1.2.2. Vaccine efficacy and waning of vaccine-induced immunity
Typbar TCV (Bharat Biotech International) is the first WHO-pre-qualified typhoid conjugate
vaccine (TCV). This TCV was licensed based on improved immunogenicity data (compared to
previous typhoid fever vaccines) and efficacy data from a human challenge study [5-7]. For this
analysis, we used results up to 24 months of follow-up from the phase 3, double-blind,
randomized active-controlled clinical trial of single-dose TCV in Blantyre, Malawi [8, 9]. These
are the first vaccine efficacy and safety results from Africa.
The TCV trial in Blantyre provided observed values for vaccine efficacy at 12 months, 18
months, and 24 months of follow-up. Due to the waning efficacy over time, we assumed that the
mean vaccine efficacy ƒ at time t followed an exponential decay pattern
ƒ (¿ ) =

~

∗ | }(ﬁﬂ ∗p)
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and that the observed response variable vaccine efficacy at time t ( (t)) was linked to ƒ with a
normally distributed sampling error with standard deviation ‡:
(¿)~≤(ƒ(¿), ‡).
We used an informative prior on duration of vaccine-induced immunity, based on data from 4
å

years of follow-up for the Vi-rEPA TCV: ﬁ ~·LááL(1.38,0.048) [3]. We used a
ﬂ

noninformative uniform prior on the standard deviation of the normally distributed sampling
error of vaccine efficacy at time t. These distributions resulted in an estimated initial TCV
efficacy of 0.89 (95% CrI: 0.78-0.98) and an estimated duration of vaccine-induced immunity of
18.87 (95% CrI: 8.40-83.33) years.

S1.1.3. Outbreak threshold definitions. We explored a range of thresholds to identify the start of
the outbreak. For the main analysis, we varied the number of standard deviations (6-16) above
the monthly mean reported typhoid fever cases in the previous 10 years to define the outbreak
start. We defined the sensitivity of each threshold as the percentage of simulations in which the
outbreak was identified within 18 months of April 2011, while the specificity was defined as the
percentage of simulations in which the outbreak threshold was not exceeded prior to April 2011.
As the standard deviation used to define the outbreak threshold increased, the specificity also
increased (Fig S2).
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Fig S2. Sensitivity and specificity of outbreak identification threshold definitions. The
sensitivity (purple) and specificity (green) are shown for each outbreak identification definition
(x-axis; ranging from 6-16 standard deviations above the mean monthly reported typhoid fever
cases).

Across the different outbreak identification thresholds, the sensitivity remained high
(76.3-100.0%) for the range of definitions we explored, while the specificity followed a sigmoid
pattern (Fig S2). At a threshold of 16 standard deviations above the monthly mean number
reported cases, the outbreak was identified within one and a half years of the pre-specified start
date with a specificity of 96.5% and a sensitivity of 76.3% (out of 1,000 stochastic iterations); a
threshold of 15 standard deviations identified the outbreak with a specificity 95.5% and
sensitivity of 91.9%; while a threshold of 12 standard deviations identified it with a specificity of
71.6% and sensitivity of 100%. Lower thresholds exhibited poor specificity and incorrectly
identified the outbreak as occurring before April 2011 more than 50% of the time (Fig S3).
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Fig S3. Estimated specificity of outbreak identification thresholds 6 to 16 standard
deviations above the monthly mean reported typhoid fever cases. The median outbreak
identification date (dot) and 95% credible interval (line) is shown for outbreak identification
thresholds of 6-16 standard deviations above the monthly mean number of typhoid cases for
1,000 simulations of the dynamic model. The black dashed line represents the “true” start date of
the outbreak, and the shaded grey area represents 0-18 months after the outbreak started
(sensitivity window).

Apart from the 6-16 standard deviations above the mean monthly typhoid infections
reported in the main analysis, we also explored other outbreak thresholds. We defined outbreaks
by raw counts and incidence rates, but these definitions, while reliable in identifying the
outbreak, would be less applicable across countries because of the variation in incidence and
population denominators for passive hospital-based surveillance across settings. We also tried to
account for variation in typhoid fever incidence due to seasonality by allowing each month of the
year to have a standard deviation threshold above the mean; however, while this method
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accounted for seasonality, the data were sparse and oftentimes the outbreak was never identified.
We did not want to include more data (farther back than 10 years) because many typhoidendemic countries do not have long-established typhoid fever surveillance platforms.

S1.1.4. Underreporting adjustment. To adjust for underreporting of observed typhoid cases, we
used estimates from an analysis that adjusted for underreporting in Malawi, Nepal, and
Bangladesh based on data from the STRATAA study [2]. We based our estimate of the
adjustment factor for Malawi on the posterior distribution obtained by adjusting for blood culture
sensitivity, the probability of receiving a blood culture diagnostic test, and healthcare seeking. In
Malawi, this adjustment factor was estimated to be 7.7 (95% CrI: 6.0-12.4), i.e. for every bloodculture confirmed case of typhoid fever presenting to healthcare facilities in Blantyre, there are
an additional 6.7 undiagnosed cases of symptomatic typhoid fever occurring in the community.
This underreporting adjustment was applied after model-fitting, which was fitted to the reported
(unadjusted) number of cases.

S1.1.5. Chronic Carriers. We explored the contribution of chronic carriers to transmission during
the model-fitting process. In previous model-fitting, the parameter for the relative infectiousness
of chronic carriers was unidentifiable. There is a tradeoff between this parameter and the
reproductive number R0, which influences the prevalence of chronic carriers in the population.
To explore this tradeoff, we fixed the relative infectiousness of chronic carriers r at different
values (0.01, 0.10, 0.25, and 0.50) and refit the remaining parameters. We also tried a variation
of model-fitting where we initialized the model with no chronic carriers.
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The overall model fit (as measured by Akaike Information Criterion) tended to be poorer
as r got farther away from the 0.1-0.5 range. This range is consistent with recent estimates of r
(based on fitting to the observed overall and indirect effectiveness of vaccination with Vipolysaccharide vaccine in a cluster-randomized trial in Kolkata [10, 11]) and what was used in
the final model. To stay consistent with recent estimates of the contribution of chronic carriers to
transmission, we applied a prior distribution of §|¿L(6.34,19.4) on the range of values for r in
the model-fitting process [3]. The mean of this prior distribution (0.25) is also within the range of
our findings in the sensitivity analysis of the contribution of chronic carriers to transmission.

S1.2. Input parameters for economic model
S1.2.1. Cost conversion and inflation
All costs were converted to 2020 USD. First, they were converted from their original
amount to USD in the same reported year using WHO exchange rates [12]. Second, they were
inflated to the year 2020 using the consumer price index [13].

S1.2.2. Disability weights
We used mild, moderate, and severe disability weights for acute infectious diseases from
the 2010 Global Burden of Disease study to reflect the severity of typhoid fever compared to
other diseases [14, 15]. We chose to use the 2010 study instead of the newer estimates due to the
fact that newer disability weights are based on updated data from upper-income countries that do
not reflect the populations in which typhoid fever is endemic. Disability weights for mild
episodes were characterized as having “low fever and mild discomfort, but no difficulty with
daily activities,” estimated to be 0.005 ± 0.002 [15]; for moderate episodes they were
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characterized as having “a fever and aches and feels weak, which causes some difficulty with
daily activities,” estimated to be 0.053 ± 0.012 [15]; and for severe episodes they were
characterized as having “a high fever and pain, and feels very weak, which causes great
difficulty with daily activities,” estimated to be 0.210 ± 0.040 [15]. These mild, moderate, and
severe categorizations corresponded to inpatient, outpatient, and non-medical care episodes of
typhoid fever in two different ways, resulting in different average disability weights, each with
equal probability of occurring (Table S1).
We assumed the duration of illness increases with the need for medical care. In this case,
we used the distribution of duration of illness for inpatients and outpatients from a previous
random effects model by Bilcke et al. that integrated multiple estimates [3]. Similar to the
previous study, we also assumed that individuals with typhoid who did not seek medical care
recovered from illness twice as fast as those who did.
Table S1. Options for disability weights assigned to different healthcare use groups.
Disability weights presented for the two options are for infectious disease, acute, and for the
specified level of typhoid episode (mild, moderate, or severe).
Option 1
Option 2
Inpatient
Severe
Severe
Outpatient
Moderate
Severe
Patient not seeking medical care Mild
Moderate
Average disability weight
0.04
0.15
S1.2.3. Probability of seeking professional medical care
To calculate the probability of seeking medical care for typhoid fever, we again used
estimates from the STRATAA study [2]. As part of STRATAA, healthcare utilization surveys
were conducted in the Ndirande township of Blantyre to assess the probability of seeking care
for fever [16]. Many methods assume that reported healthcare-seeking for a fever is the same as
that for typhoid fever; however, this is not necessarily the case. Individuals with typhoid fever
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may be more or less likely to seek healthcare. To correct for this difference, we measured the
probability of seeking care for a fever adjusted for a specified typhoid risk factor to estimate the
probability of seeking care for typhoid fever. In Malawi, this risk factor was soap available after
defecation. After adjusting for this risk factor, the probability of seeking professional medical
care in Malawi was approximately 0.71 (95% CrI: 0.64-0.77) [2].

S1.2.4. Probability of hospitalization
During the STRATAA study, we observed 8 hospitalizations among 105 blood-cultureconfirmed typhoid infections. However, since the focus of this analysis is more broadly on
Malawi as an example of a multi-year outbreak of typhoid fever associated with the emergence
of AMR, we used the STRATAA data from Blantyre, Malawi to update a previous estimate of
the probability of hospitalization among Gavi-eligible countries based on a meta-analysis by
Abboud et al [3, 17].
We modeled probability of hospitalization using a binomial distribution for the likelihood
contribution, where yhosp was the observed number of “successes”, phosp was the probability of
hospitalization among culture-confirmed typhoid infections, and nhosp was the number of “trials”,
„õΩo† ~§‰"íá‰L¡(óõΩo† , "õΩo† ).
In the previous analysis, the denominator (blood-culture-confirmed infections) was
adjusted for differences in surveillance method according to the probability of seeking
professional medical care. Using the same model for adjustment as Section 1.2.5, our
denominator for the total number of typhoid fever cases in the community could be as large as
429 (median estimate after adjusting for the probability of receiving a blood culture test and the
probability of seeking healthcare). However, it is also possible that individuals who do not seek

87

care are less severe and unlikely to be hospitalized. Hence, we allowed the denominator "õΩo† to
vary between 105 and 429 by giving it a discrete uniform prior distribution:
"õΩo† ~Ü"‰Âíäá(105,429).
The previous meta-analysis estimated the probability of hospitalization to be 0.04 (95%
prediction interval (PI): 0.00-0.25). We incorporated this estimate as a prior distribution on the
probability of hospitalization using an inverse logit of a normal distribution with mean equal to
the common estimate from the Abboud et al meta-analysis (ƒõΩo† = −3.25 on the logit scale),
and standard error equal to the standard error based on the prediction interval around the
common estimate (‡õΩo† = 1.20 on the logit scale) [17]:
¡íç‰¿âóõΩo† ã~≤âƒõΩo† , ‡õΩo† ã.
Combining the likelihood of the data with the probability of the prior distribution resulted in an
estimated probability of hospitalization of 0.04 (95% PI: 0.01-0.11).

S1.2.5. Probability of death if patients are admitted to hospital for typhoid infection
In STRATAA, we observed 1 death among the 8 individuals hospitalized for typhoid
fever in Malawi, and 1 death occurred in an individual who was not hospitalized. Similar to the
probability of hospitalization, we combined the data with prior information from a previous
meta-analysis to estimate the case fatality rate (CFR) among inpatients admitted for typhoid
fever. We again modeled this estimate using a binomial distribution for the likelihood
contribution, where yIP.CFR=1 was the observed number of “successes”, pIP.CFR was the
probability of death among inpatients, and nIP.CFR=8 was the number of “trials”,
„ÊÁ.Õñù ~§‰"íá‰L¡(óÊÁ.Õñù , "ÊÁ.Õñù ).
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In this case, we wanted to update our prior to include not only the meta-analysis by
Pieters et al [18] used in the previous analysis by Bilcke et al [3], but to also include estimates
from a more recent meta-analysis that had been carried out for inpatient CFR estimates by
Crump et al [19]. The original inpatient CFR from Pieters et al was estimated to be 0.04 (95% PI:
0.01-0.20) based on 21 studies. Crump et al’s new meta-analysis had a lower pooled inpatient
CFR estimate of 0.02 (95% PI: 0.01-0.03) overall (109 studies), or 0.05 (95% PI: 0.03-0.09)
for studies based in Africa[19]. To supplement the meta-analysis by Pieters et al, we added
studies from Crump et al’s meta-analysis that had the same inclusion criteria (no population
subgroups, hospital-based studies only). This exclusion process identified 26 additional studies
from Crump et al, 22 of which we were able to locate. Since multi-year typhoid outbreaks are
primarily occurring in sub-Saharan Africa, we further limited the studies to only include those in
sub-Saharan Africa. With this additional restriction, we included 12 additional studies and the
estimated inpatient CFR was 0.07 (95% PI: 0.01-0.38).
We incorporated the updated estimate as a prior distribution using an inverse logit of a
normal distribution with mean equal to the common estimate from the updated random-effects
meta-analysis in sub-Saharan Africa (ƒÊÁ.Õñù = −2.52), and standard error equal to the standard
error based on the prediction interval around the common estimate (‡ÊÁ.Õñù = 1.04; both on the
logit scale):
¡íç‰¿(óÊÁ.Õñù )~≤(ƒÊÁ.Õñù , ‡ÊÁ.Õñù ).
Combining the likelihood of the data with the probability of the prior distribution resulted in a
final estimated inpatient CFR of 0.09 (95% PI: 0.02-0.28).

S1.2.6. Time-varying proportion of typhoid infections that are resistant to antimicrobial
treatment
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Since the recent typhoid outbreaks are thought to be caused by antimicrobial resistant
(AMR) strains, the proportion of typhoid infections resistant to antimicrobial treatment is
assumed to be time-varying. A recent study from Feasey et al documented the annual proportion
of AMR infections at Queen Elizabeth Central Hospital in Blantyre from 1998-2014 [20]. We
supplemented these data points with estimates from Blantyre in the community-based
STRATAA Programme in 2017-2018. With change point analysis, we identified that the AMR
increase began in 2010, consistent with when we estimated the outbreak to begin using our
transmission model. We fit a beta regression model with the logit-transformed proportion of
AMR infections as the outcome and third-degree polynomial terms of time (year) as the
independent variables. The beta regression model ensured that the proportions of AMR stayed in
the interval (0,1). We compared commonly used links for the outcome variable (identity, log,
log-log, and logit) and differing degrees of polynomial terms for time and chose the model with
the lowest Akaike Information Criteria (AIC) value. This model provided time-varying estimates
with prediction intervals for 1995-2018. We assumed that after 2018, the proportion AMR stayed
the same; we doubled the standard deviations for the prediction intervals to allow for additional
uncertainty in our future extrapolation (Fig S4).
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Fig S4. Observed and fitted proportion of typhoid infections that are resistant to
antimicrobial treatment in Blantyre, Malawi from 1995-2025. Observed data points of the
yearly proportion of antimicrobial resistant typhoid fever infections over time are shown in black
dots, while the fitted estimates from the beta regression model are shown in the dashed blue line
and the prediction intervals are shown in the turquoise dotted lines.

S1.2.9. All other parameters
All other parameters not mentioned above that were used in the cost-effectiveness
analysis (Table 3) have been described in detail elsewhere [3].
Table S2. Input parameters for transmission model and cost-effectiveness analysis, with
distributions.
Characteristic
Uncertainty distribution
Typhoid incidence and age distribution
Annual number of
Estimated from dynamic
symptomatic typhoid
transmission model
fever cases per 100,000
people (without
vaccination)
Average age of patients
Estimated from dynamic
with typhoid infection
transmission model
(without vaccination)
(years)
Typhoid mortality
Probability of death if
Binomial likelihood (1 success, 8
patients are admitted to
trials), inverse-logit-normal prior
hospital for typhoid
(mean=-2.52; standard
infection
deviation=1.04)
Proportion of deaths from Uniform from 0.25 to 1
typhoid infection

Page location
Based on output from
transmission dynamic model fit to
incidence of typhoid
Based on output from
transmission dynamic model fit to
incidence of typhoid

Page 11

[3]
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occurring in patients not
hospitalized
Average age at death
from typhoid infection
Antimicrobial resistance
Proportion of patients
with typhoid infection
with an AMR strain
Burden of AMR cases
relative to antimicrobialsensitive cases
Healthcare use
Probability of infected
patients seeking
healthcare
Probability that infected
patients are admitted to
hospital

Length of stay in hospital
(days)
Treatment, vaccine-related costs
All treatment and
vaccine-related costs
Disability-adjusted life-years
Disability-weights from 0
(perfect health) to 1
(death)
Relationship between
disability weights for
mild, moderate, and
severe illness and
outcomes on healthcare
use
Duration of illness in
inpatients and outpatients
(days)
Relative duration of
illness for patients not
seeking medical care (vs
inpatients and
outpatients)
Life expectancy

Estimated from dynamic
transmission model

Assuming age distribution of
deaths is the same as the age
distribution of patients with
typhoid

Change point analysis; beta
regression

[16, 20]

Uniform from 1 to 3

[3]

Based on posterior distribution
obtained by adjusting populationbased incidence of typhoid
Binomial likelihood (8 successes,
number of trials follow uniform
distribution from 104 to 429),
inverse-logit-normal prior
(mean=-3.25; standard
deviation=1.20)
Gamma distribution based on
meta-analysis

[2]; Page 9

Varied

[3]

Equal probability based on two
scenarios

[15]; page 8

See description in supplement

[15]; page 8

Based on meta-analyses

[3]

Uniform from 0 to 1

[3]

Fixed

[21]

Page 10

[3]
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S1.3. Cost-effectiveness analysis. Determining the optimal strategy for each scenario.
We calculated the associated costs and disability-adjusted life-years (DALYs) for each
strategy (preventive routine vaccination, preventive routine vaccination with a catchup
campaign, and reactive routine vaccination with a catchup campaign) and compared to no
vaccination using the net monetary benefit (NMB) framework, where ≤–§ = ∆“ ∗ ”Øµ − ∆∞
(where ∆“ is the averted DALYs through a strategy compared to the base case of no vaccination,
∆∞ is the incremental cost of the strategy compared to the base case, and WTP is the willingnessto-pay threshold). Our measure of cost-effectiveness is the incremental net monetary benefit as
opposed to the incremental cost-effectiveness ratio (ICER), because calculating the preferred
strategy for more than two strategies is not always straightforward when using ICERs.
Since there is no standard WTP threshold to define whether an intervention is “costeffective,” we identified the optimal strategy (the highest average NMB) for a range of WTP
values ranging from $0-$1,000 per DALY averted. For comparison, Malawi’s 2019 gross
domestic product (GDP) per capita was $411.55 [22], within the range of these WTP values.

S1.3.1. Uncertainty surrounding the optimal strategy in each analysis
We randomly drew 5,000 independent samples from the uncertainty distributions of each
input parameter in the economic evaluation and combined each sample with one of the samples
from the stochastic transmission model to estimate 5,000 net monetary benefit values for each
strategy and for a range of WTP values from $0-$1,000 in increments of $10. The proportion of
the 5,000 samples for which a strategy has the highest net monetary benefit among all strategies
reflects our certainty regarding that strategy as the preferred one, presented as a costeffectiveness acceptability frontier (CEAF). For example, in the non-outbreak scenario with low
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incidence (pre-outbreak), the preferred strategy is no vaccination for all WTP values less than
$980. However, the probability that no vaccination results in the highest net benefit decreases
from 1.00 at $0 WTP to 0.66 at $970 WTP (Fig 1d). The optimal strategy is then routine
vaccination with a catch-up campaign with increasing probability from 0.31 at $980 WTP to 0.32
at $1000 WTP. In the non-outbreak scenario with high incidence (post-outbreak), the probability
that no vaccination is the optimal strategy decreases from 1.00 at $0 WTP to 0.63 at WTP $280.
Then, our certainty that routine vaccination with a catchup campaign is preferred increases from
0.27 at a WTP of $290 to 0.56 at a WTP of $1000 (Fig 1f).

S1.4.1. Identifying the main drivers of uncertainty.
The expected value of partially perfect information (EVPPI) is the maximum willingness to pay
for additional research regarding a specified parameter. Parameters with the highest EVPPI
numbers contribute the most to uncertainty for a particular scenario and across a range of WTP
values [23]. For each cost-effectiveness analysis and each uncertainty parameter, we estimated
the EVPPI (Fig S9-S11).
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Fig S5. Predicted and observed typhoid fever infections in the absence of vaccination. The
1,000 stochastic realizations of weekly typhoid infections individuals in the absence of
vaccination from the dynamic transmission model are show in purple. The observed (reported)
typhoid incidence used to fit the dynamic model is represented by the bold black line, while the
observed incidence collected after model fitting is represented by the dashed red line.
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Fig S6. Observed versus fitted age distribution of reported typhoid cases. The proportion of
observed cases in each age group are denoted by light blue bars, while the model-predicted age
distribution is shown in darker blue.

Fig S7. Predicted typhoid fever cases per 100,000 individuals in preventive vaccination
scenarios. The 1,000 stochastic realizations of weekly typhoid cases per 100,000 people are
shown in purple, with the median of all simulations shown in orange for each preventive
vaccination strategy. Eight situations are shown, representing each preventive routine
vaccination timing strategy (10, 5, 2, and 1 year(s) before; routine vaccination at 9 months of
age) with and without a catchup campaign up to 15 years of age. The median number of typhoid
infections per 100,000 individuals in the absence of vaccination from 1,000 realizations is shown
in black, and the date of vaccination deployment for each situation is denoted by the vertical
dashed green line.
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Fig S8. Predicted typhoid infections per 100,000 individuals in reactive vaccination
scenarios. The 1,000 simulated predictions for weekly typhoid infections per 100,000 people are
shown in purple, with the median of all stochastic realizations shown in orange for each reactive
vaccination strategy. Four situations are shown, representing the four different delays in timing
to implement vaccination once the outbreak is identified (1, 6, 12, and 24 months). The median
typhoid infections per 100,000 individuals in the absence of vaccination from 1,000 realizations
is shown in black, and the median date of vaccination deployment for each situation is denoted
by the vertical dashed green line.
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Table S3. Predicted disease and economic burden in the absence of vaccination. The median
(95% credible interval) estimates for predicted cases, deaths, DALYs, and treatment costs are
shown for each non-vaccination strategy.
Scenario
Randomized
outbreak timing
(starts year 0-10)
Fixed outbreak
timing (starts year
10)
Non-outbreak: preoutbreak incidence
Non-outbreak: postoutbreak incidence

Cases

Deaths

DALYs

Treatment Costs

7,019 (742-12,380)

63 (3-517)

1,389 (76-11,394)

32,672 (2,099-133,417)

24,084 (18,201-39,943)

274 (33-1,832)

4,929 (742-31,596)

126,470 (35,688-446,186)

528 (259-882)

4 (0-27)

92 (13-645)

1,014 (264-4177)

55,107 (41,594-87,417)

523 (65-3,405)

13,379 (1,996-83,772)

249,766 (70,140-882,877)

98

99

137 (-1,185-3,558)

7,573 (-9,184-61,951)
3,219 (-22,319-52,342)
34,199 (-26,488-208,519)

102,677 (0-296,295)
86,562 (0-279,698)
810,759 (371,538-1,846,111)
839,435 (395,514-1,872,884)
693,563 (317,090-1,568,645)
733,275 (355,445-1,609,560)
590,663 (272,194-1,350,104)
643,118 (319,071-1,391,903)
549,938 (254,861-1,248,632)

86,580 (-2,648-286,133)

78,158 (-6,830-271,612)

765,534 (299,001-1,795,847)

779,499 (306,879-1,820,621)

657,558 (248,612-1,544,369)

678,503 (270,336-1,549,494)

560,966 (213,666-1,317,147)

592,795 (238,565-1,348,901)

526,046 (203,912-1,233,829)

562,810 (223,034-1,260,712)

reactive 12m

reactive 24m

preventive R 10y

preventive RC

preventive R 5y

preventive RC

preventive R 2y
10y

preventive RC

preventive R 1y
5y

preventive RC

reactive 1m
2y

2,788,933 (1,131,853-6,659,140)

3,059,779 (1,378,529-6,876,800)

preventive RC

101,474 (3,853-448,009)
125,363 (9,826-541,592)

2,918,379 (1,289,445-6,793,822)
3,222,488 (1,584,078-6,990,784)

728 (115-3,301)

6,740 (441-51,249)

5,193 (170-40,515)

260 (11-2,086)

205 (6-1,658)

3 (0-22)

preventive R

103,143 (55,225-218,880)

66 (6-511)

102,145 (54,123-217,929)

1 (-1-15)

37 (-22-353)

preventive RC

95,341 (48,304-211,430)

434 (-223-2,381)

94,781 (47,775-210,401)

52 (-135-647)

997 (-2,130-11,389)

preventive R

456,973 (245,547-984,038)

26,630 (-52,510-175,003)

424,831 (172,084-960,493)

69 (-52-730)

1,375 (-682-13,068)

34,019 (-21,563-197,724)

reactive 24m

493,471 (259,415-1,047,490)

450,169 (171,307-1,012,565)

reactive 12m
1y

72 (-57-791)

74 (-41-774)
1,458 (-684-14,299)

519,150 (269,346-1,106,166)

470,039 (184,171-1,071,152)

reactive 6m

1,532 (-394-14,463)
35,802 (-25,577-207,822)

37,066 (-17,873-210,272)

536,347 (277,278-1,172,571)

488,439 (188,101-1,116,378)

78 (-68-803)

1,630 (-719-15,271)
38,620 (-31,308-217,423)

612,637 (311,868-1,300,391)

37 (-159-580)

787 (-2,290-10,771)

19,911 (-57,442-157,859)

29,398 (3,764-62,036)

23,761 (1,817-55,030)

389 (95-761)

236 (-110-646)

5,770 (-8,344-21,143)

7,056 (-5,045-23,137)

7,281 (-5,357-24,274)

7,695 (-3,836-23,693)

8,257 (-6,029-24,581)

4,584 (-9,515-20,481)

8,180 (-4,230-24,351)

5,108 (-9,111-21,838)

42 (-142-589)
79 (-45-810)

8,908 (-3,515-25,455)

6,023 (-6,330-22,975)

9,685 (-3,366-25,521)

7,266 (-5,362-23,101)

86 (-41-842)

53 (-94-681)

93 (-40-929)

68 (-68-748)

738 (-3,208-6,718)

1,664 (-1,808-7,232)

13 (-25-204)
6 (-59-162)

2,369 (-1,045-7,542)

2,547 (-589-7,921)

3,142 (6-9,154)

20 (-12-246)

1,646 (-349-14,970)

900 (-2,002-10,750)

1,778 (-286-15,408)

1,154 (-1,164-12,305)

1,959 (-249-17,441)

1,481 (-770-14,206)

480 (-216-5,301)

23 (-6-247)

29 (0-295)

39,483 (-20,364-214,667)

22,518 (-51,963-166,904)

41,761 (-19,483-225,826)

27,476 (-36,801-189,218)

45,690 (-19,734-240,875)

320 (-496-4,440)

10,707 (-5,741-69,999)

112,177 (0-313,708)

92,217 (-1,186-300,704)

reactive 6m

563 (-109-5,330)

11,948 (-2,683-73,634)

119,345 (0-322,656)

99,007 (-787-312,044)

reactive 1m

704 (22-6,262)

1,713 (-1,974-6,939)

15 (-32-197)

376 (-569-4,223)

14,975 (-95-83,638)

7,959 (-13,557-61,334)

Cases Averted

Deaths Averted

DALYs Averted

223,297 (108245-489,334)

203,159 (90,632-468,040)

Averted Treatment Costs

202,723 (76,770-471,912)

191,479 (72,058-456,733)

preventive R

Cost of Vaccination

preventive RC

Net Costs

Strategy

Table S4. Predicted vaccine impact with randomized outbreak timing, fixed outbreak timing, pre-outbreak incidence and post-outbreak incidence. The median (95% credible interval)
estimates for averted cases, deaths, DALYs, treatment costs, costs of vaccinations and net costs are shown for each vaccination strategy compared to no vaccination for randomized outbreak timing
(“ randomized” ), fixed outbreak timing (“ fixed” ), pre-outbreak incidence (“ pre” ), and post-outbreak incidence (“ post” ). Preventive routine vaccination strategies include routine vaccination
at nine months of age in year 0 with or without a catchup campaign up to 15 years of age. Reactive routine vaccination strategies (with a catchup campaign) include delays of 1, 6, 12, and 24 months
to deployment (“ 1m” , “ 6m” , “ 12m” , “ 24m” , respectively). In the fixed outbreak timing scenario, preventive strategy results are shown for 10, 5, 2, and 1 year(s) (“ 10y” , “ 5y” , “ 2y” ,
“ 1y” ) before the outbreak starts. Results for the randomized and fixed outbreak timing strategies are shown using an outbreak identification definition of 15 standard deviations above the monthly
mean number of typhoid cases. R=routine vaccination; RC=routine vaccination plus a catchup campaign.

randomized

fixed

pre

post
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S2.2.3. Consolidated Health Economics Evaluation Reportings Standards (CHEERS)
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Abstract
Investments in water and sanitation systems are believed to have led to the decline in typhoid
fever in developed countries, such that most cases now occur in regions lacking adequate clean
water and sanitation. Exploring seasonal and long-term patterns in historical typhoid mortality in
the United States can offer deeper understanding of disease drivers. We fit modified Time-series
Susceptible-Infectious-Recovered models to city-level weekly mortality counts to estimate
seasonal and long-term typhoid transmission. We examined seasonal transmission separately by
city and aggregated by water source. Typhoid transmission peaked in late summer/early fall.
Seasonality varied by water source, with the greatest variation occurring in cities with reservoirs.
We then fit hierarchical regression models to measure associations between long-term
transmission and annual financial investments in water and sewer systems. Overall historical $1
per capita ($16.13 in 2017) investments in the water supply were associated with approximately
5% (95% confidence interval: 3-6%) decreases in typhoid transmission, while $1 increases in the
overall sewer system investments were associated with estimated 6% (95% confidence interval:
4-9%) decreases. Our findings aid in the understanding of typhoid transmission dynamics and
potential impacts of water and sanitation improvements, and can inform cost-effectiveness
analyses of interventions to reduce the typhoid burden.
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Author summary
Typhoid fever remains a major source of morbidity and mortality in low- and middleincome countries. Historical investments in water and sanitation systems are thought to have led
to the decline in typhoid fever in developed countries, such that most of the global burden of
disease now occurs in regions with poor sanitary conditions and inadequate access to clean water
and sanitation. However, there is limited empirical evidence to quantify the impact of
investments in water and sanitation on typhoid fever incidence. We developed a mathematical
model to examine trends in weekly typhoid mortality data from 1889-1931 in 16 U.S. cities.
Through this analysis, we were able to examine how seasonal patterns of typhoid transmission
varied geographically and historically depending on the water supply and treatment, and quantify
the relationship between investments in water and sanitation infrastructures and long-term
typhoid transmission rates. Our findings have important implications for the understanding of
typhoid transmission dynamics and potential impact of improvements in water and sanitation
infrastructure. Resource-poor countries must prioritize spending on public health issues,
weighing the costs and benefits of interventions. Our results can help to inform comparative
cost-effectiveness analyses of different interventions to reduce the global burden of typhoid
fever.
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Introduction
Typhoid fever is caused by infection with the bacteria Salmonella enterica serovar Typhi,
which is mainly transmitted through fecal contamination of food or water [1]. In many developed
countries, including the United States (U.S.), investments in water and sewer infrastructures led
to the decline in typhoid incidence in the beginning of the 20th century, such that the majority of
the global burden now occurs in countries where sanitary conditions are poor and access to clean
water and sanitation is lacking [1-3].
Examining short- and long-term trends in typhoid incidence can provide insights into
factors driving transmission [4]. In many countries, typhoid fever follows a seasonal pattern,
with peak incidence occurring around the same time every year [5, 6]. Seasonality in typhoid
exhibits distinct patterns by region and latitude, and can be influenced by rainfall, temperature,
and other climatic factors [6]. However, drivers of seasonal patterns in typhoid are not yet fully
understood.
Long-term patterns in typhoid cases have also been investigated, particularly in countries
where cases have declined to almost zero [4]. In the U.S., the number of typhoid deaths
decreased from a reported 35,000 in 1900 to three from 1999-2006 despite a 4.3-fold population
increase [7-10]. While it is commonly accepted that investments in water and sanitation are
responsible for the decline in typhoid fever, there is limited empirical evidence to support this
claim. In one study, Cutler and Miller found that the introduction of clean water technologies
was responsible for almost half of the mortality reduction in major cities at the beginning of the
20th century; however, they did not consider complexities of the disease transmission process
[11].
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In this study, we developed mathematical and statistical models to examine seasonal and
long-term trends in typhoid transmission from 1889-1931 in 16 U.S. cities. Our objectives were
two-fold: (1) to examine how seasonal patterns of typhoid transmission varied geographically
and historically depending on the water supply and treatment; and (2) to quantify the relationship
between investments in water and sanitation infrastructures and long-term typhoid transmission
rates.

Methods
Study Design, Data, and Variables
We extracted reported weekly typhoid mortality from 1889 to 1931 at the city level from
the Project Tycho database [12, 13]. Cities were chosen based on two criteria: (1) at least 1,000
typhoid deaths were reported during the study period, and (2) less than 25% of weekly data was
missing. These exclusion criteria resulted in data for 16 U.S. cities (S1 Fig). While errors in
disease diagnosis and missing data make underreporting likely, the consistency of reporting over
time allows for our analysis [13, 14].
Yearly population estimates were obtained from the U.S. Census Bureau [15]. The
population <1 year of age was used as a proxy for births, since birth rate data was not available
and typhoid is rare in <1-year-olds [16]. New York City population estimates were adjusted for
the consolidation of the five boroughs (including Brooklyn) in 1898 [17]. We also accounted for
this change by multiplying the number of reported typhoid deaths in Brooklyn by a factor of 1.28
(i.e. the relative population size of the other boroughs, for which we did not have separate
mortality data) and adding this to typhoid mortality data from New York City (previously only
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Manhattan). For all cities, cubic splines were used to extrapolate weekly population estimates
(S2 Fig).
Financial data on water supply and sewer systems for each city were extracted from U.S.
Census Bureau yearly reports [15]. We obtained data on water and sewer systems across five
categories: “receipts,” “expenses,” “outlays,” “value,” and “funded debt”, and used the first three
to estimate the “overall investment” (Table 1). The main financial variable of interest, “overall
investment”, represents the cumulative per capita investment in water supply and sewer systems.
It was calculated as the sum of the annual acquisition/construction costs (cumulative outlays) and
maintenance/operation costs (expenses) after subtracting yearly receipts (Table 1). All variables
were adjusted yearly for inflation to 1931 dollars using the Bureau of Labor Statistics’ Consumer
Price Index [18], then divided by the yearly city population to generate per capita estimates. Data
on specific water supply interventions for each city were extracted from a variety of sources (S1
Table) [19].
Table 1. Definitions of financial variables. Each of the six categories of financial variables
used in this study are described, as defined by the U.S. Census Bureau in its annual
“Financial Statistics” series (the source of these variables).
Description
Maintenance and operation
Receipts for payments for governmental costs. These receipts usually take
Receipts

Expenses

the form of money, bills receivable, land, and services. All city revenue
receipts were recorded in the city books for municipally-operated water
supply and sewer systems for the public or city (excluding interest from
current deposits).
City government costs, other than interest, of (1) services employed,
property rented, and materials consumed in connection with maintenance
and operation; (2) losses from deflation, bank failures, and related causes;
and (3) depreciation of permanent properties and public improvements.

Acquisition and construction
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Outlays

Value and debt
Value

Funded debt
Cumulative investment
Overall investment

Total annual amounts paid by the city for the acquisition or construction of
permanent lands, properties and public improvements. These include
payments for additions made to previously acquired or constructed
properties.

Total estimated value of the public properties (including depreciation),
including both the business value and the physical value of the building and
equipment. This amount is estimated separately by city officials, and is
acknowledged to not be estimated uniformly across cities.
Long-term debts or debt liabilities in the form of bonds or certificates of
indebtedness that the city government is under obligation to pay.
Overall investment in the water supply or sewer systems, defined as the
cumulative sum of the amount spent each year on acquisition/construction
(outlays) and maintenance/operation (expenses minus receipts) of water or
sewer infrastructure.

All cities had missing data on weekly typhoid mortality, due to the nature of the historical
data. In many cases, missing mortality counts were instances of zero cases, because cities
frequently only reported during weeks when deaths occurred. To account for both true zero
counts and missing data, mortality data were coded as zeroes if there were fewer than 13
consecutive weeks of missing death counts, and imputed as missing data if there were 13 or more
consecutive weeks. We imputed missing data using the package “imputeTS” in R[20],
performing Kalman smoothing (function na_kalman) to preserve the seasonality and overall
trends of the time series (S3 Fig). This package and algorithm are commonly used for univariate
time series imputation. We conducted a sensitivity analysis to assess how this arbitrary 13-week
cut-off could impact our results (S2 Text).
After imputation, weekly typhoid mortality counts and population estimates were
aggregated into four-week periods to approximate the generation interval of typhoid [21, 22].
The generation interval can be defined as the time between when an infector is infected and
when an individual is infected by that the infector [22, 23]. In this study, the generation interval
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was based on data from the natural history of typhoid infection, derived from human challenge
studies. Other studies suggest that TSIR models are not overly sensitive to having a precise
estimate for the generation interval [24]. Since the mortality data were later log-transformed, we
added one to every four-week data point before adjusting for underreporting and before fitting
the model; a sensitivity analysis was again performed to assess the impact of adding different
values.
Statistical Methods
We conducted preliminary analyses to describe differences in typhoid mortality trends
between cities and pre- to post-intervention. First, we fit generalized linear models (GLMs) with
linear time trends and one-year and six-month harmonics to the pre- and post-intervention time
series (defined as two years after the first water supply intervention) for each city. The “first”
intervention is defined as the initial occurrence of a municipally-reported method or process that
aimed to improve the water quality in a city’s main water source, and was used only in the
preliminary analyses to define the pre- and post- intervention period. The six- and 12-month
harmonics allow for an overall annual variation plus additional fluctuations, if any; these were
identified using Fourier and wavelet analyses. We compared intercepts, slopes, and six-month
and one-year amplitudes for the pre- and post- periods in the GLMs, and plotted the overall sixand 12-month amplitudes on a map of the U.S. to examine spatial patterns.
We then fit Time-series Susceptible-Infectious-Recovered (TSIR) models [25] to each
city’s pre- and post-intervention time series to investigate seasonal and long-terms trends in
typhoid transmission rates. TSIR models are a well-established approach to examine associations
between external variables and infectious disease transmission rates by conditioning on the
susceptible population and exposure to a pathogen to extract rates of infectiousness inferred from
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the time series [26]. These models estimate the disease transmission rate by reconstructing the
underlying susceptible and infectious populations. This method explicitly attributes
autocorrelation in the data to the interaction between susceptible and infectious individuals.
In general, new infections at time t+1 (It+1) arise from transmission from infectious (It) to
susceptible (St) individuals at time t:
’pÇå = ◊p ’pÈ ëp

(1)

where ◊p is the disease transmission rate at time t. The exponent » allows for heterogeneous
population mixing and corrects for discretization of the continuous-time infection process [27].
We modified Equation 1 to account for the unique features of typhoid epidemiology,
including the contribution of chronic carriers (C) to the prevalence of infection. Furthermore, we
separated the transmission parameter ◊p into seasonal and long-term components (◊oq$o and ◊Íp ,
respectively). Thus, the TSIR model for typhoid is as follows:
’pÇå = ◊Íp ◊oq$o,m (’p + ∞)È ëp

(2)

where ◊oq$o,m reflects the annual seasonally varying transmission parameter (j = 1,2,…13 for the
number of distinct four-week generation intervals in one year), and ◊Íp (558 distinct values for
the number of generation intervals over the 43-year period, minus 1 for the reconstruction of
’pÇå ) captures trends and any seasonal variation lasting longer than one year. We fixed ◊oq$o,åÅ =
1 and estimated the remaining j = 1,2,…,12 seasonal transmission parameter in comparison to
the thirteenth month. We estimated ◊Íp using a semi-parametric method described below and in
more detail in the S1 Text.
Equation 2 can then be log-transformed:
¡íç(’pÇå ) = ¡íç(◊Íp ) + ¡íçâ◊oq$o,m ã + » ¡íç(’p + ∞ ) + log(ëp ).

(3)
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The TSIR equation is now on the additive scale, and can be incorporated into regression
frameworks (S1 Text). This method has been explained in detail elsewhere [25].
With the goal of extracting the seasonal and long-term transmission rates (◊Íp and
◊oq$o,m ), we needed to first reconstruct the susceptible, infectious, and chronic carrier
populations. We estimated some of these terms differently for our exploratory and main
analyses, but both analyses utilized regression and maximum likelihood estimation to infer these
terms from the disease and census data.
The susceptible population at time t is equal to the previous susceptible population plus
new births minus new infections, summarized as follows:
p}å
ëp = ë̅ + Œ~ + ∑p}å
è¶~ •è − ∑è¶~ ’è

(4)

where ë̅ is the mean susceptible population over the study period, Œ~ is the deviation of the
susceptible population from the mean at time zero, ∑p}å
è¶~ •è is the sum of births up to time t,
∑p}å
è¶~ ’è is the sum of “true” infections up to (but not including) time t, and k denotes the time
point ranging from the beginning of the study up until just before time t. The number of “true”
infections at time t (It) is estimated from the observed deaths at time t (Yt) divided by the
underreporting fraction (Ï), which in this case also accounts for the case fatality rate. Equation 4
can be rearranged as
å

∑pè¶~ •è = ª º ∑pè¶~ ¥è − Œ~ + Œp
Ì

(5)

to estimate the underreporting fraction (slope), deviation at time zero (intercept), and model
residuals (Œp = ëp − ë̅) using linear regression. We used only the first ten years of typhoid
mortality and census data (prior to the introduction of water and sanitation interventions) [24, 25]
to estimate the rate of underreporting of infectious individuals, and assumed that r remained
constant over the entire 43-year study period.
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To estimate C and St (= Œp + ë̅) in the preliminary analysis, we maximized the likelihood
of the fitted regression (Equation 5) over different values of C and ë̅, each ranging from 0 to the
maximum population size over the time period. For the preliminary analysis, we then fit
Equation 3 using ordinary least squares regression.
For our main analysis, we used the same estimates for the infectious population (adjusted
for underreporting) and chronic carriers from the preliminary analysis, but modified the
calculation for the susceptible population to include waning of immunity. Instead of using the
residuals from Equation 5, we modelled the susceptible population at time t as a function of the
total population at time t minus the previously infectious and recovered individuals:
ëp = ≤p − ∑Ó
x¶~ ’p}x Ãx

(6)

where Ãx is the degree of immunity i generation intervals after infection.
Once we had estimates for the susceptible, infectious, and chronic carrier components of
Equation 3, we fit the model via weighted least squares regression using a range of values for
smoothing and spline penalty parameters. For the final model, we chose the one with the
smoothing and spline penalty parameters that resulted in the lowest sum of squared differences
between each point and its out-of-sample prediction over all points.
The model-fitting process is described in detail in the S1 Text; additional details about
TSIR models can be found elsewhere [25, 28, 29]. We performed sensitivity analyses on the
various components of the model, as described in the S2 Text.
Examining predictors of seasonal and long-terms trends in transmission
Once we fit the optimal TSIR model for each city, we extracted the seasonal and longterm transmission rates. Seasonal transmission parameters were plotted separately for each city
and aggregated by water source type. We calculated the mean estimate (among all cities and
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across water source types) in each month. Months were considered to have significantly low or
high seasonal transmission if their confidence intervals were entirely below or above one,
respectively. The percentage of cities with seasonal transmission significantly below or above
one in each month were calculated overall and by water source type.
To examine associations between long-term typhoid transmission and financial
investments in water and sewer systems, we fit hierarchical regression models for each financial
variable separately. We fit several variable transformations and model formulations and chose a
linear model with a log-transformed outcome following exploratory analyses. The final approach
has fixed and varying city-level intercepts and slopes:
logâ◊Íp,x,p ã = (à~ + ≈~,x ) + (àå +≈å,x )Ôx,p

(7)

where fixed intercept d0 is the average log-transmission rate of typhoid across cities with no
investments in water and sanitation, random intercept ≈~,x represents the deviation from the fixed
intercept for city i, fixed slope d1 is the average change in log-transformed typhoid transmission
across cities for a $1 per capita increase in the financial variable, random slope ≈x is the deviation
from the fixed slope for city i, and Xi,t is the financial investment for city i in year t.
Missing financial variable data were assumed to be missing completely at random and
were omitted from analyses. Due to multicollinearity between most of the financial variables, it
was not possible to fit regression models with multiple predictors. However, the main variables
of interest, overall investments in the water supply and sewer systems, provide a representation
of cumulative financial investments as a whole over the time period.
Model Validation
To validate the TSIR models and assess their predictive ability, we went back and fit each
TSIR model to the first 38 years of data (1889-1926). Using the fitted model parameters, we
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projected forward for the last five years (1927-1931) and compared the observed and predicted
typhoid mortality. To predict the long-term typhoid transmission rate, we used the relationship
with overall investment in the water supply identified by the hierarchical regression analysis.
This variable had the highest marginal and conditional R2 among the financial variables.
All analyses were performed using R version 3.4.0 [30].

Results
Data description and preliminary analyses
From 1889-1931, there were 86,023 typhoid deaths across all cities (median: 3,382
deaths per city). S3 Fig shows the weekly time series of typhoid mortality in each city. Of the 16
cities, four used reservoirs or lakes as their water source, three drew water from the Great Lakes,
and nine accessed water from rivers (Table 2; additional details in S2 Table). Most cities
introduced water chlorination or filtration during the study period, but some cities implemented
other interventions. Boston’s Metropolitan Water District completed a new reservoir in 1908,
while New York built several additional reservoirs between 1905-1915. The Sanitary District of
Chicago changed the direction of flow of the Chicago River so sewage from the city would no
longer be discharged into Lake Michigan, the city’s water source. To address flooding problems
from periodic hurricanes and its location below sea level, the New Orleans Drainage
Commission began to periodically drain the water supply in 1900. San Francisco had no water
supply interventions that we could identify; however, a major earthquake in 1906 resulted in
severe infrastructure damage and changes to the water supply system, and was included as a
proxy intervention in our analysis.
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Table 2. Descriptive statistics of cities and their water supplies. "Total Deaths" are the
number reported after imputation for missing data. Missing data numbers represent
estimates after correcting for “true zeros” in the datasets, and before imputation.
% (Number)
Weekly
Missing
Mortality
Data

City

State

Total
Deaths
18891931

Baltimore

MD

5,198

4.5% (100)

431,000

Reservoirs

1910

Boston

MA

3,412

5.4% (117)

414,000

Lakes/
Reservoirs

1908

Chicago

IL

13,161

6.8% (150)

981,000

Great Lake

1900

Cincinnati

OH

3,292

7.5% (167)

289,000

River

1908

Cleveland

OH

3,622

5.1% (115)

241,000

Great Lake

1913

Milwaukee

WI

1,912

16.0% (358)

187,000

Great Lake

1910

Nashville

TN

1,535

10.2% (227)

69,594

River

1908

New Orleans

LA

3,352

2.0% (45)

237,000

River

1900

New York

NY

16,991

3.5% (79)

2,370,000

Reservoirs

1903

Philadelphia

PA

13,927

16.3% (364)

1,010,000

River

1902

Pittsburgh

PA

7,864

17.3% (386)

322,000

River

1908

Providence

RI

1,106

13.1% (294)

127,000

River

1902

Saint Louis

MO

3,271

21.9% (490)

432,000

River

1904

San Francisco

CA

2,348

17.6% (393)

286,000

Lakes/
Reservoirs

1906

Population
in 1888

Water
Source
Type

Year of (1st)
Intervention

Type of Water
Supply
Intervention(s)
1889-1931
Chlorination;
Filtration
New reservoir
Changed river flow;
Chlorination
Chlorination;
Filtration
Chlorination;
Filtration
Chlorination
Chlorination;
Filtration
Drainage; Filtration
New Reservoirs;
Chlorination;
Filtration
Chlorination;
Filtration
Chlorination;
Filtration
Filtration
Chlorination;
Filtration
Earthquake*

Chlorination;
Filtration
Chlorination;
Washington
DC
3,651
5.1% (113)
214,000
River
1903
Filtration
*No interventions were identified for San Francisco, but the 1906 earthquake was used as a proxy due to the necessary
infrastructure improvements that followed.
Toledo

OH

1,381

22.8% (510)

75,167

River

1910

In the preliminary harmonic regression analysis, fluctuations in typhoid mortality
generally became less extreme from pre- to post-intervention periods. The six-month amplitude
in typhoid mortality decreased in all but two cities (Milwaukee and Nashville), while the oneyear seasonal amplitude decreased in all cities but New Orleans post-intervention (S4-S5 Fig, S3
Table). In the two cities where the six-month amplitude increased, the amplitude was already
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extremely low in the pre-intervention period and did not increase by much in the postintervention period. In every city, typhoid mortality significantly decreased with time in the
post-intervention period. The pre-intervention time trend was less consistent across cities.
While the harmonic regression analyses suggested changes in the seasonality of typhoid
mortality following interventions, there was little to no difference in seasonality of typhoid
transmission pre- versus post-intervention estimated using TSIR models upon visual inspection
(S6 Fig). Thus, we estimated the seasonal transmission rate for the entire 43-year study period in
subsequent analyses. The similarity between pre- and post-intervention seasonality in the TSIR
models but not in the harmonic regression models in the preliminary analyses suggests the need
for using models that incorporate disease dynamics as opposed to simpler analyses that do not
take disease dynamics into account (S4, S6 Fig).
Variations in seasonal patterns
Based on the full TSIR model (including waning of immunity), seasonal typhoid
transmission increased at the beginning of the year and peaked around late summer or early fall
in most cities (months 8-10; Fig 1, S4 Table). This trend varied somewhat across cities. In New
Orleans, peak transmission occurred earlier (months 7), while in San Francisco the peak occurred
later (months 10-11). In several cities, there were additional peaks in the winter (months 1-3).
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Fig 1. Annual seasonal typhoid transmission estimated from Time-Series SusceptibleInfectious-Recovered models. The estimated seasonal transmission rate in each 4-week period
is plotted for each city (color-coded by water source type; solid lines are the mean estimates and
dashed lines are the 95% confidence intervals). The second-to-last panel shows the mean
seasonal transmission across all cities in bold black. The last panel shows the mean seasonal
transmission rate for cities with a particular water source type, with reservoirs in blue, rivers in
green, and Great Lakes in purple. Seasons are shown in the background in shades of grey
(medium-light grey for winter, light grey for spring, dark grey for summer, and medium-dark
grey for fall).

Seasonality in typhoid transmission also varied by water source type. While the seasonal
trend was similar across different water source types, the magnitude of the peaks in transmission
differed (bottom-right panel of Fig 1, S4 Table). Cities that relied on reservoirs had the highest
amplitude of seasonal typhoid transmission, while cities that drew water from the Great Lakes
had the least variability.
Long-term typhoid transmission and investments in water and sanitation
After the 1900s, long-term typhoid transmission began to decrease almost monotonically
in every city (Fig 2). Conversely, overall investments in water and sewer systems increased over
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time (Fig 2). Overall investments in both the water supply and sewer system were significantly
associated with long-term typhoid transmission. Each $1 (in 1931) per capita increase in overall
cumulative investment in water and sewer systems was associated with an estimated average 5%
(95% confidence interval: 3-6%) and 6% (95% confidence interval: 4-9%) decrease in typhoid
transmission, respectively (Table 3). Overall investments in both the water supply and sewer
system were also significantly inversely associated (i.e. confidence interval entirely below one)
with city-level transmission in 15 of the 16 cities (Table 3). The proportion of variability in longterm typhoid transmission explained by the both the fixed effects and random effects for overall
investments was 98% for both variables, while average overall investments (i.e. fixed effects
alone) explained 33% and 28% of the variability in typhoid transmission for the water supply
and sewer system, respectively (S5 Table).
Fig 2. Long-term typhoid transmission rate by city estimated from Time-series SusceptibleInfectious-Recovered models. The estimated long-term transmission rate (blt, solid black line)
is plotted for each city, by four-week generation interval. Overall per capita investments in the
water supply (blue circles) and sewer system (green pluses) in 1931 US dollars are also shown
for each city from 1902 – 1931.
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Table 3. Results of hierarchical regression analyses for overall investment variables:
Random and fixed effects for yearly average long-term typhoid transmission vs. overall
investments in water and sewer systems. Each estimate shows the associated multiplicative
change in the estimated long-term typhoid transmission rate for each $1 per capita increase in
overall investment for the water supply and sewer system (in 1931 US dollars). Both random and
fixed effects are shown, with their 95% confidence intervals.
Estimate
Water Supply
Sewer System
Baltimore
0.95 (0.93-0.96)
0.97 (0.95-0.99)
Boston
0.94 (0.93-0.96)
0.93 (0.91-0.96)
Chicago
0.91 (0.90-0.93)
0.95 (0.92-0.97)
Cincinnati
0.95 (0.94-0.97)
0.95 (0.92-0.97)
Cleveland
0.97 (0.95-0.98)
0.94 (0.92-0.97)
Milwaukee
0.93 (0.91-0.94)
0.98 (0.96-1.00)
Nashville
0.91 (0.90-0.93)
0.82 (0.79-0.85)
New Orleans
0.97 (0.95-0.99)
0.98 (0.96-1.01)
Random + Fixed
New York
0.98 (0.97-1.00)
0.93 (0.90-0.96)
Philadelphia
0.93 (0.91-0.95)
0.93 (0.91-0.96)
Pittsburgh
0.94 (0.92-0.95)
0.85 (0.82-0.88)
Providence
0.98 (0.97-1.00)
0.95 (0.92-0.98)
Saint Louis
0.99 (0.98-1.00)
0.94 (0.92-0.97)
San Francisco
0.98 (0.96-0.99)
0.97 (0.94-0.99)
Toledo
0.96 (0.95-0.98)
0.95 (0.93-0.98)
Washington, D.C.
0.98 (0.97-0.99)
0.94 (0.92-0.97)
Fixed
0.95 (0.94-0.97)
0.94 (0.91-0.96)
When considering the other financial variables, the associations were not as consistent
across cities. Annual investments in maintenance or operation (receipts or expenses) had more
city-level associations as compared to acquisition or construction variables (outlays) (S6 Table).
In some instances, the relationship between the individual investment variables and typhoid
transmission was positive (S6 Table, S7-16 Figs).
TSIR model fit
In general, the TSIR models fit to the full 43-year time series provided an adequate fit to
the data. The full TSIR models (including waning of immunity) explained approximately 66%
(range: 45-90%) of the variability in typhoid mortality counts over the study period (S7 Table).
When we validated the models by fitting to the data through 1926 then using the fitted models to
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predict the last five years of typhoid mortality, in most cases the overall predicted trend and
seasonal peaks in typhoid mortality were captured, but the model could not explain some of the
mortality spikes (S17-S20 figs). Nevertheless, the models generally provided a good fit to the
data, with small out-of-sample mean squared prediction errors (S5 Table).
Our results were not sensitive to methods of handling missing data and zeros or variations
in model structure (S2 Text, S8-S10 Tables). Seasonal transmission patterns remained the same,
and long-term trends retained their general shape (S2 Text, S21-36 Figs). Our results were also
not sensitive to the threshold for the maximum duration of immunity (S8-S9 Tables). All cities
had different patterns and functions of immunity decay, but the shapes of the seasonal and longterm transmission rates of typhoid were mostly preserved when the models were fit assuming the
maximum duration of immunity (173 generation intervals, or approximately 13 years) or no
waning of immunity.

Discussion
The decline in typhoid mortality in the early 20th century U.S. has been attributed to
investments in water and sewer systems. Our analysis strengthens this hypothesis. Furthermore,
we characterized seasonal and long-terms trends in typhoid transmission and quantified the
relationship between overall infrastructure investments and declines in transmission rates.
Historically, typhoid fever cases peaked during late summer/early fall in the U.S. [5, 31].
Yearly peaks of typhoid transmission coincide with warmer temperatures, similar to global
trends [6, 32-34]. This pattern may be related to the enhanced growth of the bacteria at warmer
temperatures, seasonal changes in diet (i.e. increased consumption of uncooked fruit and
vegetables in summer and fall), or the increased abundance of flies that may serve as mechanical
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vectors of the bacteria [5, 6, 35, 36]. Additional fluctuations in typhoid transmission seen in
some cities might be explained by seasonal variation in rainfall, which typically peaks in spring
and summer in the eastern U.S. and winter on the west coast, and can impact the water supply to
a city [33, 34, 37].
The overall amplitudes in typhoid seasonality did not appear to cluster geographically (S5
Fig), which led us to the hypothesis that the differences between cities may be due to differences
in water source type. Variations due to water source type have a number of possible
explanations. Cities relying on the Great Lakes for water had the least seasonal variability in
transmission. Large bodies of water tend to be less impacted by seasonal changes in temperature
and rainfall [38, 39]. The Great Lakes have a moderating effect on climate, absorbing heat and
cooling the air in the summer, yet radiating heat and protecting from frost in the fall [40, 41].
Flowing water can slow down the movement of microbes [42], which may explain the lower
seasonal variability in typhoid transmission among cities that draw water from rivers. Reservoirs
and lakes are mostly smaller stagnant water sources, and may be more sensitive to seasonal
changes in climate.
Differences in water source type may help to explain why some nearby cities exhibited
different seasonal patterns. For example, New York and Philadelphia, though less than 100 miles
apart, had different patterns of seasonal typhoid mortality and transmission (Fig 1, S3-S5 Figs).
From 1890-1910, the typhoid mortality rate in New York was considerably lower than in
Philadelphia (22.4 versus 43.1 deaths per 100,000 people per year, respectively). However,
typhoid transmission was more seasonal in New York (which relied on rural reservoirs)
compared to Philadelphia (which drew its water from rivers running through the city). While
typhoid transmission consistently peaked in the late summer/early fall in New York, Philadelphia

127

had only small seasonal variations in the transmission rate. It is possible that these differences
reflect differences in the predominant route of typhoid transmission (i.e. food- versus waterborne) in the two cities. Strong seasonality in typhoid incidence was also noted in Santiago,
Chile in the 1970-80s, and was linked to seasonal irrigation of crops with contaminated
wastewater; typhoid incidence declined sharply once this practice was ended [4, 43, 44]. A better
understanding of the drivers underlying seasonal patterns of typhoid transmission, and the
differences noted among the various water sources, can aid typhoid control efforts.
Overall investments in the water supply and sewer system were inversely associated with
long-term typhoid transmission in every city. These two predictors explained most of the
variability in long-term typhoid transmission when taking into account city-level random effects.
These findings demonstrate the strong influence of investments in water and sanitation on
typhoid transmission over time. However, other factors may also contribute. Associations also
varied across cities, perhaps reflecting differences in water source types, public versus private
ownership of water supplies, and rates of migration and poverty in the different cities.
A previous study by Cutler and Miller had similar findings [11]. They estimated that on
average, filtration and chlorination reduced typhoid fever mortality by 25% from 1900 to 1936.
They claimed that clean water technologies explained almost all of the decline in typhoid
mortality, estimating that the cost of clean water technologies per person-year saved was $500 in
2003 ($666 in 2017), suggesting it was highly cost-effective. However, their analysis did not
consider the complexities of typhoid transmission, such as chronic carriers, host immunity, and
interactions between susceptible and infectious individuals, which makes it difficult to
extrapolate their findings to better understand the impact of water and sanitation investments on
typhoid transmission in modern contexts.
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In the early 20th century, William Sedgwick studied what he referred to as the “MillsReincke Phenomenon”, in which the introduction of sanitation and subsequent decrease in
typhoid deaths was also associated with decreases in mortality from other diseases [45]. In the
first half of the 20th century, all-cause mortality fell by 40% [11]. Typhoid fever and other
waterborne diseases were not the only diseases to decline during this period; many non-enteric
diseases were also reduced by 1931 [7].
It has thus far been difficult to evaluate the benefits of water and sanitation infrastructure
investments compared to the deployment of new typhoid conjugate vaccines without data to
quantify the costs and impact of the former [46]. With the recent World Health Organization
recommendation for typhoid conjugate vaccine use and pilot studies underway [47, 48],
governments are looking to prioritize the allocation of resources to yield the greatest decrease in
typhoid burden. While long-term investments in water and sanitation systems are associated with
decreased typhoid transmission, they also have benefits that extend beyond typhoid.
Nevertheless, future studies should focus on comparing the cost-effectiveness and budget impact
of the two interventions, bearing in mind the context and feasibility of deployment.
This study had some limitations. The weekly mortality counts likely suffer from lack of
sensitivity and specificity in the diagnosis of typhoid fever. Additionally, we implicitly account
for case fatality rates in our analysis. These issues are unlikely to bias our results provided the
under- or over-reporting of typhoid mortality (and case fatality rate) was consistent over the
study period. The cities chosen for our analysis were also limited by data availability. As a result,
all of the cities were primarily in the northeastern U.S. All cities also had missing data, which
had to be imputed. Furthermore, the roles of chronic carriers and immunity to typhoid are not
fully understood. Our inclusion of carriers in the model matches the natural history of typhoid,
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but we did not examine whether it was necessary to model carriers separately. Patterns in the
decay of immunity to typhoid varied widely across cities. Nevertheless, transmission rate
estimates were not sensitive to the way we modelled immunity to infection. Finally, due to high
levels of correlation between the financial variables, we were not able to estimate the combined
effect of water supply and sewer system variables. Some of the overall decline in transmission
may have been attributable to other interventions such as economic and nutritional gains, and
behavior-change campaigns targeting hand and food washing [11, 49-51].
Our results aid in the understanding of the dynamics of typhoid transmission and
potential impact of improvements in water and sanitation infrastructure, which is still lacking in
many parts of the world. Before improvements in water and sanitation systems in the U.S.,
typhoid fever and other water-borne diseases were common. In 1900, infectious diseases (and
typhoid in particular) accounted for 44% (2.4%) of deaths in major cities in the U.S. [7],
compared to 30-51% (0.3-0.7%) in current day low- and middle-income countries [52-54].
Worldwide, approximately 1.1 billion people lack access to clean water, and roughly 2.5 billion
people lack adequate sanitation [55]. Water and sanitation technologies can have substantial
health returns; however, the continued operation and maintenance of these systems can be costly.
Resource-poor countries must prioritize spending on public health issues, bearing in mind the
cost-effectiveness and affordability of implementing and maintaining interventions. Our results
can help to inform comparative cost-effectiveness analyses of different interventions to reduce
the global burden of typhoid fever.
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Supporting Information
S1 Text: Model-fitting process.
We fit Time-series Susceptible-Infectious-Recovered (TSIR) models to each city’s time
series to investigate seasonal and long-terms trends in typhoid transmission rates. In general, new
infections at time t+1 (It+1) arise from transmission from infectious (It) to susceptible (St)
individuals at time t:
’pÇå = ◊p ’pÈ ëp

(S1)

where ◊p is the disease transmission rate at time t and » is a scaling factor that adjusts for
heterogeneous mixing in the population (a=1 corresponds to homogeneous mixing, a=0
corresponds to no auto-correlation in the time series).
After modifying Equation S1 to account for the unique features of typhoid epidemiology
(Equation 2 main text) and log-transforming the model, the equation is as follows:
log (’pÇå ) = log (◊Íp ) + log â◊oq$o,m ã + » log (’p + ∞ ) + log(ëp ).

(S2)

We reconstructed the infectious and chronic carrier populations via maximum likelihood
estimation using Equation 5 (main text) and adjusting for underreporting. We then we modelled
the susceptible population at time t as a function of the total population at time t minus the
previously infectious and recovered individuals:
ëp = ≤p − ∑Ó
x¶~ ’p}x Ãx

(S3)

where Ãx is the degree of immunity i generation intervals after infection (determined by a decay
of immunity function). We initially approximated St using a log-transformation and first-degree
Taylor series expansion around the average susceptible population size:
log(ëp ) ≈ Òlog(ëÓq$Ú ) + t

ŸÛ

Ùı6ˆ

Ê

˘

Û¯É É
− 1˜ − ∑Ó
.
x¶~ t
Ùı6ˆ

(S4)
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Penalized cubic splines on Ã were used to account for non-linearity in the duration and decay
patterns in immunity. Equation S2 can then be rewritten as:
log (’pÇå ) = log (◊Íp ) + log â◊oq$o,m ã + » log (’p + ∞ )
Ê

Û¯É
− ∑Ó
x¶~ t

˘É

Ùı6ˆ

+ Òlog(ëÓq$Ú ) + t

ŸÛ

Ùı6ˆ

− 1˜

(S5)

Note that the waning of immunity affects the number of susceptible individuals at time t, thereby
indirectly affecting the number of new infections at time t+1. Since the duration of immunity to
typhoid infection and disease is not well understood, we performed sensitivity analyses exploring
different durations of immunity (S2 Text).
We used Equation S5 and the semi-parametric method described by Koelle and Pascual
[1, 2] to estimate the variation in ◊Íp over the full 43-year study period from 1889-1931. One
value of ◊Íp was estimated for each four-week period from 1889-1931 (except for the first, to be
able to calculate ’pÇå ), resulting in 558 estimations. We also estimated 13 values of ◊oq$o,m
corresponding to transmission during the same four-week period each year. This parameter was
estimated as a categorical variable with 13 values, where the first 12 four-week months were
estimated in comparison to the last month (◊oq$o,åÅ = 1).
To fit the model, we used a back-fitting algorithm comprised of repeated penalized cubic
splines on Ã, recursive first-order Taylor series expansion approximations on the log (ëp ) term,
and weighted least squares regressions on iterations of Equation S5. The iterative process was
necessary to allow for the more accurate approximation of the Taylor series expansion and the
cubic splines to converge. For the weighted least squares regressions, the weights were
calculated as I-W, where I was the identity matrix of the same dimension, and W was the
truncated Gaussian kernel weight matrix calculated from the spline penalty weights.
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After the above algorithm converged, we used the same truncated Gaussian kernel weight
matrix W to smooth the residuals of the model fit with all other parameters estimated. The
smoothed residuals were then used to estimate the nonparametric variation in the long-term
transmission rate (◊Íp ). The final long-term transmission rate was multiplied by the population at
each time point to calculate per capita estimates.
The smoothing parameter and spline penalty weights were selected using cross-validation
and testing across a range of values. Each city was fit using all possible values of the smoothing
parameter from 1 to 35 in one-unit increments and spline penalty values from -2 to 30 in one-unit
increments. If the parameters chosen were at the ends of the respective ranges, the intervals were
extended until the optimal values fell within the values tested. To identify the optimal model, we
used leave-one-out validation, in which we dropped one data point at a time (for all data points),
fit the model to the remaining data, and then used the fitted model to predict the out-of-sample
data point. We calculated the sum of squared differences between each point and its out-ofsample prediction over all points, and stored this as the cross-validated (CV) value for each
model fit. The optimal model for each city was the one with the smallest CV value.
S2 Text. Sensitivity analyses.
Description of different components of the model that were tested
We performed several sensitivity analyses to test the robustness of our model
assumptions. We examined different components of the model, including our method of
imputing missing data, the addition of small values to the reported death counts prior to logtransformation (to avoid taking the log of zero), the duration (or inclusion) of waning immunity,
and the inclusion of chronic carriers in our TSIR models. We determined the impact of these
assumptions on the seasonal and long-term transmission parameters, the relationship with the
overall investment variables identified by the hierarchical regression models, and estimates of
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the heterogeneous mixing parameter (a). The results of these sensitivity analyses can be found in
S21-36 Figs and S8-10 tables.
Missing data
To address the issue of missing data, we had to make some decisions about what the
meaning of the missing values might be. In many instances, cities only reported typhoid deaths if
there were any; however, we had to differentiate between these zero counts and truly missing
data points. For the primary analysis, we used a cut-off of 13 consecutive weeks to differentiate
between when missing values represented zeros versus missing data. If there were fewer than 13
weeks of missing death counts, the data points were coded as zeroes, and if there were more, we
used Kalman smoothing to impute the missing values based on the previous observation and the
“filter,” updated at each time point [3, 4]. Since this 13-week cut-off was arbitrarily chosen, we
also fit the TSIR models using an 8-week and 26-week cut-off and compared the results.
Log-transformation
Some of the death counts were zero, which posed a problem for the logarithmic
transformation in our main TSIR model equation. In our main analysis, we added one to every
data point to preserve the shape of the distribution. As a sensitivity analysis, we re-ran all of the
models instead adding 0.5 to every data point to compare the impact of this assumption.
Duration of immunity
Waning of immunity against typhoid infection is poorly understood. While
epidemiological studies and human challenge studies indicate that individuals can be re-infected
with typhoid after approximately one year, mathematical models of typhoid infection
consistently estimate that immunity to typhoid disease is long-lived in order to explain why the
incidence tends to decline with age, particularly in high incidence settings. We assessed the
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assumption of waning immunity in our model, fitting additional models assuming only one year
of immunity following infection and models with no waning of immunity (i.e. lifelong immunity
following infection).
Chronic carriers
In fitting the TSIR models, we noted that the heterogeneous mixing parameter (») was
lower than estimated for other pathogens (e.g. measles) using TSIR models [5]. We hypothesized
that this was likely due to the contribution of long-cycle transmission in the epidemiology of
typhoid, i.e. transmission from chronic carriers and the environmental reservoir. To test this, we
compared the a values estimated for TSIR models without waning immunity, without chronic
carriers, or without either, and in the simple TSIR model (Equation S1).
Results of sensitivity analyses
The results of the analyses in this study were generally robust to the changes in the
assumptions examined. The seasonal transmission rates remained almost unchanged, regardless
of variations in missing data imputation, addition of small amounts to the reported death counts,
and duration or exclusion of waning immunity (S21-36 Figs, top half of panels).
The long-term transmission rates mostly retained their overall shape, but the scale of the
transmission rate changed in some instances (S21-36 Figs, bottom half of the panels). However,
the results of the hierarchical regression models with the overall financial variables were all quite
similar, and results were mostly within 2% of the original estimates (S8-9 Tables).
The heterogeneous mixing parameter varied slightly between the different models, but
mostly kept their order between cities (S10 Table). New Orleans, New York, Philadelphia, and
Pittsburgh typically had the highest estimated a values regardless of the model formulation. The
highest a values were estimated for the model with no immunity, suggesting that there may be
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some identifiability issues between the duration of immunity and the heterogeneous mixing
parameter. Nevertheless, our results were robust to different durations of immunity, as noted
above. Removing chronic carriers from the model generally led to estimated a values closer to
zero, as expected, suggesting typhoid incidence is less dependent on acute cases in the previous
generation. This suggests that long-cycle transmission of typhoid, which does not occur in direct
proportion to cases in the previous generation, can help to explain some of the lack of
autocorrelation in the data. Long-cycle transmission may be related to cases occurring two to
three generations prior (since evidence suggests typhoid bacteria is not long-lived in the
environment [6]) and/or cases residing in surrounding populations that could contaminate water
catchment areas, which would not be captured by our model.
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S1 Fig. Map of 16 cities with water supply types. Each city included in the analysis is denoted
by a different color in its geographical location in the United States. Squares denote cities with
reservoirs, triangles denote those using the Great Lakes, and circles denote those with rivers as
their main water source. The underlying map is adapted from the United States Geological
Survey LandsatLook < https://landlook.usgs.gov/viewer.html#>.
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S2 Fig. Yearly reported population, extrapolated monthly population, and estimated
susceptible population over study period. The yearly U.S. Census Bureau reported population
(red Xs), monthly population extrapolated using cubic splines (solid black line), and susceptible
population (dashed black line) estimated from the main TSIR models are shown for each city
over the study period. Note that in some cities, the susceptible and total population are very close
and cannot be differentiated in the plots.
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S3 Fig. Weekly time-series of reported typhoid mortality in each city. The observed (including imputation, in blue) time series of
weekly deaths reportedly due to typhoid (black lines) and the yearly typhoid deaths per 100,000 people (red Xs) is shown for each city
from 1889-1931.
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S4 Fig. Pre- -and post-intervention sinusoid curves from preliminary harmonic regression
analyses. The pre- (blue) and post-intervention (red) six- and 12-month sinusoid curves fitted to
the typhoid mortality data are shown for each city, along with the seasonal transmission rate
estimated by the main TSIR model (dashed black line).
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S5 Fig. Map of 12- and 6-month amplitudes of typhoid mortality counts, from preliminary
harmonic regression analyses. The average 12- and 6-month amplitudes of seasonal variation
in reported typhoid mortality estimated from the harmonic regression analyses are shown
separately according to the color scale and plotted by geographic location.

145

S6 Fig. Seasonal transmission rate for pre- and post- water supply intervention periods.
The estimated four-week seasonal transmission rates extracted from each city’s simple TSIR
model (not including waning of immunity) are shown for each pre- (blue) and post- (red) water
supply intervention period.
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S7-16 Figs. Financial variable time series. The yearly time series of each of the ten financial
water supply or sewer system variables is plotted over the study period in per capita increments.
Dollar amounts are adjusted for inflation to 1931 US$.
S7 Fig. Annual per capita water supply receipts. Annual water supply receipts from 19021931 are shown for each city in per capita increments (US$ per person).
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S8 Fig. Annual per capita water supply expenses. Annual spending on water supply expenses
from 1902-1931 is shown for each city in per capita increments (US$ per person).
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S9 Fig. Annual per capita sewer system expenses. Annual spending on sewer system expenses
from 1902-1931 is shown for each city in per capita increments (US$ per person).
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S10 Fig. Annual per capita water supply outlays. Annual spending on water supply outlays
from 1902-1931 is shown for each city (green dots) in per capita increments (US$ per person).
The year in which interventions were introduced are represented by the dashed lines for filtration
(red), chlorination (blue), or other interventions (purple). The inclusion of intervention dates is
for illustrative purposes. Outliers not seen: In 1930, water supply outlays from San Francisco
totalled $70.97 per capita; this was the year in which the city purchased the water supply
previously owned and operated by the Spring Valley Water Company. Chicago and New Orleans
introduced water supply interventions in 1900, prior to the time period shown.
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S11 Fig. Annual per capita sewer system outlays. Annual spending on sewer system outlays
from 1902-1931 is shown for each city in per capita increments (US$ per person).
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S12 Fig. Annual per capita value of the water supply system. The overall annual value of the
water supply system from 1902-1931 is shown for each city in per capita increments (US$ per
person). Outliers not seen: In 1897, the value of the water supply system totalled $508.55 per
capita in Washington, D.C.
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S13 Fig. Annual per capita funded debt of the water supply system. The overall annual
accrued debt and/or funded loans for the water supply system from 1902-1931 is shown for each
city in per capita increments (US$ per person). Note: Data were not available for this variable in
Washington, D.C.
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S14 Fig. Annual per capita funded debt of the sewer system. The overall annual accrued debt
and/or funded loans for the sewer system from 1902-1931 are shown for each city in per capita
increments (US$ per person). Note: Data were not available for this variable in Washington,
D.C.
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S15 Fig. Overall investment in the water supply system. The overall cumulative investments
in the water supply system from 1902-1931 are shown for each city in per capita increments
(US$ per person). This was calculated as the cumulative sum of annual expenses and annual
outlays minus annual receipts for the water supply system.
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S16 Fig. Overall investment in the sewer system. The overall cumulative investments in the
sewer system from 1902-1931 are shown for each city in per capita increments (US$ per person).
This was calculated as the cumulative sum of annual expenses and annual outlays for the sewer
system.
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S17-S20 Figs. TSIR model predictions. For each city, the TSIR model is fit using the first 38 years of data, then used to predict the
last 5 years of data. In each plot, the observed data is shown in black, the model fit to the first 38 years is shown in blue, and the
predicted last 5 years is shown in red.
S17 Fig. TSIR model predictions for Baltimore, Boston, Chicago, and Cincinnati.

157

S18 Fig. TSIR model predictions for Cleveland, Milwaukee, Nashville, and New Orleans.
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S19 Fig. TSIR model predictions for New York, Philadelphia, Pittsburgh, and Providence.
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S20 Fig. TSIR model predictions for St. Louis, San Francisco, Toledo, and Washington, D.C.
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S21-S36 Figs. Plots of seasonal and long-term transmission from sensitivity analyses for
imputation, log-transformation, and duration of immunity. The plot of seasonal and longterm transmission is shown for each city separately. Plots are shown for imputation of missing
data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in the solid
line in every panel; +0.5 shown in the dashed line in the second panel); and duration of immunity
(13-year, 1-year, and no waning of immunity). Instances of outliers are noted, and are sometimes
not entirely shown in the plot.
S21 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Baltimore. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Baltimore data.
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S22 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Boston. Plots are shown for imputation of missing
data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in the solid
line in every panel; +0.5 shown in the dashed line in the second panel); and duration of immunity
(13-year, 1-year, and no waning of immunity) in the Boston data.
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S23 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Chicago. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Chicago data.
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S24 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Cincinnati. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Cincinnati data.
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S25 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Cleveland. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Cleveland data. Note that the 26week imputation plot is not shown entirely in the plot due to its outlier.
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S26 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Milwaukee. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Milwaukee data.

166

S27 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Nashville. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Nashville data.
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S28 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: New Orleans. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the New Orleans data.
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S29 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: New York. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the New York data.
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S30 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Philadelphia. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Philadelphia data.
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S31 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Pittsburgh. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Pittsburgh data. Note that the
imputed 13-week algorithm (+0.5) and the imputed 26-week algorithm (+1) are not shown
entirely in the plots due to outliers
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S32 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Providence. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Providence data.
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S33 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Saint Louis. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the Saint Louis data.
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S34 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: San Francisco. Plots are shown for imputation of
missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in
the solid line in every panel; +0.5 shown in the dashed line in the second panel); and duration of
immunity (13-year, 1-year, and no waning of immunity) in the San Francisco data.
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S35 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Toledo. Plots are shown for imputation of missing
data (8-, 13-, and 26-week algorithm); addition to all weekly death counts (+1 shown in the solid
line in every panel; +0.5 shown in the dashed line in the second panel); and duration of immunity
(13-year, 1-year, and no waning of immunity) in the Toledo data.
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S36 Fig. Plots of seasonal transmission from sensitivity analyses for imputation, logtransformation, and duration of immunity: Washington, D.C.. Plots are shown for
imputation of missing data (8-, 13-, and 26-week algorithm); addition to all weekly death counts
(+1 shown in the solid line in every panel; +0.5 shown in the dashed line in the second panel);
and duration of immunity (13-year, 1-year, and no waning of immunity) in the Washington, D.C.
data.
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S1 Table. References for water supply source, interventions and dates. Information on water supply interventions and water
sources were extracted from a variety of references, noted below. Most cities had data available from the U.S. Census Bureau in
addition to individual municipal sources, noted in the table as “U.S. Census Bureau (Yes/No)”.
City

State Water Source

U.S. Census Bureau (Yes/No) Additional Sources

Baltimore

MD

Jones Falls reservoir, Lake Roland/Lake
Hampden/Mount Royal reservoirs (1862),
Druid Hill reservoir (1873), Loch Raven
reservoir and Lake Montebello (1881);
chlorination 1910, filtration 1915

Yes (Filtration, Chlorination)

Boston

MA

Long Pond (Lake Cochituate) via Cochituate Yes (Filtration)
aqueduct and Brookline Reservoir; several
reservoirs, aqueducts built between 1864 and
1900; Wachusett Reservoir/Dam/aqueduct
completed in 1908

http://www.bwsc.org/ABOUT_BWSC/systems/wat
er/Water_history.asp

Chicago

IL

Lake Michigan; flow direction of Chicago
Yes (Filtration, Chlorination)
River reversed in 1900 to prevent waste water
from entering lake

http://encyclopedia.chicagohistory.org/pages/1325.
html

Cincinnati

OH

Ohio River (with subsiding, storage, &
filtering reservoirs, e.g. Eden Park)

Yes (Filtration, Chlorination)

http://books.google.com/books?id=6vzVAAAAM
AAJ&pg=PA42&lpg=PA42&dq=cincinnati+water
+works+history&source=bl&ots=Qe82LaTBvG&s
ig=zGhGv6VH7yZ2LwXvdLySJ7B8OnI&hl=en&
sa=X&ei=um7rTuCUPIT30gGDgpXQCQ&ved=0
CGIQ6AEwBw#v=onepage&q=cincinnati%20wat
er%20works%20history&f=false

Cleveland

OH

Lake Erie west of the Cuyahoga River; offshore intake (Kinsman Reservoir) began
operation in 1885; further off-shore intakes
created 1890-1916; chlorination began in
1911, daily testing 1913, filtration 1917

Yes (Filtration, Chlorination)

http://www.clevelandwater.com/about_us/history.a
spx

http://cityservices.baltimorecity.gov/dpw/waterwas
tewater02/waterquality3.html
http://www.baltimorecity.gov/Government/Agenci
esDepartments/PublicWorks/BureauofWaterWaste
water/FactSheet.aspx
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Milwaukee

WI

Lake Michigan via Kilbourne Reservoir;
Yes (Chlorination)
second pumping station at Milwaukee River
in 1924
Cumberland River via reservoirs used for
Yes (Filtration, Chlorination)
settling and storage; pumping station
relocated upstream of Brown's Creek in 1889;
treatment with hypochlorite in 1908, liquid
chlorine in 1920, filtration in 1928

http://city.milwaukee.gov/water/customer/FAQs/ad
ditionalinfo#4

Nashville

TN

New Orleans LA

Rainwater cisterns, Mississippi River, artesian Yes (Filtration)
wells; city subject to regular flooding at late
as mid-1880s; drainage plan initiated in 1896;
water treatment authorized/built in 1899

http://www.swbno.org/history_history.asp

New York

Old Croton Reservoir (via Old Croton
Yes (Filtration, Chlorination)
aqueduct, since 1842); distribution reservoirs
at 42nd St, Central Park, Boyds Corner,
Middle Branch; additional reservoirs in
Catskills in 1905-1915

http://www.nyc.gov/html/dep/html/drinking_water/
history.shtml

Philadelphia PA

Schuylkill River, Delaware River, Leigh
River, various creeks

http://www.phillyh2o.org/
http://www.phila.gov/water/PWD_Historical.html

Pittsburgh

PA

Allegheny River (with holding reservoirs);
Yes (Filtration, Chlorination)
filtration began in 1909 (Southside) and 1914
(Northside); chlorination began in 1911; City
of Pittsburgh merged with City of Allegheny
(Northside) in 1907

http://www.pgh2o.com/history02.htm

Providence

RI

Pawtuxet River (at Cranston); filtration began Yes (Filtration)
1906; filtered water stored in 3 open
reservoirs; shortages during dry weather;
Scituate Reservoir and treatment plant
constructed in 1926 (by damming river)

http://www.provwater.com/history.htm

Saint Louis

MO

Mississippi River (via High Service pumping Yes (Filtration, Chlorination)
station at Bissels Point since 1871, also via
Low Service Chain of Rocks plant since
1894); filtration plant dedicated in 1915

http://www.stlwater.com/history2.php

NY

Yes (Filtration, Chlorination)

http://www.nashville.gov/water/docs/other/water_h
istory_additional_information.pdf
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San
Francisco

CA

Arroyo de la Laguna, Alameda Creek,
No
artesian wells in Pleasanton (Hetch Hetchy
reservoir in Yosemite since 1923);
owned/operated by private company -- Spring
Valley Water Co

http://www.sfmuseum.org/hist3/perry.html

Toledo

OH

Maumee River; filtration plant upstream of
Broadway Pumping Station began operation
in 1910; source changed to Lake Erie in
1940s
Potomac River via Washington Aqueduct;
McMillan Reservoir and Bryant Street highlift pump after 1905

Yes (Filtration, Chlorination)

http://www.ci.toledo.oh.us/Departments/PublicUtil
ities/DivisionofWaterTreatment/HistoryofWaterTr
eatmentinToledo/tabid/375/Default.aspx

Yes (Filtration, Chlorination)

https://www.dcwater.com/history-water-system

Washington, D.C.
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S2 Table. Initial and estimated values for main TSIR models. Initial parameters (median susceptible population, median overall
population, infectious, susceptible, and newborn populations) and values estimated from the TSIR models (chronic carriers,
underreporting factors, and heterogeneous mixing parameters) are shown for each city.
Median values

Baltimore
Boston
Chicago
Cincinnati
Cleveland
Milwaukee
Nashville
New Orleans
New York
Philadelphia
Pittsburgh
Providence
Saint Louis
San
Francisco
Toledo
Washington,
D.C.

Initial Values (at time 0)

Median
susceptible
population
over time
period

Median
population
over time
period

Infectious
Susceptible
Population population
(after
adjusting for
underreportin
g)

84000
70125
273750
45500
70563
46875
13750
42500
597500
193750
66875
28125
86000
52250

672000
561000
2190000
364000
564500
375000
110000
340000
4780000
1550000
535000
225000
688000
418000

908
597
214
412
747
419
158
140
7335
1803
602
249
684
469

21250
41625

170000
333000

76
157

Estimated from model

Births

Number of
chronic
carriers

Underreporti Heterogeneo
ng factor (r) us mixing
parameter
(a)

443653
425614
973056
281345
266174
180566
66245
227335
3006890
1024268
190287
118344
431141
277260

670
725
2147
517
476
432
112
393
8059
1738
658
190
802
368

87.4
173.9
19.9
112.8
5.1
3.8
78.1
204
43.5
170.5
58.9
0
213.3
46

0.017
0.014
0.023
0.022
0.017
0.01
0.025
0.014
0.005
0.021
0.022
0.016
0.012
0.017

0.25
-0.27
0.18
0.11
0.07
0.04
-0.4
0.59
0.39
0.41
0.31
0.09
0.29
-0.1

85298
244920

144
340

0
0

0.013
0.038

0.04
0.25
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S3 Table. Harmonic regression analyses of typhoid mortality data pre- and post- water supply intervention. Time trends and
seasonal amplitudes were estimated for each city pre- and post- intervention in preliminary analyses with harmonic regression.
Values shown in grey were not statistically significant at the 0.05-level, while values in black had p-values<0.05. In the last column,
the ratio (post-/pre- water supply intervention) was calculated from the six-month and one-year amplitudes estimated from the
regression models.
Ratio (Post/Pre)
Pre-Intervention
Post-Intervention
Time trend

Baltimore
Boston
Chicago
Cincinnati
Cleveland
Milwaukee
Nashville
New Orleans
New York
Philadelphia
Pittsburgh
Providence
Saint Louis
San
Francisco
Toledo
Washington,
D.C.

Seasonal Amplitude Time trend

intercept

slope

6-mo.

1-yr.

intercept

slope

Seasonal
Amplitude
6-mo.
1-yr

-3.35
27.1
27.78
-18.04
41.5
2.28
-11.36
-151.79
-23.7
27.96
-154.97
12.81
31.39
16.32

0
-0.01
-0.01
0.01
-0.02
0
0.01
0.08
0.01
-0.01
0.08
-0.01
-0.02
-0.01

0.15
0.22
0.14
0.15
0.15
0.02
0.06
0.14
0.12
0.17
0.14
0.03
0.21
0.08

0.62
0.55
0.26
0.18
0.08
0.07
0.17
0.13
0.74
0.16
0.23
0.12
0.47
0.21

76.94
25.75
141.03
4.85
17.29
27.95
12.44
43.97
162.4
199.33
64.03
7.48
43.31
20.84

-0.04
-0.01
-0.07
0
-0.01
-0.01
-0.01
-0.02
-0.08
-0.1
-0.03
0
-0.02
-0.01

0.08
0.04
0.04
0
0.04
0.04
0.07
0.14
0.11
0.05
0.04
0.01
0.09
0.02

-25.43
15.94

0.01
-0.01

0.06
0.07

0.12
0.64

26.07
53.81

-0.01
-0.03

0.03
0.05

of Seasonal Amplitude
.

6-mo.

1-yr.

0.24
0.07
0.18
0.02
0.06
0.06
0.14
0.2
0.47
0.04
0.11
0.03
0.24
0.04

0.49
0.19
0.32
0.03
0.25
1.91
1.16
0.97
0.88
0.32
0.31
0.43
0.43
0.26

0.39
0.13
0.68
0.1
0.67
0.81
0.83
1.51
0.64
0.24
0.49
0.26
0.51
0.18

0.08
0.17

0.5
0.77

0.66
0.26
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S4 Table. Estimates of seasonal transmission from TSIR models, with confidence intervals. Results of the seasonal transmission
parameters estimated from the TSIR models are shown. In the top half of the table, the estimated values for each four-week month's
typhoid transmission compared to the 13th month are shown with their 95% confidence intervals, by city. Estimates with confidence
intervals that are entirely below one are shown in red, and those with confidence intervals entirely above one are shown in blue. In
the bottom half of the table, the percentage of each water type with confidence intervals entirely below or above one are shown for
each month, highlighted from lighter to darker red or blue indicating the magnitude of the percentage.
City

Month
Water
Type

Baltimore

Reservoir

Boston

Reservoir

Chicago

Great Lake

Cincinnati

River

Cleveland

Great Lake

Milwaukee

Great Lake

Nashville

River

New
Orleans

River

New York

Reservoir

Philadelphia

River

Pittsburgh

River

1

2

3

4

5

6

7

8

9

10

11

12

0.78

0.82

1.01

1.03

0.78

1.16

1.34

1.63

1.77

1.68

1.38

0.95

(0.63-0.97)

(0.66-1.02)

(0.81-1.26)

(0.83-1.27)

(0.63-0.97)

(0.94-1.44)

(1.08-1.66)

(1.31-2.02)

(1.42-2.20)

(1.35-2.10)

(1.11-1.72)

(0.76-1.17)

0.97

1.03

1.03

1.03

0.98

0.98

1.1

1.52

1.57

1.56

1.01

1.02

(0.76-1.24)

(0.80-1.32)

(0.80-1.33)

(0.80-1.32)

(0.76-1.26)

(0.76-1.26)

(0.86-1.42)

(1.18-1.95)

(1.22-2.03)

(1.21-2.02)

(0.78-1.30)

(0.79-1.31)

0.75

0.9

0.58

0.77

0.75

0.88

1.06

1.34

1.07

1.15

0.92

1.13

(0.61-0.93)

(0.73-1.12)

(0.47-0.72)

(0.62-0.95)

(0.61-0.93)

(0.71-1.09)

(0.86-1.31)

(1.08-1.65)

(0.87-1.32)

(0.94-1.42)

(0.74-1.13)

(0.92-1.39)

1.04

0.93

1

0.99

0.94

1.01

1.38

1.09

1.17

1.14

1.05

1.25

(0.84-1.28)

(0.75-1.15)

(0.81-1.24)

(0.80-1.22)

(0.76-1.17)

(0.82-1.25)

(1.12-1.71)

(0.88-1.35)

(0.94-1.44)

(0.92-1.41)

(0.85-1.30)

(1.01-1.55)

0.83

1.05

0.91

0.94

1.16

0.8

1.14

1.62

1.66

1.4

0.88

1.15

(0.67-1.02)

(0.85-1.30)

(0.73-1.12)

(0.76-1.15)

(0.94-1.43)

(0.65-0.99)

(0.93-1.41)

(1.31-1.99)

(1.34-2.04)

(1.13-1.74)

(0.71-1.10)

(0.93-1.42)

0.81

1.05

0.94

0.98

0.87

0.84

0.93

1.04

0.97

0.9

0.89

0.81

(0.65-0.99)

(0.86-1.30)

(0.77-1.16)

(0.80-1.21)

(0.71-1.08)

(0.68-1.04)

(0.75-1.15)

(0.85-1.29)

(0.78-1.19)

(0.73-1.11)

(0.73-1.10)

(0.66-1.00)

0.81

0.69

0.69

0.78

0.74

1.43

2.16

2.53

1.92

2.01

1.54

1.06

(0.65-0.99)

(0.56-0.85)

(0.56-0.85)

(0.63-0.96)

(0.60-0.91)

(1.16-1.77)

(1.74-2.68)

(2.01-3.17)

(1.53-2.41)

(1.63-2.49)

(1.24-1.91)

(0.86-1.31)

0.63

0.68

0.78

0.72

1.01

1.07

1.44

1.17

0.73

0.73

0.95

1.2

(0.49-0.80)

(0.53-0.87)

(0.61-1.00)

(0.56-0.92)

(0.79-1.30)

(0.84-1.37)

(1.12-1.84)

(0.92-1.50)

(0.57-0.93)

(0.57-0.94)

(0.75-1.22)

(0.94-1.54)

1.07

1.14

1.13

1.13

1.19

1.56

2.31

2.91

2.36

1.93

1.5

1.51

(0.91-1.27)

(0.96-1.35)

(0.95-1.34)

(0.95-1.34)

(1.00-1.40)

(1.32-1.84)

(1.96-2.72)

(2.47-3.44)

(1.99-2.79)

(1.63-2.29)

(1.27-1.77)

(1.28-1.77)

0.83

0.81

0.88

0.95

1

0.86

1.07

1.16

1.28

0.95

1.07

0.87

(0.70-0.98)

(0.68-0.95)

(0.75-1.04)

(0.81-1.13)

(0.85-1.19)

(0.72-1.01)

(0.91-1.27)

(0.98-1.37)

(1.09-1.52)

(0.80-1.12)

(0.90-1.26)

(0.74-1.03)

0.88

0.7

0.63

0.65

0.78

0.84

1.19

1.26

1.22

1.34

1.22

0.85
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Providence

River

Saint Louis

River

San
Francisco

Reservoir

Toledo

River

Washington,
D.C.

River

% of
confidence
intervals
below 1

% of (4)
Reservoirs
% of (3)
Great Lakes
% of (9)
Rivers
% of (16) All

% of
confidence
intervals
above 1

% of
(4)Reservoirs
% of (3)
Great Lakes
% of (9)
Rivers
% of (16) All

(0.71-1.10)

(0.57-0.88)

(0.50-0.78)

(0.52-0.81)

(0.63-0.98)

(0.67-1.04)

(0.95-1.48)

(1.01-1.58)

(0.98-1.52)

(1.07-1.67)

(0.97-1.52)

(0.68-1.05)

0.77

0.96

0.85

0.87

0.78

0.67

0.96

0.89

0.94

0.94

0.96

1.1

(0.63-0.95)

(0.78-1.18)

(0.69-1.04)

(0.70-1.07)

(0.64-0.96)

(0.54-0.82)

(0.77-1.18)

(0.72-1.09)

(0.76-1.16)

(0.77-1.16)

(0.78-1.18)

(0.90-1.36)

1.04

1.51

1.58

1.61

1.39

1.66

2.09

2.47

2.07

1.92

1.81

1.17

(0.84-1.29)

(1.21-1.87)

(1.27-1.96)

(1.30-2.00)

(1.12-1.73)

(1.33-2.06)

(1.69-2.60)

(1.98-3.09)

(1.65-2.61)

(1.53-2.41)

(1.46-2.25)

(0.94-1.46)

0.94

1.19

1.14

1.35

1.48

1.25

1.15

1.17

1.37

1.53

1.54

1.42

(0.75-1.17)

(0.95-1.49)

(0.91-1.43)

(1.08-1.69)

(1.18-1.85)

(1.00-1.57)

(0.92-1.44)

(0.94-1.47)

(1.10-1.71)

(1.22-1.91)

(1.23-1.92)

(1.14-1.77)

0.97

1.35

1.16

1.06

0.79

0.89

1.16

1.46

2.02

1.74

1.15

1.21

(0.79-1.18)

(1.10-1.65)

(0.95-1.42)

(0.87-1.30)

(0.65-0.97)

(0.72-1.09)

(0.95-1.41)

(1.20-1.78)

(1.66-2.46)

(1.43-2.12)

(0.94-1.40)

(0.99-1.47)

0.92

0.89

0.97

0.91

0.93

0.89

1.08

1.05

1.04

1.07

0.87

0.95

(0.73-1.16)

(0.71-1.12)

(0.77-1.22)

(0.72-1.14)

(0.74-1.17)

(0.71-1.11)

(0.86-1.35)

(0.83-1.32)

(0.82-1.30)

(0.85-1.34)

(0.69-1.09)

(0.76-1.19)

25%

0%

0%

0%

25%

0%

0%

0%

0%

0%

0%

0%

67%

0%

33%

33%

33%

33%

0%

0%

0%

0%

0%

0%

44%

44%

33%

33%

44%

11%

0%

0%

11%

11%

0%

0%

44%

25%

25%

25%

38%

13%

0%

0%

6%

6%

0%

0%

0%

0%

0%

25%

50%

50%

25%

75%

100%

100%

75%

75%

0%

0%

0%

0%

0%

0%

0%

67%

33%

33%

0%

0%

0%

22%

11%

11%

11%

22%

44%

44%

44%

44%

22%

11%

0%

13%

6%

13%

19%

25%

31%

56%

56%

56%

31%

19%
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S5 Table. Variability in long-term typhoid transmission explained by financial water
supply and sewer system variables. Values shown are the conditional and marginal R2 from the
hierarchical linear regression analyses for each financial variable.
Marginal R2 Conditional R2
Receipts: Water supply
Expenses: Water supply
Expenses: Sewer system
Outlays: Water supply
Outlays: Sewer system
Value: Water supply
Funded debt: Water supply
Funded debt: Sewer system
Overall investment: Water supply
Overall investment: Sewer system

0.00
0.01
0.01
0.01
0.01
0.00
0.01
0.04
0.33
0.28

0.85
0.86
0.84
0.87
0.88
0.91
0.93
0.93
0.98
0.98
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Receipts: Water supply

Expenses: Water supply

Expenses: Sewer system

Outlays: Water supply

Outlays: Sewer system

Value: Water supply

Funded debt: Water supply

Funded debt: Sewer system

Overall investment: Water supply

Overall investment: Sewer system

S6 Table. Random and fixed effects for associations between yearly average long-term typhoid transmission and investments in water
and sewer systems for individual financial variables. Each estimate shows the associated change (and 95% confidence interval) in typhoid
transmission for each $1 (1931 US$) per capita increase in the financial variable for the water supply (WS) and sewer system (SS) for fixed
and random effects. No data were available for Washington, D.C. for the variables Funded Debt of the Water Supply System or Funded Debt
of the Sewer System.

Baltimore

0.57 (0.38-0.86)

0.76 (0.45-1.33)

1.05 (0.72-1.55)

0.94 (0.81-1.08)

1.05 (0.87-1.26)

0.98 (0.96-1.00)

0.99 (0.95-1.04)

0.98 (0.93-1.02)

0.95 (0.93-0.96)

0.97 (0.95-0.99)

Boston

1.59 (1.15-2.22)

0.70 (0.40-1.22)

1.35 (0.82-2.18)

0.95 (0.84-1.07)

1.53 (1.10-2.12)

1.02 (0.99-1.05)

1.12 (1.06-1.19)

1.06 (1.01-1.12)

0.94 (0.92-0.96)

0.93 (0.91-0.96)

Chicago

1.15 (0.71-1.84)

0.79 (0.46-1.35)

0.46 (0.27-0.80)

1.05 (0.88-1.24)

0.77 (0.62-0.96)

1.02 (0.97-1.07)

1.03 (0.93-1.13)

0.95 (0.90-1.00)

0.91 (0.90-0.93)

0.95 (0.92-0.97)

Cincinnati

0.71 (0.47-1.09)

1.21 (0.70-2.10)

1.44 (0.69-2.99)

1.16 (1.03-1.30)

0.98 (0.69-1.41)

1.02 (0.99-1.04)

1.02 (0.98-1.06)

0.92 (0.87-0.98)

0.96 (0.94-0.97)

0.95 (0.92-0.97)

Cleveland

0.66 (0.47-0.93)

0.43 (0.27-0.69)

1.99 (0.93-4.25)

0.97 (0.88-1.08)

0.77 (0.59-1.02)

0.94 (0.91-0.97)

0.91 (0.87-0.95)

1.12 (1.05-1.20)

0.97 (0.95-0.98)

0.94 (0.92-0.97)

Milwaukee

0.58 (0.40-0.84)

0.57 (0.37-0.87)

0.73 (0.44-1.20)

0.98 (0.83-1.16)

0.85 (0.72-1.00)

1.02 (0.98-1.06)

1.03 (0.93-1.15)

0.97 (0.93-1.01)

0.93 (0.92-0.95)

0.98 (0.96-1.00)

Nashville

0.93 (0.58-1.52)

0.38 (0.21-0.67)

1.73 (0.72-4.12)

0.91 (0.79-1.05)

0.89 (0.63-1.26)

1.02 (1.00-1.04)

1.01 (0.95-1.07)

0.84 (0.77-0.93)

0.92 (0.90-0.93)

0.82 (0.79-0.85)

New Orleans

0.82 (0.52-1.28)

0.84 (0.46-1.52)

0.85 (0.46-1.52)

1.04 (0.95-1.14)

0.99 (0.83-1.19)

0.99 (0.96-1.01)

1.00 (0.96-1.03)

1.02 (0.97-1.07)

0.97 (0.96-0.99)

0.98 (0.96-1.01)

New York

1.25 (0.78-1.97)

1.19 (0.60-2.33)

1.14 (0.63-2.12)

1.08 (0.97-1.20)

0.79 (0.51-1.23)

0.99 (0.97-1.01)

0.98 (0.94-1.02)

1.00 (0.88-1.14)

0.98 (0.97-1.00)

0.93 (0.90-0.96)

Philadelphia

1.73 (1.16-2.55)

2.02 (1.28-3.17)

1.34 (0.69-2.58)

1.16 (1.00-1.33)

0.68 (0.51-0.91)

1.04 (1.01-1.06)

1.07 (1.02-1.13)

0.93 (0.88-0.98)

0.92 (0.91-0.94)

0.93 (0.91-0.96)

Pittsburgh

0.78 (0.54-1.12)

0.37 (0.23-0.58)

2.14 (1.02-4.54)

1.23 (1.11-1.37)

0.79 (0.54-1.18)

0.99 (0.97-1.01)

1.05 (1.01-1.09)

0.89 (0.82-0.98)

0.94 (0.93-0.95)

0.85 (0.82-0.88)

Providence

1.05 (0.72-1.56)

0.85 (0.51-1.41)

0.99 (0.45-2.21)

0.96 (0.88-1.05)

0.83 (0.61-1.12)

0.99 (0.96-1.02)

0.99 (0.96-1.02)

1.04 (0.99-1.09)

0.98 (0.97-1.00)

0.95 (0.92-0.98)

Saint Louis

0.93 (0.73-1.19)

0.78 (0.51-1.20)

1.95 (0.94-4.06)

0.98 (0.92-1.05)

1.11 (0.91-1.34)

0.99 (0.97-1.00)

0.99 (0.96-1.02)

0.96 (0.90-1.04)

0.99 (0.98-1.01)

0.94 (0.92-0.97)

San Francisco

1.22 (0.78-1.88)

0.72 (0.35-1.45)

1.28 (0.72-2.28)

1.02 (0.90-1.15)

0.91 (0.73-1.15)

1.01 (0.99-1.03)

1.00 (0.94-1.06)

0.95 (0.88-1.02)

0.97 (0.96-0.99)

0.97 (0.94-0.99)

Toledo

0.74 (0.54-1.02)

0.63 (0.40-0.98)

1.25 (0.59-2.68)

1.06 (0.91-1.23)

0.83 (0.65-1.06)

0.99 (0.95-1.03)

1.06 (1.00-1.13)

0.95 (0.91-1.00)

0.97 (0.95-0.98)

0.95 (0.93-0.98)

Washington, D.C.

1.09 (0.64-1.79)

0.94 (0.57-1.54)

1.33 (0.73-2.42)

1.02 (0.95-1.09)

1.22 (0.95-1.56)

1.00 (0.99-1.02)

--

--

0.98 (0.97-0.99)

0.94 (0.92-0.97)

Average (Fixed)
Effects

0.94 (0.76-1.17)

0.75 (0.56-1.00)

1.23 (0.90-1.72)

1.03 (0.97-1.10)

0.92 (0.79-1.06)

1.00 (0.98-1.01)

1.01 (0.98-1.05)

0.97 (0.93-1.01)

0.96 (0.94-0.97)

0.94 (0.91-0.96)
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S7 Table. Fit of the TSIR models to within- and out-of-sample data for each city. Variability in typhoid deaths explained (R2)
by TSIR models fit to data for the full study period (1889-1931) is shown, along with the within-sample mean squared errors (MSE)
for 1922-1926 (i.e. the last five years of within-sample data used to generate the prediction model), the out-of-sample mean squared
prediction errors (MSPE) for 1927-1931 (i.e. the out-of-sample data), and their ratio (MSPE/MSE) for comparison.
City
R2 (full
MSE
MSPE (outRatio
model fit)
(within- of-sample) (MSPE/
sample)
MSE)
Baltimore
Boston
Chicago
Cincinnati
Cleveland
Milwaukee
Nashville
New Orleans
New York
Philadelphia
Pittsburgh
Providence
Saint Louis
San Francisco

0.64
0.64
0.86
0.71
0.73
0.56
0.48
0.5
0.86
0.9
0.82
0.45
0.6
0.61

3.53
2.56
8.1
0.98
1.28
0.54
2.82
7.52
39.59
4.57
1.01
0.3
2.43
0.88

3.84
0.71
1.85
0.65
6.55
0.21
2.14
14.7
38.17
6.56
1.32
0.39
1.8
1.9

1.09
0.28
0.23
0.66
5.13
0.39
0.76
1.96
0.96
1.44
1.3
1.31
0.74
2.16

Toledo
Washington, D.C.

0.52
0.74

0.83
0.04

0.73
0

0.88
0
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S8 Table. Sensitivity analyses for hierarchical regression: Random and fixed effects for yearly average long-term typhoid
transmission vs. overall investments in the water supply system. Each estimate shows the associated multiplicative change in the
estimated long-term typhoid transmission rate for each $1 per capita increase in overall investment for the water supply system (in
1931 US dollars) for each model fit. Both random and fixed effects are shown, with their 95% confidence intervals.
Effect

City

Main Model
(imputation 13
weeks, +1 to
deaths)

Imputation 8
weeks

Imputation 26
weeks

+0.5 to deaths

1-year
immunity

No waning of
immunity

Random + Fixed

Baltimore

0.95 (0.93-0.96) 0.95 (0.94-0.97) 0.95 (0.93-0.97) 0.93 (0.91-0.95) 0.96 (0.95-0.97) 0.96 (0.95-0.98)

Boston

0.94 (0.93-0.96) 0.93 (0.92-0.95) 0.94 (0.92-0.96) 0.93 (0.91-0.95) 0.95 (0.93-0.96) 0.96 (0.95-0.97)

Chicago

0.91 (0.90-0.93) 0.91 (0.89-0.92) 0.91 (0.89-0.93) 0.90 (0.88-0.92) 0.93 (0.92-0.94) 0.93 (0.92-0.94)

Cincinnati

0.95 (0.94-0.97) 0.96 (0.94-0.97) 0.96 (0.94-0.98) 0.94 (0.92-0.96) 0.96 (0.94-0.97) 0.96 (0.95-0.97)

Cleveland

0.97 (0.95-0.98) 0.97 (0.95-0.98) 0.96 (0.94-0.98) 0.96 (0.94-0.98) 0.98 (0.97-0.99) 0.98 (0.97-0.99)

Milwaukee

0.93 (0.91-0.94) 0.93 (0.91-0.94) 0.94 (0.91-0.96) 0.91 (0.88-0.93) 0.93 (0.92-0.95) 0.95 (0.93-0.96)

Nashville

0.91 (0.90-0.93) 0.91 (0.90-0.93) 0.91 (0.89-0.93) 0.90 (0.88-0.92) 0.96 (0.94-0.97) 0.97 (0.96-0.98)

New Orleans

0.97 (0.95-0.99) 0.97 (0.95-0.99) 0.97 (0.95-1.00) 0.97 (0.94-0.99) 0.98 (0.96-0.99) 0.98 (0.97-0.99)

New York

0.98 (0.97-1.00) 0.98 (0.96-0.99) 0.98 (0.96-1.00) 0.98 (0.96-1.00) 0.98 (0.97-0.99) 0.98 (0.98-0.99)

Philadelphia

0.93 (0.91-0.95) 0.92 (0.90-0.93) 0.87 (0.85-0.89) 0.92 (0.90-0.94) 0.94 (0.93-0.95) 0.94 (0.93-0.95)

Pittsburgh

0.94 (0.92-0.95) 0.94 (0.93-0.96) 0.91 (0.89-0.93) 0.88 (0.86-0.90) 0.95 (0.93-0.96) 0.96 (0.95-0.97)

Providence

0.98 (0.97-1.00) 0.98 (0.97-1.00) 0.99 (0.97-1.01) 0.98 (0.96-1.00) 0.99 (0.98-1.00) 0.99 (0.98-1.00)

Saint Louis

0.99 (0.98-1.00) 0.99 (0.97-1.00) 0.99 (0.97-1.01) 0.99 (0.97-1.01) 0.99 (0.98-1.00) 0.99 (0.98-1.00)

San Francisco 0.98 (0.96-0.99) 0.97 (0.96-0.99) 0.97 (0.95-0.99) 0.97 (0.95-0.99) 0.97 (0.96-0.99) 0.97 (0.96-0.98)

Fixed

Toledo

0.96 (0.95-0.98) 0.96 (0.94-0.98) 0.97 (0.94-0.99) 0.95 (0.93-0.97) 0.96 (0.95-0.97) 0.96 (0.95-0.97)

Washington,
D.C.
-

0.98 (0.97-0.99) 0.98 (0.97-1.00) 0.98 (0.96-1.00) 0.98 (0.96-0.99) 0.98 (0.97-0.99) 0.98 (0.97-0.99)
0.95 (0.94-0.97) 0.95 (0.94-0.97) 0.95 (0.93-0.97) 0.94 (0.93-0.96) 0.96 (0.95-0.97) 0.97 (0.96-0.98)
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S9 Table. Sensitivity analyses for hierarchical regression: Random and fixed effects for yearly average long-term typhoid
transmission vs. overall investments in the sewer system. Each estimate shows the associated multiplicative change in the
estimated long-term typhoid transmission rate for each $1 per capita increase in overall investment for the sewer system (in 1931 US
dollars) for each model fit. Both random and fixed effects are shown, with their 95% confidence intervals.
Effect

Random

Fixed

City

Main Model
(imputation 13
weeks, +1 to
deaths)

Imputation 8
weeks

Imputation 26
weeks

+0.5 to deaths

1-year immunity

No waning of
immunity

Baltimore

0.97 (0.95-0.99)

0.97 (0.95-1.00)

0.97 (0.94-1.00)

0.96 (0.93-1.00)

0.98 (0.96-0.99)

0.98 (0.97-0.99)

Boston

0.93 (0.91-0.96)

0.92 (0.90-0.95)

0.93 (0.90-0.97)

0.92 (0.88-0.96)

0.94 (0.92-0.95)

0.95 (0.94-0.97)

Chicago

0.95 (0.92-0.97)

0.94 (0.92-0.97)

0.95 (0.92-0.98)

0.94 (0.91-0.98)

0.96 (0.94-0.97)

0.96 (0.95-0.97)

Cincinnati

0.95 (0.92-0.97)

0.95 (0.92-0.97)

0.95 (0.92-0.99)

0.93 (0.89-0.97)

0.95 (0.93-0.97)

0.95 (0.94-0.97)

Cleveland

0.94 (0.92-0.97)

0.94 (0.92-0.97)

0.94 (0.91-0.97)

0.93 (0.90-0.97)

0.96 (0.95-0.98)

0.97 (0.96-0.98)

Milwaukee

0.98 (0.96-1.00)

0.98 (0.95-1.00)

0.98 (0.95-1.01)

0.97 (0.94-1.01)

0.98 (0.97-1.00)

0.99 (0.97-1.00)

Nashville

0.82 (0.79-0.85)

0.82 (0.79-0.85)

0.82 (0.78-0.86)

0.80 (0.76-0.84)

0.90 (0.88-0.93)

0.94 (0.92-0.96)

New Orleans

0.98 (0.96-1.01)

0.98 (0.96-1.01)

0.98 (0.95-1.02)

0.98 (0.94-1.02)

0.99 (0.97-1.01)

0.99 (0.97-1.00)

New York

0.93 (0.90-0.96)

0.91 (0.88-0.94)

0.93 (0.89-0.97)

0.92 (0.88-0.97)

0.92 (0.90-0.94)

0.93 (0.92-0.95)

Philadelphia

0.93 (0.91-0.96)

0.92 (0.90-0.95)

0.89 (0.85-0.92)

0.92 (0.89-0.96)

0.94 (0.92-0.96)

0.94 (0.93-0.96)

Pittsburgh

0.85 (0.82-0.88)

0.85 (0.83-0.88)

0.79 (0.76-0.83)

0.73 (0.70-0.77)

0.87 (0.84-0.89)

0.89 (0.87-0.91)

Providence

0.95 (0.92-0.98)

0.95 (0.92-0.97)

0.95 (0.92-0.99)

0.93 (0.90-0.98)

0.96 (0.94-0.98)

0.96 (0.95-0.98)

Saint Louis

0.94 (0.92-0.97)

0.94 (0.91-0.96)

0.95 (0.92-0.98)

0.92 (0.88-0.96)

0.95 (0.93-0.96)

0.96 (0.94-0.97)

San Francisco

0.97 (0.94-0.99)

0.97 (0.94-0.99)

0.96 (0.93-1.00)

0.96 (0.92-1.00)

0.97 (0.95-0.98)

0.97 (0.95-0.98)

Toledo

0.95 (0.93-0.98)

0.95 (0.92-0.97)

0.95 (0.92-0.99)

0.94 (0.90-0.98)

0.95 (0.93-0.97)

0.95 (0.94-0.97)

Washington,
D.C.

0.94 (0.92-0.97)

0.94 (0.92-0.97)

0.95 (0.91-0.98)

0.93 (0.89-0.97)

0.94 (0.93-0.96)

0.95 (0.93-0.96)

-

0.94 (0.91-0.96)

0.93 (0.91-0.96)

0.93 (0.90-0.96)

0.92 (0.88-0.95)

0.95 (0.93-0.96)

0.95 (0.94-0.97)
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S10 Table. Heterogeneous mixing from sensitivity analyses for assumptions of waning immunity, chronic carriers, or using a
simple TSIR model. Values are shown for each city and assumption. The second column shows the heterogeneous mixing
parameter value in the final models fit, the “No K” column shows the value for models fit without including waning immunity, the
“No C” column shows the value for models excluding chronic carriers as part of the transmission process, the “No K, No C” column
shows the values for models excluding both waning immunity and chronic carrier populations, and the last column (“Simple TSIR
Model”) shows the value for models fit using ordinary least squares regression and does not use splines or smoothing weights.

Baltimore
Boston
Chicago
Cincinnati
Cleveland
Milwaukee
Nashville
New Orleans
New York
Philadelphia
Pittsburgh
Providence
Saint Louis
San Francisco
Toledo
Washington,
D.C.

Final
Model
Used

No K

No C

No K, No
C

Simple
TSIR
Model

0.25
-0.27
0.18
0.11
0.07
0.04
-0.4
0.59
0.39
0.41
0.31
0.09
0.29
-0.1
0.04

0.42
0.29
0.21
0.56
0.24
0.29
0.05
0.53
0.61
0.74
0.43
0.12
0.23
0.14
0.05

0.17
-0.08
0.15
0.08
0.08
0.01
-0.05
0.25
0.37
0.27
0.2
0.09
0.07
-0.06
0.05

0.29
0.14
0.18
0.31
0.23
0.28
0.05
0.28
0.41
0.5
0.33
0.12
0.12
0.09
0.05

0.17
0.2
0.28
0.4
0.22
0.13
0.07
0.28
0.35
0.51
0.34
0.01
0.14
0.07
-0.03

0.25

0.28

0.25

0.28

0.18
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Conclusion
This dissertation was innovative in both its methods and conclusions. The approaches we
have taken allowed us to gain insights that otherwise would have been difficult to obtain. A
variety of statistical and mathematical modelling made it possible to evaluate the costeffectiveness of typhoid interventions in different settings. In this dissertation, we have
estimated the true population-based incidence of typhoid fever in Africa and Asia; weighed the
costs and effects of vaccination strategies in an outbreak setting; and estimated the impact of
water and sanitation investments in a historical endemic setting. Governments are always
looking to prioritize their allocation of resources for typhoid control. These findings fill in some
gaps in knowledge and can help to inform decision-making for typhoid control and prevention.

190

